A Phase 2 interventional study of Belimumab in Systemic Lupus Erythematosus, sponsored by Human Genome Sciences Inc., a GSK Company. Completed at 57 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-23.
Sponsored by Human Genome Sciences Inc., a GSK Company (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 11th largest by enrollment, is the only one that started in 2005, is one of 8 in phase 2, and was the 4th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Nanjing University School of Medicine · Sites in China
Ages 14–65
National University Hospital, Singapore · Sites in Singapore
Ages 21–70
First Affiliated Hospital Xi'an Jiaotong University
Ages 18+
By country, each count listing its studies:
belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 298 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 81 across the 36 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Human Genome Sciences Inc., a GSK Company, one of the names counted as GlaxoSmithKline. Under that name alone:
Human Genome Sciences Inc., a GSK Company is the lead sponsor of 13 studies on the registry; none are open to participants now.
43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 26 (72%) have results posted.
Among the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, this one is the 11th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2005, is one of 7 in phase 2, and was the 4th registered.
GlaxoSmithKline’s Lupus Erythematosus, Systemic studies by the year they started, since 2002.
2 of the studies testing belimumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340463Nanjing University School of MedicineThe Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | 2027-06 |
| NCT06411249GlaxoSmithKlineA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | 2027-06-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, from their registry updates:
Among GlaxoSmithKline’s 43 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
This is a continuation study to evaluate the long-term safety and efficacy of LymphoStat-B™ in subjects with SLE disease, that completed study LBSL02 and benefitted from treatment.
The purpose of this continuation study to evaluate the long-term safety and efficacy of LymphoStat-B™ in subjects with Systemic Lupus Erythematosus (SLE), that completed study LBSL02 and benefitted from treatment.
Primary Inclusion Criteria
Primary Exclusion Criteria
Used any of the following prohibited medications during their participation in LBSL02:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Belimumab 10 mg/kg IV over one hour every 28 days.
Biological: Belimumab
Belimumab 10mg/kg IV over one hour every 28 days
Also known as: LymphoStat-B™, HGS1006, BENLYSTA
Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs)
An AE is defined as any unfavorable or unintended sign, symptom, or disease that is temporally associated with the use of a study agent but is not necessarily caused by the study agent. This includes worsening (example \[eg\], increase in frequency or severity) of pre-existing conditions. An SAE is defined as an AE resulting in any of the following outcomes: death, is life threatening (that is, an immediate threat to life), inpatient hospitalization, prolongation of an existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, and is medically important.
Time frame: Approximately up to 13 years
Adverse Event (AE) Rates by System Organ Class (SOC) During the Study
AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatmentemergent AEs are summarized. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an AE was calculated as the number of events per 100 participant years: Event Rate=100\* number of events divided by participant years. Participant years were calculated as sum across all participants (\[last visit of interval day minus first visit of interval day plus 1\] divided by 365).
Time frame: Approximately up to 13 years
SAE Rates by System Organ Class (SOC) During the Study
SAE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatmentemergent SAEs are summarized. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pretreatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an SAE was calculated as the number of events per 100 participant years: Event Rate=100\* number of events divided by participant years. Participant years were calculated as sum across all participants (\[last visit of interval day minus first visit of interval day plus 1\] divided by 365).
Time frame: Approximately up to 13 years
Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points
Hematology parameters were assessed at Baseline, Week 8, 16, 24, 40, and 48 during Year 1 to 8; Week 8, 16, 24, and 40 during Year 9; Week 24 and 40 during Year 10; Week 48 during Year 11; Week 32 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points
Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils segmented and platelets is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Change From Baseline in Erythrocytes at the Indicated Time Points
Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in erythrocytes is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Change From Baseline in Hematocrit at the Indicated Time Points
Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in hematocrit is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Change From Baseline in Hemoglobin at the Indicated Time Points
Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in hemoglobin is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Change From Baseline in Albumin and Protein at the Indicated Time Points
Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in albumin and protein is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points
Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in BUN, glucose, calcium, carbon dioxide, chloride, magnesium, phosphate, potassium and sodium is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points
Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in creatinine, urate, and bilirubin is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Change From Baseline in BUN/Creatinine at the Indicated Time Points
Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in BUN/creatinine is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points
Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in ALT, AP, AST, GGT and LD are summarized. Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points
SRI response was assessed at Week 16, 32, and 48 during Year 1 to 12 and Week 16 and 32 during Year 13. Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. SRI response is defined as:\>=4 point reduction from the Baseline in safety of estrogen in lupus national assessment (SELENA) SLE disease activity index (SLEDAI) score and no worsening (increase of \<0.30 points from the Baseline) in Physician's Global Assessment (PGA), and no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with the Baseline at the time of assessment.
Time frame: Approximately up to 13 years
Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points
Anti-double stranded DNA levels in participants positive at Baseline were assessed at Baseline, Week 16, 32, and 48 during Year 1 to 11, Week 16 and 32 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study.
Time frame: Approximately up to 13 years
Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points
Anti-double stranded DNA levels for participants positive at Baseline were assessed at Baseline, Week 16, 32, and 48 during Year 1 to 11, Week 16 and 32 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points
Complement C3 and C4 levels were assessed in participants low at Baseline at Baseline, Week 16, 32, and 48 during Year 1 to 12, Week 16 and 32 during Year 13, and Exit visit. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study.
Time frame: Approximately up to 13 years
Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points
Complement C3 and C4 levels were assessed in participants low at Baseline at Baseline, Week 16, 32, and 48 during Year 1 to 12, Week 16 and 32 during Year 13, and Exit visit. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points
Daily prednisone dose reduction was assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13. Percentage of participants with daily prednisone dose reduced to \<=7.5 mg/day from \>7.5 mg/kg at the Baseline are summarized. Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
Time frame: Approximately up to 13 years
Absolute Serum Immunoglobulin G Values at Indicated Time Points
Serum immunoglobulin G values were assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study.
Time frame: Approximately up to 13 years
Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points
Serum immunoglobulin G values were assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value.
Time frame: Baseline and approximately up to 13 years
Participants who completed the parent study LBSL02 (NCT00071487) through the 24-week extension period, who received belimumab 1 milligram (mg)/kilogram (kg), 4 mg/kg, 10 mg/kg or placebo in the parent study and achieved a satisfactory response were enrolled in the study.
| Milestone | Belimumab 10 mg/kg IV |
|---|---|
| Started | 298 |
| Completed | 96 |
| Not completed | 202 |
| Withdrew: Adverse event | 44 |
| Withdrew: Lack of efficacy | 22 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Non-compliance with study drug | 28 |
| Withdrew: Pregnancy | 7 |
| Withdrew: Miscommunication of visit window | 5 |
| Withdrew: Current site closed | 7 |
| Withdrew: Subject not dosed in lbsl99 | 1 |
| Withdrew: Subject moved out of the country/state | 2 |
| Withdrew: Missed visits due to staff changes | 1 |
| Withdrew: Misunderstanding of protocol | 1 |
| Withdrew: Behavioral problems and non-compliance | 1 |
| Withdrew: Sponsor request due to missed doses | 1 |
| Withdrew: Physician decision | 19 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Withdrawal by subject | 57 |
An AE is defined as any unfavorable or unintended sign, symptom, or disease that is temporally associated with the use of a study agent but is not necessarily caused by the study agent. This includes worsening (example \[eg\], increase in frequency or severity) of pre-existing conditions. An SAE is defined as an AE resulting in any of the following outcomes: death, is life threatening (that is, an immediate threat to life), inpatient hospitalization, prolongation of an existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, and is medically important.
| Participants | Belimumab 10 mg/kg IV |
|---|---|
| AE, Any time post baseline, n=296 | 294 |
| AE, Year 0-1, n=296 | 291 |
| AE, Year 1-2, n=294 | 283 |
| AE, Year 2-3, n=276 | 260 |
| AE, Year 3-4, n=250 | 239 |
| AE, Year 4-5, n=223 | 203 |
| AE, Year 5-6, n=209 | 190 |
| AE, Year 6-7, n=192 | 182 |
| AE, Year 7-8, n=178 | 162 |
| AE, Year 8-9, n=169 | 157 |
| AE, Year 9-10, n=152 | 137 |
| AE, Year 10-11, n=131 | 105 |
| AE, Year 11 plus, n=88 | 45 |
| SAE, Any time post baseline, n=296 | 182 |
| SAE, Year 0-1, n=296 | 41 |
| SAE, Year 1-2, n=294 | 43 |
| SAE, Year 2-3, n=276 | 50 |
| SAE, Year 3-4, n=250 | 30 |
| SAE, Year 4-5, n=223 | 40 |
| SAE, Year 5-6, n=209 | 33 |
| SAE, Year 6-7, n=192 | 35 |
| SAE, Year 7-8, n=178 | 34 |
| SAE, Year 8-9, n=169 | 28 |
| SAE, Year 9-10, n=152 | 25 |
| SAE, Year 10-11, n=131 | 14 |
| SAE, Year 11 plus, n=88 | 7 |
AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatmentemergent AEs are summarized. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an AE was calculated as the number of events per 100 participant years: Event Rate=100\* number of events divided by participant years. Participant years were calculated as sum across all participants (\[last visit of interval day minus first visit of interval day plus 1\] divided by 365).
| Events per 100 participant years | Belimumab 10 mg/kg IV |
|---|---|
| Infections and infestations | 285 |
| Musculoskeletal and connective tissue disorders | 276 |
| Gastrointestinal disorders | 257 |
| Skin and subcutaneous tissue disorders | 256 |
| General disorders, administration site conditions | 247 |
| Nervous system disorders | 244 |
| Respiratory, thoracic and mediastinal disorders | 241 |
| Investigations | 227 |
| Injury, poisoning and procedural complications | 221 |
| Psychiatric disorders | 180 |
| Metabolism and nutrition disorders | 144 |
| Vascular disorders | 134 |
| Eye disorders | 133 |
| Blood and lymphatic system disorders | 127 |
| Reproductive system and breast disorders | 114 |
| Renal and urinary disorders | 109 |
| Immune system disorders | 101 |
| Neoplasms benign, malignant and unspecified | 100 |
| Cardiac disorders | 86 |
| Ear and labyrinth disorders | 69 |
| Endocrine disorders | 40 |
| Hepatobiliary disorders | 27 |
| Social circumstances | 15 |
| Congenital, familial and genetic disorders | 7 |
| Pregnancy, puerperium and perinatal conditions | 5 |
SAE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatmentemergent SAEs are summarized. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pretreatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an SAE was calculated as the number of events per 100 participant years: Event Rate=100\* number of events divided by participant years. Participant years were calculated as sum across all participants (\[last visit of interval day minus first visit of interval day plus 1\] divided by 365).
| Events per 100 participant years | Belimumab 10 mg/kg IV |
|---|---|
| Infections and infestations | 69 |
| Musculoskeletal and connective tissue disorders | 44 |
| Gastrointestinal disorders | 38 |
| Nervous system disorders | 35 |
| General disorders, administration site conditions | 31 |
| Injury, poisoning and procedural complications | 29 |
| Respiratory, thoracic and mediastinal disorders | 25 |
| Cardiac disorders | 23 |
| Neoplasms benign, malignant and unspecified | 23 |
| Renal and urinary disorders | 20 |
| Vascular disorders | 19 |
| Reproductive system and breast disorders | 18 |
| Metabolism and nutrition disorders | 14 |
| Hepatobiliary disorders | 10 |
| Blood and lymphatic system disorders | 8 |
| Skin and subcutaneous tissue disorders | 8 |
| Investigations | 7 |
| Psychiatric disorders | 6 |
| Immune system disorders | 2 |
| Pregnancy, puerperium and perinatal conditions | 2 |
| Congenital, familial and genetic disorders | 1 |
| Eye disorders | 1 |
| Social circumstances | 1 |
Hematology parameters were assessed at Baseline, Week 8, 16, 24, 40, and 48 during Year 1 to 8; Week 8, 16, 24, and 40 during Year 9; Week 24 and 40 during Year 10; Week 48 during Year 11; Week 32 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
| Seconds | Belimumab 10 mg/kg IV |
|---|---|
| APTT, Year 1, Week 8, n=274 | 0.3 ± 12.60 |
| APTT, Year 1, Week 16, n=276 | -1.3 ± 7.46 |
| APTT, Year 1, Week 24, n=222 | -1.6 ± 13.61 |
| APTT, Year 1, Week 32, n=221 | -1.9 ± 7.24 |
| APTT, Year 1, Week 40, n=219 | -1.6 ± 7.00 |
| APTT, Year 1, Week 48, n=218 | -1.0 ± 7.29 |
| APTT, Year 2, Week 8, n=220 | -0.3 ± 6.73 |
| APTT, Year 2, Week 16, n=214 | -0.2 ± 8.79 |
| APTT, Year 2, Week 24, n=212 | 0.6 ± 13.81 |
| APTT, Year 2, Week 32, n=35 | 1.5 ± 9.20 |
| APTT, Year 2, Week 40, n=28 | 2.6 ± 7.53 |
| APTT, Year 2, Week 48, n=21 | 3.0 ± 8.69 |
| APTT, Year 3, Week 8, n=25 | 2.4 ± 10.70 |
| APTT, Year 3, Week 16, n=23 | 2.3 ± 7.77 |
| APTT, Year 3, Week 24, n=23 | 1.7 ± 6.30 |
| APTT, Year 3, Week 32, n=22 | 5.4 ± 10.01 |
| APTT, Year 3, Week 40, n=18 | 2.1 ± 9.62 |
| APTT, Year 3, Week 48, n=18 | 3.9 ± 17.23 |
| APTT, Year 4, Week 8, n=14 | 2.9 ± 11.42 |
| APTT, Year 4, Week 16, n=16 | 3.1 ± 8.97 |
| APTT, Year 4, Week 24, n=10 | 1.1 ± 10.29 |
| APTT, Year 4, Week 32, n=18 | 2.1 ± 11.37 |
| APTT, Year 4, Week 40, n=13 | -2.1 ± 10.02 |
| APTT, Year 4, Week 48, n=11 | 2.2 ± 11.83 |
| APTT, Year 5, Week 8, n=4 | 3.0 ± 14.76 |
| APTT, Year 5, Week 16, n=11 | 1.3 ± 5.62 |
| APTT, Year 5, Week 24, n=3 | 13.0 ± 11.53 |
| APTT, Year 5, Week 32, n=12 | 3.1 ± 6.64 |
| APTT, Year 5, Week 40, n=10 | -0.5 ± 8.03 |
| APTT, Year 5, Week 48, n=3 | 12.3 ± 5.51 |
| APTT, Year 6, Week 8, n=3 | -2.3 ± 19.50 |
| APTT, Year 6, Week 16, n=3 | 9.0 ± 12.12 |
| APTT, Year 6, Week 24, n=3 | 14.0 ± 16.52 |
| APTT, Year 6, Week 32, n=2 | 6.5 ± 17.68 |
| APTT, Year 6, Week 40, n=8 | 9.9 ± 9.11 |
| APTT, Year 6, Week 48, n=4 | 18.3 ± 4.99 |
| APTT, Year 7, Week 8, n=1 | 27.0 ± NA |
| APTT, Year 7, Week 16, n=2 | 24.5 ± 14.85 |
| APTT, Year 7, Week 24, n=2 | 19.5 ± 6.36 |
| APTT, Year 7, Week 32, n=1 | 7.0 ± NA |
| APTT, Year 7, Week 40, n=2 | 16.5 ± 16.26 |
| APTT, Year 7, Week 48, n=2 | 18.5 ± 2.12 |
| APTT, Year 8, Week 8, n=3 | 11.7 ± 18.04 |
| APTT, Year 8, Week 16, n=3 | 15.7 ± 10.07 |
| APTT, Year 8, Week 24, n=3 | 21.3 ± 22.50 |
| APTT, Year 8, Week 32, n=3 | 8.7 ± 14.36 |
| APTT, Year 8, Week 40, n=2 | 25.0 ± 5.66 |
| APTT, Year 8, Week 48, n=3 | 13.3 ± 15.01 |
| APTT, Year 9, Week 8, n=3 | 10.3 ± 9.07 |
| APTT, Year 9, Week 16, n=3 | 11.0 ± 9.85 |
| APTT, Year 9, Week 24, n=2 | 24.0 ± 25.46 |
| APTT, Year 9, Week 32, n=4 | -11.0 ± 21.91 |
| APTT, Year 9, Week 40, n=1 | 20.0 ± NA |
| APTT, Year 10, Week 24, n=1 | 10.0 ± NA |
| APTT, Year 10, Week 40, n=1 | -9 ± NA |
| APTT, Year 11, Week 48, n=1 | -27.0 ± NA |
| APTT, Year 13, Week 32, n=1 | 26 ± NA |
| APTT, Exit, n=10 | 2.3 ± 9.66 |
| APTT, 8-Week Follow-up, n=6 | 3.8 ± 6.24 |
| APTT, 24-Week Follow-up, n=3 | -12.3 ± 16.56 |
| PT, Year 1, Week 8, n=278 | -0.67 ± 12.222 |
| PT, Year 1, Week 16, n=276 | -0.98 ± 12.134 |
| PT, Year 1, Week 24, n=222 | -1.00 ± 13.859 |
| PT, Year 1, Week 32, n=223 | -0.89 ± 13.887 |
| PT, Year 1, Week 40, n=221 | -0.67 ± 14.262 |
| PT, Year 1, Week 48, n=219 | -0.95 ± 13.496 |
| PT, Year 2, Week 8, n=221 | -0.87 ± 13.364 |
| PT, Year 2, Week 16, n=215 | -0.84 ± 13.682 |
| PT, Year 2, Week 24, n=214 | -0.66 ± 14.156 |
| PT, Year 2, Week 32, n=35 | 0.85 ± 6.887 |
| PT, Year 2, Week 40, n=28 | 3.28 ± 11.046 |
| PT, Year 2, Week 48, n=22 | 1.75 ± 8.747 |
| PT, Year 3, Week 8, n=25 | 1.75 ± 12.409 |
| PT, Year 3, Week 16, n=23 | 0.39 ± 5.469 |
| PT, Year 3, Week 24, n=23 | 0.98 ± 3.120 |
| PT, Year 3, Week 32, n=22 | 4.29 ± 10.640 |
| PT, Year 3, Week 40, n=18 | 2.02 ± 8.833 |
| PT, Year 3, Week 48, n=18 | 3.23 ± 15.863 |
| PT, Year 4, Week 8, n=14 | 4.14 ± 9.948 |
| PT, Year 4, Week 16, n=16 | 0.69 ± 8.188 |
| PT, Year 4, Week 24, n=10 | 2.10 ± 8.506 |
| PT, Year 4, Week 32, n=18 | 1.87 ± 11.251 |
| PT, Year 4, Week 40, n=13 | -2.70 ± 6.698 |
| PT, Year 4, Week 48, n=11 | 0.60 ± 9.651 |
| PT, Year 5, Week 8, n=4 | -0.43 ± 12.189 |
| PT, Year 5, Week 16, n=11 | 2.52 ± 6.118 |
| PT, Year 5, Week 24, n=3 | 9.90 ± 8.347 |
| PT, Year 5, Week 32, n=12 | 0.67 ± 3.731 |
| PT, Year 5, Week 40, n=10 | -0.33 ± 5.443 |
| PT, Year 5, Week 48, n=3 | 13.23 ± 9.064 |
| PT, Year 6, Week 8, n=3 | -2.93 ± 7.859 |
| PT, Year 6, Week 16, n=3 | 2.10 ± 5.336 |
| PT, Year 6, Week 24, n=3 | 7.60 ± 11.623 |
| PT, Year 6, Week 32, n=2 | 4.55 ± 21.425 |
| PT, Year 6, Week 40, n=8 | 2.30 ± 5.865 |
| PT, Year 6, Week 48, n=4 | 6.18 ± 10.637 |
| PT, Year 7, Week 8, n=1 | 19.90 ± NA |
| PT, Year 7, Week 16, n=2 | 18.20 ± 14.425 |
| PT, Year 7, Week 24, n=2 | 7.35 ± 0.636 |
| PT, Year 7, Week 32, n=1 | 4.00 ± NA |
| PT, Year 7, Week 40, n=2 | 11.15 ± 19.587 |
| PT, Year 7, Week 48, n=2 | 11.50 ± 4.808 |
| PT, Year 8, Week 8, n=3 | 12.47 ± 15.546 |
| PT, Year 8, Week 16, n=3 | 7.57 ± 6.799 |
| PT, Year 8, Week 24, n=3 | 12.87 ± 13.787 |
| PT, Year 8, Week 32, n=3 | 5.63 ± 9.850 |
| PT, Year 8, Week 40, n=2 | 26.60 ± 13.435 |
| PT, Year 8, Week 48, n=3 | 11.07 ± 9.845 |
| PT, Year 9, Week 8, n=3 | 8.23 ± 7.976 |
| PT, Year 9, Week 16, n=3 | 4.60 ± 6.773 |
| PT, Year 9, Week 24, n=2 | 25.75 ± 36.416 |
| PT, Year 9, Week 32, n=4 | -10.08 ± 8.139 |
| PT, Year 9, Week 40, n=1 | 21.40 ± NA |
| PT, Year 10, Week 24, n=1 | 1.30 ± NA |
| PT, Year 10, Week 40, n=1 | -8.00 ± NA |
| PT, Year 11, Week 48, n=1 | -22.80 ± NA |
| PT, Year 13, Week 32, n=1 | 14.80 ± NA |
| PT, Exit, n=10 | 0.64 ± 5.559 |
| PT, 8-Week Follow-up, n=6 | -0.95 ± 4.561 |
| PT, 24-Week Follow-up, n=3 | -10.23 ± 11.657 |
Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils segmented and platelets is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
| 10^9 per liter | Belimumab 10 mg/kg IV |
|---|---|
| Basophils, Year 1, Week 8, n=287 | 0.001 ± 0.0163 |
| Basophils, Year 1, Week 16, n=288 | 0.000 ± 0.0181 |
| Basophils, Year 1, Week 24, n=293 | 0.000 ± 0.0171 |
| Basophils, Year 1, Week 32, n=290 | 0.002 ± 0.0166 |
| Basophils, Year 1, Week 40, n=287 | 0.001 ± 0.0159 |
| Basophils, Year 1, Week 48, n=287 | 0.001 ± 0.0178 |
| Basophils, Year 2, Week 8, n=288 | 0.001 ± 0.0164 |
| Basophils, Year 2, Week 16, n=279 | 0.002 ± 0.0172 |
| Basophils, Year 2, Week 24, n=276 | 0.001 ± 0.0168 |
| Basophils, Year 2, Week 32, n=281 | 0.003 ± 0.0179 |
| Basophils, Year 2, Week 40, n=262 | 0.002 ± 0.0162 |
| Basophils, Year 2, Week 48, n=260 | 0.003 ± 0.0174 |
| Basophils, Year 3, Week 8, n=260 | 0.003 ± 0.0167 |
| Basophils, Year 3, Week 16, n=258 | 0.004 ± 0.0177 |
| Basophils, Year 3, Week 24, n=242 | 0.002 ± 0.0160 |
| Basophils, Year 3, Week 32, n=248 | 0.004 ± 0.0204 |
| Basophils, Year 3, Week 40, n=242 | 0.004 ± 0.0178 |
| Basophils, Year 3, Week 48, n=240 | 0.002 ± 0.0172 |
| Basophils, Year 4, Week 8, n=234 | 0.001 ± 0.0189 |
| Basophils, Year 4, Week 16, n=238 | 0.003 ± 0.0183 |
| Basophils, Year 4, Week 24, n=227 | 0.003 ± 0.0160 |
| Basophils, Year 4, Week 32, n=229 | 0.003 ± 0.0174 |
| Basophils, Year 4, Week 40, n=216 | 0.004 ± 0.0174 |
| Basophils, Year 4, Week 48, n=220 | 0.002 ± 0.0181 |
| Basophils, Year 5, Week 8, n=215 | 0.004 ± 0.0173 |
| Basophils, Year 5, Week 16, n=214 | 0.003 ± 0.0182 |
| Basophils, Year 5, Week 24, n=207 | 0.003 ± 0.0174 |
| Basophils, Year 5, Week 32, n=207 | 0.002 ± 0.0159 |
| Basophils, Year 5, Week 40, n=196 | 0.003 ± 0.0184 |
| Basophils, Year 5, Week 48, n=209 | 0.004 ± 0.0177 |
| Basophils, Year 6, Week 8, n=206 | 0.004 ± 0.0183 |
| Basophils, Year 6, Week 16, n=195 | 0.004 ± 0.0203 |
| Basophils, Year 6, Week 24, n=192 | 0.003 ± 0.0212 |
| Basophils, Year 6, Week 32, n=197 | 0.004 ± 0.0177 |
| Basophils, Year 6, Week 40, n=183 | 0.003 ± 0.0157 |
| Basophils, Year 6, Week 48, n=188 | 0.002 ± 0.0174 |
| Basophils, Year 7, Week 8, n=180 | 0.002 ± 0.0194 |
| Basophils, Year 7, Week 16, n=181 | 0.001 ± 0.0186 |
| Basophils, Year 7, Week 24, n=176 | 0.003 ± 0.0178 |
| Basophils, Year 7, Week 32, n=179 | 0.004 ± 0.0173 |
| Basophils, Year 7, Week 40, n=177 | 0.004 ± 0.0172 |
| Basophils, Year 7, Week 48, n=173 | 0.004 ± 0.0171 |
| Basophils, Year 8, Week 8, n=172 | 0.003 ± 0.0184 |
| Basophils, Year 8, Week 16, n=173 | 0.005 ± 0.0167 |
| Basophils, Year 8, Week 24, n=170 | 0.005 ± 0.0160 |
| Basophils, Year 8, Week 32, n=169 | 0.003 ± 0.0165 |
| Basophils, Year 8, Week 40, n=162 | 0.005 ± 0.0177 |
| Basophils, Year 8, Week 48, n=161 | 0.004 ± 0.0187 |
| Basophils, Year 9, Week 8, n=164 | 0.006 ± 0.0227 |
| Basophils, Year 9, Week 16, n=161 | 0.005 ± 0.0194 |
| Basophils, Year 9, Week 24, n=163 | 0.004 ± 0.0170 |
| Basophils, Year 9, Week 32, n=159 | 0.004 ± 0.0167 |
| Basophils, Year 9, Week 40, n=156 | 0.004 ± 0.0180 |
| Basophils, Year 9, Week 48, n=151 | 0.003 ± 0.0153 |
| Basophils, Year 10, Week 8, n=149 | 0.002 ± 0.0183 |
| Basophils, Year 10, Week 16, n=145 | 0.006 ± 0.0205 |
| Basophils, Year 10, Week 24, n=147 | 0.003 ± 0.0186 |
| Basophils, Year 10, Week 32, n=142 | 0.005 ± 0.0214 |
| Basophils, Year 10, Week 40, n=137 | 0.004 ± 0.0192 |
| Basophils, Year 10, Week 48, n=137 | 0.006 ± 0.0185 |
| Basophils, Year 11, Week 8, n=137 | 0.004 ± 0.0200 |
| Basophils, Year 11, Week 16, n=130 | 0.004 ± 0.0188 |
| Basophils, Year 11, Week 24, n=130 | 0.005 ± 0.0176 |
| Basophils, Year 11, Week 32, n=128 | 0.006 ± 0.0187 |
| Basophils, Year 11, Week 40, n=122 | 0.006 ± 0.0232 |
| Basophils, Year 11, Week 48, n=106 | 0.005 ± 0.0189 |
| Basophils, Year 12, Week 8, n=109 | 0.007 ± 0.0209 |
| Basophils, Year 12, Week 16, n=97 | 0.004 ± 0.0197 |
| Basophils, Year 12, Week 24, n=86 | 0.007 ± 0.0204 |
| Basophils, Year 12, Week 32, n=88 | 0.004 ± 0.0213 |
| Basophils, Year 12, Week 40, n=83 | 0.007 ± 0.0201 |
| Basophils, Year 12, Week 48, n=72 | 0.006 ± 0.0172 |
| Basophils, Year 13, Week 8, n=53 | 0.005 ± 0.0173 |
| Basophils, Year 13, Week 16, n=42 | 0.006 ± 0.0178 |
| Basophils, Year 13, Week 24, n=20 | 0.008 ± 0.0170 |
| Basophils, Year 13, Week 32, n=7 | 0.014 ± 0.0151 |
| Basophils, Year 13, Week 40, n=1 | 0.020 ± NA |
| Basophils, Exit, n=241 | 0.005 ± 0.0171 |
| Basophils, 8-Week Follow-up, n=219 | 0.006 ± 0.0205 |
| Basophils, 24-Week Follow-up, n=198 | 0.006 ± 0.0213 |
| Eosinophils, Year 1, Week 8, n=287 | 0.003 ± 0.0999 |
| Eosinophils, Year 1, Week 16, n=288 | 0.007 ± 0.1213 |
| Eosinophils, Year 1, Week 24, n=293 | 0.008 ± 0.1222 |
| Eosinophils, Year 1, Week 32, n=290 | 0.011 ± 0.1219 |
| Eosinophils, Year 1, Week 40, n=287 | 0.007 ± 0.1070 |
| Eosinophils, Year 1, Week 48, n=287 | 0.006 ± 0.1130 |
| Eosinophils, Year 2, Week 8, n=288 | 0.003 ± 0.1135 |
| Eosinophils, Year 2, Week 16, n=279 | 0.034 ± 0.1312 |
| Eosinophils, Year 2, Week 24, n=276 | 0.023 ± 0.1375 |
| Eosinophils, Year 2, Week 32, n=281 | 0.028 ± 0.1423 |
| Eosinophils, Year 2, Week 40, n=262 | 0.028 ± 0.1280 |
| Eosinophils, Year 2, Week 48, n=260 | 0.042 ± 0.1635 |
| Eosinophils, Year 3, Week 8, n=260 | 0.033 ± 0.1353 |
| Eosinophils, Year 3, Week 16, n=258 | 0.038 ± 0.1391 |
| Eosinophils, Year 3, Week 24, n=242 | 0.038 ± 0.1610 |
| Eosinophils, Year 3, Week 32, n=248 | 0.029 ± 0.1427 |
| Eosinophils, Year 3, Week 40, n=242 | 0.035 ± 0.1539 |
| Eosinophils, Year 3, Week 48, n=240 | 0.033 ± 0.1369 |
| Eosinophils, Year 4, Week 8, n=234 | 0.035 ± 0.1331 |
| Eosinophils, Year 4, Week 16, n=238 | 0.034 ± 0.1273 |
| Eosinophils, Year 4, Week 24, n=227 | 0.033 ± 0.1384 |
| Eosinophils, Year 4, Week 32, n=229 | 0.039 ± 0.1381 |
| Eosinophils, Year 4, Week 40, n=216 | 0.038 ± 0.1284 |
| Eosinophils, Year 4, Week 48, n=220 | 0.030 ± 0.1261 |
| Eosinophils, Year 5, Week 8, n=215 | 0.035 ± 0.1242 |
| Eosinophils, Year 5, Week 16, n=214 | 0.019 ± 0.1294 |
| Eosinophils, Year 5, Week 24, n=207 | 0.023 ± 0.1078 |
| Eosinophils, Year 5, Week 32, n=207 | 0.027 ± 0.1201 |
| Eosinophils, Year 5, Week 40, n=196 | 0.019 ± 0.1224 |
| Eosinophils, Year 5, Week 48, n=209 | 0.022 ± 0.1224 |
| Eosinophils, Year 6, Week 8, n=206 | 0.020 ± 0.1288 |
| Eosinophils, Year 6, Week 16, n=195 | 0.021 ± 0.1103 |
| Eosinophils, Year 6, Week 24, n=192 | 0.034 ± 0.1335 |
| Eosinophils, Year 6, Week 32, n=197 | 0.026 ± 0.1171 |
| Eosinophils, Year 6, Week 40, n=183 | 0.044 ± 0.1580 |
| Eosinophils, Year 6, Week 48, n=188 | 0.026 ± 0.1299 |
| Eosinophils, Year 7, Week 8, n=180 | 0.021 ± 0.1317 |
| Eosinophils, Year 7, Week 16, n=181 | 0.015 ± 0.1170 |
| Eosinophils, Year 7, Week 24, n=176 | 0.014 ± 0.1239 |
| Eosinophils, Year 7, Week 32, n=179 | 0.010 ± 0.1149 |
| Eosinophils, Year 7, Week 40, n=177 | 0.009 ± 0.1167 |
| Eosinophils, Year 7, Week 48, n=173 | -0.008 ± 0.1176 |
| Eosinophils, Year 8, Week 8, n=172 | -0.003 ± 0.1389 |
| Eosinophils, Year 8, Week 16, n=173 | -0.009 ± 0.1234 |
| Eosinophils, Year 8, Week 24, n=170 | -0.007 ± 0.1309 |
| Eosinophils, Year 8, Week 32, n=169 | -0.023 ± 0.1136 |
| Eosinophils, Year 8, Week 40, n=162 | -0.009 ± 0.1263 |
| Eosinophils, Year 8, Week 48, n=161 | -0.011 ± 0.1341 |
| Eosinophils, Year 9, Week 8, n=164 | -0.004 ± 0.1373 |
| Eosinophils, Year 9, Week 16, n=161 | -0.020 ± 0.1204 |
| Eosinophils, Year 9, Week 24, n=163 | -0.020 ± 0.1134 |
| Eosinophils, Year 9, Week 32, n=159 | -0.012 ± 0.1154 |
| Eosinophils, Year 9, Week 40, n=156 | -0.029 ± 0.1200 |
| Eosinophils, Year 9, Week 48, n=151 | -0.018 ± 0.1307 |
| Eosinophils, Year 10, Week 8, n=149 | -0.020 ± 0.1343 |
| Eosinophils, Year 10, Week 16, n=145 | -0.010 ± 0.1438 |
| Eosinophils, Year 10, Week 24, n=147 | -0.019 ± 0.1237 |
| Eosinophils, Year 10, Week 32, n=142 | -0.002 ± 0.1332 |
| Eosinophils, Year 10, Week 40, n=137 | -0.021 ± 0.1184 |
| Eosinophils, Year 10, Week 48, n=137 | -0.021 ± 0.1274 |
| Eosinophils, Year 11, Week 8, n=137 | -0.018 ± 0.1167 |
| Eosinophils, Year 11, Week 16, n=130 | -0.004 ± 0.1336 |
| Eosinophils, Year 11, Week 24, n=130 | 0.004 ± 0.1445 |
| Eosinophils, Year 11, Week 32, n=128 | 0.003 ± 0.1360 |
| Eosinophils, Year 11, Week 40, n=122 | -0.013 ± 0.1298 |
| Eosinophils, Year 11, Week 48, n=106 | -0.021 ± 0.1435 |
| Eosinophils, Year 12, Week 8, n=109 | -0.021 ± 0.1242 |
| Eosinophils, Year 12, Week 16, n=97 | -0.020 ± 0.1349 |
| Eosinophils, Year 12, Week 24, n=86 | -0.000 ± 0.1535 |
| Eosinophils, Year 12, Week 32, n=88 | -0.008 ± 0.1356 |
| Eosinophils, Year 12, Week 40, n=83 | -0.020 ± 0.1242 |
| Eosinophils, Year 12, Week 48, n=72 | -0.016 ± 0.1319 |
| Eosinophils, Year 13, Week 8, n=53 | -0.001 ± 0.1436 |
| Eosinophils, Year 13, Week 16, n=42 | -0.009 ± 0.1244 |
| Eosinophils, Year 13, Week 24, n=20 | 0.035 ± 0.1810 |
| Eosinophils, Year 13, Week 32, n=7 | 0.081 ± 0.0722 |
| Eosinophils, Year 13, Week 40, n=1 | 0.080 ± NA |
| Eosinophils, Exit, n=241 | 0.006 ± 0.1430 |
| Eosinophils, 8-Week Follow-up, n=219 | -0.002 ± 0.1436 |
| Eosinophils, 24-Week Follow-up, n=198 | 0.013 ± 0.2255 |
| Lymphocytes, Year 1, Week 8, n=287 | 0.006 ± 0.4143 |
| Lymphocytes, Year 1, Week 16, n=288 | -0.046 ± 0.4612 |
| Lymphocytes, Year 1, Week 24, n=293 | -0.035 ± 0.4725 |
| Lymphocytes, Year 1, Week 32, n=290 | -0.057 ± 0.4425 |
| Lymphocytes, Year 1, Week 40, n=287 | -0.074 ± 0.5084 |
| Lymphocytes, Year 1, Week 48, n=287 | -0.075 ± 0.4832 |
| Lymphocytes, Year 2, Week 8, n=288 | -0.049 ± 0.4324 |
| Lymphocytes, Year 2, Week 16, n=279 | -0.025 ± 0.4774 |
| Lymphocytes, Year 2, Week 24, n=276 | -0.053 ± 0.4949 |
| Lymphocytes, Year 2, Week 32, n=281 | -0.038 ± 0.5080 |
| Lymphocytes, Year 2, Week 40, n=262 | -0.025 ± 0.5046 |
| Lymphocytes, Year 2, Week 48, n=260 | 0.006 ± 0.4874 |
| Lymphocytes, Year 3, Week 8, n=260 | -0.037 ± 0.5202 |
| Lymphocytes, Year 3, Week 16, n=258 | -0.019 ± 0.5004 |
| Lymphocytes, Year 3, Week 24, n=242 | -0.045 ± 0.5131 |
| Lymphocytes, Year 3, Week 32, n=248 | -0.008 ± 0.4702 |
| Lymphocytes, Year 3, Week 40, n=242 | -0.015 ± 0.5407 |
| Lymphocytes, Year 3, Week 48, n=240 | -0.016 ± 0.5858 |
| Lymphocytes, Year 4, Week 8, n=234 | -0.041 ± 0.4933 |
| Lymphocytes, Year 4, Week 16, n=238 | -0.012 ± 0.4974 |
| Lymphocytes, Year 4, Week 24, n=227 | 0.034 ± 0.5406 |
| Lymphocytes, Year 4, Week 32, n=229 | 0.017 ± 0.5270 |
| Lymphocytes, Year 4, Week 40, n=216 | 0.003 ± 0.4347 |
| Lymphocytes, Year 4, Week 48, n=220 | 0.017 ± 0.4826 |
| Lymphocytes, Year 5, Week 8, n=215 | 0.012 ± 0.4654 |
| Lymphocytes, Year 5, Week 16, n=214 | 0.050 ± 0.5205 |
| Lymphocytes, Year 5, Week 24, n=207 | 0.052 ± 0.5355 |
| Lymphocytes, Year 5, Week 32, n=207 | 0.031 ± 0.5323 |
| Lymphocytes, Year 5, Week 40, n=196 | 0.057 ± 0.5482 |
| Lymphocytes, Year 5, Week 48, n=209 | 0.031 ± 0.5125 |
| Lymphocytes, Year 6, Week 8, n=206 | 0.059 ± 0.5734 |
| Lymphocytes, Year 6, Week 16, n=195 | 0.045 ± 0.5931 |
| Lymphocytes, Year 6, Week 24, n=192 | 0.087 ± 0.5757 |
| Lymphocytes, Year 6, Week 32, n=197 | 0.066 ± 0.5970 |
| Lymphocytes, Year 6, Week 40, n=183 | 0.075 ± 0.5984 |
| Lymphocytes, Year 6, Week 48, n=188 | 0.043 ± 0.5839 |
| Lymphocytes, Year 7, Week 8, n=180 | 0.110 ± 0.6114 |
| Lymphocytes, Year 7, Week 16, n=181 | 0.077 ± 0.6114 |
| Lymphocytes, Year 7, Week 24, n=176 | 0.091 ± 0.5944 |
| Lymphocytes, Year 7, Week 32, n=179 | 0.104 ± 0.5944 |
| Lymphocytes, Year 7, Week 40, n=177 | 0.075 ± 0.5385 |
| Lymphocytes, Year 7, Week 48, n=173 | 0.060 ± 0.6039 |
| Lymphocytes, Year 8, Week 8, n=172 | 0.036 ± 0.5942 |
| Lymphocytes, Year 8, Week 16, n=173 | -0.005 ± 0.5480 |
| Lymphocytes, Year 8, Week 24, n=170 | 0.030 ± 0.6126 |
| Lymphocytes, Year 8, Week 32, n=169 | -0.020 ± 0.5269 |
| Lymphocytes, Year 8, Week 40, n=162 | 0.065 ± 0.6260 |
| Lymphocytes, Year 8, Week 48, n=161 | 0.087 ± 0.7204 |
| Lymphocytes, Year 9, Week 8, n=164 | 0.090 ± 0.6612 |
| Lymphocytes, Year 9, Week 16, n=161 | 0.022 ± 0.5664 |
| Lymphocytes, Year 9, Week 24, n=163 | 0.062 ± 0.5704 |
| Lymphocytes, Year 9, Week 32, n=159 | 0.017 ± 0.5326 |
| Lymphocytes, Year 9, Week 40, n=156 | 0.069 ± 0.6410 |
| Lymphocytes, Year 9, Week 48, n=151 | 0.064 ± 0.5979 |
| Lymphocytes, Year 10, Week 8, n=149 | 0.046 ± 0.5547 |
| Lymphocytes, Year 10, Week 16, n=145 | 0.089 ± 0.6336 |
| Lymphocytes, Year 10, Week 24, n=147 | 0.033 ± 0.5811 |
| Lymphocytes, Year 10, Week 32, n=142 | 0.076 ± 0.5914 |
| Lymphocytes, Year 10, Week 40, n=137 | 0.071 ± 0.5621 |
| Lymphocytes, Year 10, Week 48, n=137 | 0.073 ± 0.5807 |
| Lymphocytes, Year 11, Week 8, n=137 | 0.112 ± 0.5764 |
| Lymphocytes, Year 11, Week 16, n=130 | 0.112 ± 0.6926 |
| Lymphocytes, Year 11, Week 24, n=130 | 0.129 ± 0.7026 |
| Lymphocytes, Year 11, Week 32, n=128 | 0.139 ± 0.6249 |
| Lymphocytes, Year 11, Week 40, n=122 | 0.143 ± 0.6927 |
| Lymphocytes, Year 11, Week 48, n=106 | 0.133 ± 0.5942 |
| Lymphocytes, Year 12, Week 8, n=109 | 0.145 ± 0.5976 |
| Lymphocytes, Year 12, Week 16, n=97 | 0.179 ± 0.5839 |
| Lymphocytes, Year 12, Week 24, n=86 | 0.150 ± 0.5857 |
| Lymphocytes, Year 12, Week 32, n=88 | 0.135 ± 0.6319 |
| Lymphocytes, Year 12, Week 40, n=83 | 0.150 ± 0.6512 |
| Lymphocytes, Year 12, Week 48, n=72 | 0.106 ± 0.5855 |
| Lymphocytes, Year 13, Week 8, n=53 | 0.133 ± 0.6269 |
| Lymphocytes, Year 13, Week 16, n=42 | 0.078 ± 0.6783 |
| Lymphocytes, Year 13, Week 24, n=20 | 0.131 ± 0.6760 |
| Lymphocytes, Year 13, Week 32, n=7 | 0.293 ± 0.8019 |
| Lymphocytes, Year 13, Week 40, n=1 | 0.160 ± NA |
| Lymphocytes, Exit, n=241 | 0.088 ± 0.6208 |
| Lymphocytes, 8-Week Follow-up, n=219 | 0.119 ± 0.6554 |
| Lymphocytes, 24-Week Follow-up, n=198 | 0.054 ± 0.6847 |
| Monocytes, Year 1, Week 8, n=287 | 0.014 ± 0.1795 |
| Monocytes, Year 1, Week 16, n=288 | 0.018 ± 0.1903 |
| Monocytes, Year 1, Week 24, n=293 | 0.007 ± 0.1834 |
| Monocytes, Year 1, Week 32, n=290 | 0.016 ± 0.1666 |
| Monocytes, Year 1, Week 40, n=287 | 0.020 ± 0.1750 |
| Monocytes, Year 1, Week 48, n=287 | 0.018 ± 0.1739 |
| Monocytes, Year 2, Week 8, n=288 | 0.009 ± 0.1718 |
| Monocytes, Year 2, Week 16, n=279 | 0.016 ± 0.1783 |
| Monocytes, Year 2, Week 24, n=276 | 0.029 ± 0.1764 |
| Monocytes, Year 2, Week 32, n=281 | 0.018 ± 0.1842 |
| Monocytes, Year 2, Week 40, n=262 | 0.014 ± 0.1848 |
| Monocytes, Year 2, Week 48, n=260 | 0.030 ± 0.1594 |
| Monocytes, Year 3, Week 8, n=260 | 0.024 ± 0.1677 |
| Monocytes, Year 3, Week 16, n=258 | 0.038 ± 0.1705 |
| Monocytes, Year 3, Week 24, n=242 | 0.034 ± 0.1632 |
| Monocytes, Year 3, Week 32, n=248 | 0.022 ± 0.1776 |
| Monocytes, Year 3, Week 40, n=242 | 0.044 ± 0.1650 |
| Monocytes, Year 3, Week 48, n=240 | 0.039 ± 0.1855 |
| Monocytes, Year 4, Week 8, n=234 | 0.035 ± 0.1687 |
| Monocytes, Year 4, Week 16, n=238 | 0.039 ± 0.1665 |
| Monocytes, Year 4, Week 24, n=227 | 0.032 ± 0.1667 |
| Monocytes, Year 4, Week 32, n=229 | 0.027 ± 0.1566 |
| Monocytes, Year 4, Week 40, n=216 | 0.035 ± 0.1688 |
| Monocytes, Year 4, Week 48, n=220 | 0.015 ± 0.1771 |
| Monocytes, Year 5, Week 8, n=215 | 0.018 ± 0.1824 |
| Monocytes, Year 5, Week 16, n=214 | 0.036 ± 0.1527 |
| Monocytes, Year 5, Week 24, n=207 | 0.041 ± 0.1632 |
| Monocytes, Year 5, Week 32, n=207 | 0.039 ± 0.1625 |
| Monocytes, Year 5, Week 40, n=196 | 0.049 ± 0.1510 |
| Monocytes, Year 5, Week 48, n=209 | 0.050 ± 0.1628 |
| Monocytes, Year 6, Week 8, n=206 | 0.045 ± 0.1670 |
| Monocytes, Year 6, Week 16, n=195 | 0.033 ± 0.1700 |
| Monocytes, Year 6, Week 24, n=192 | 0.030 ± 0.1556 |
| Monocytes, Year 6, Week 32, n=197 | 0.048 ± 0.1635 |
| Monocytes, Year 6, Week 40, n=183 | 0.051 ± 0.1342 |
| Monocytes, Year 6, Week 48, n=188 | 0.038 ± 0.1665 |
| Monocytes, Year 7, Week 8, n=180 | 0.028 ± 0.1507 |
| Monocytes, Year 7, Week 16, n=181 | 0.030 ± 0.1482 |
| Monocytes, Year 7, Week 24, n=176 | 0.033 ± 0.1583 |
| Monocytes, Year 7, Week 32, n=179 | 0.039 ± 0.1534 |
| Monocytes, Year 7, Week 40, n=177 | 0.047 ± 0.1391 |
| Monocytes, Year 7, Week 48, n=173 | 0.055 ± 0.1508 |
| Monocytes, Year 8, Week 8, n=172 | 0.071 ± 0.1536 |
| Monocytes, Year 8, Week 16, n=173 | 0.072 ± 0.1464 |
| Monocytes, Year 8, Week 24, n=170 | 0.075 ± 0.1545 |
| Monocytes, Year 8, Week 32, n=169 | 0.049 ± 0.1414 |
| Monocytes, Year 8, Week 40, n=162 | 0.070 ± 0.1480 |
| Monocytes, Year 8, Week 48, n=161 | 0.072 ± 0.1744 |
| Monocytes, Year 9, Week 8, n=164 | 0.069 ± 0.1513 |
| Monocytes, Year 9, Week 16, n=161 | 0.063 ± 0.1462 |
| Monocytes, Year 9, Week 24, n=163 | 0.077 ± 0.1603 |
| Monocytes, Year 9, Week 32, n=159 | 0.074 ± 0.1393 |
| Monocytes, Year 9, Week 40, n=156 | 0.075 ± 0.1440 |
| Monocytes, Year 9, Week 48, n=151 | 0.063 ± 0.1576 |
| Monocytes, Year 10, Week 8, n=149 | 0.084 ± 0.1511 |
| Monocytes, Year 10, Week 16, n=145 | 0.083 ± 0.1439 |
| Monocytes, Year 10, Week 24, n=147 | 0.087 ± 0.1874 |
| Monocytes, Year 10, Week 32, n=142 | 0.077 ± 0.1517 |
| Monocytes, Year 10, Week 40, n=137 | 0.064 ± 0.1522 |
| Monocytes, Year 10, Week 48, n=137 | 0.070 ± 0.1454 |
| Monocytes, Year 11, Week 8, n=137 | 0.077 ± 0.1622 |
| Monocytes, Year 11, Week 16, n=130 | 0.077 ± 0.1484 |
| Monocytes, Year 11, Week 24, n=130 | 0.079 ± 0.1775 |
| Monocytes, Year 11, Week 32, n=128 | 0.080 ± 0.1849 |
| Monocytes, Year 11, Week 40, n=122 | 0.075 ± 0.1435 |
| Monocytes, Year 11, Week 48, n=106 | 0.075 ± 0.1854 |
| Monocytes, Year 12, Week 8, n=109 | 0.088 ± 0.2166 |
| Monocytes, Year 12, Week 16, n=97 | 0.104 ± 0.1829 |
| Monocytes, Year 12, Week 24, n=86 | 0.073 ± 0.1616 |
| Monocytes, Year 12, Week 32, n=88 | 0.065 ± 0.1682 |
| Monocytes, Year 12, Week 40, n=83 | 0.078 ± 0.1734 |
| Monocytes, Year 12, Week 48, n=72 | 0.060 ± 0.1635 |
| Monocytes, Year 13, Week 8, n=53 | 0.013 ± 0.1453 |
| Monocytes, Year 13, Week 16, n=42 | 0.061 ± 0.1882 |
| Monocytes, Year 13, Week 24, n=20 | 0.074 ± 0.1471 |
| Monocytes, Year 13, Week 32, n=7 | 0.097 ± 0.1452 |
| Monocytes, Year 13, Week 40, n=1 | 0.120 ± NA |
| Monocytes, Exit, n=241 | 0.062 ± 0.1813 |
| Monocytes, 8-Week Follow-up, n=219 | 0.061 ± 0.2153 |
| Monocytes, 24-Week Follow-up , n=198 | 0.049 ± 0.2118 |
| Neutrophils segmented, Year 1, Week 8, n=287 | 0.003 ± 1.7881 |
| Neutrophils segmented, Year 1, Week 16, n=288 | -0.107 ± 1.7909 |
| Neutrophils segmented, Year 1, Week 24, n=293 | -0.166 ± 1.9241 |
| Neutrophils segmented, Year 1, Week 32, n=290 | -0.129 ± 2.0814 |
| Neutrophils segmented, Year 1, Week 40, n=287 | -0.140 ± 1.7884 |
| Neutrophils segmented, Year 1, Week 48, n=287 | -0.223 ± 1.7187 |
| Neutrophils segmented, Year 2, Week 8, n=288 | -0.301 ± 2.0434 |
| Neutrophils segmented, Year 2, Week 16, n=279 | -0.392 ± 2.0076 |
| Neutrophils segmented, Year 2, Week 24, n=276 | -0.250 ± 2.2163 |
| Neutrophils segmented, Year 2, Week 32, n=281 | -0.129 ± 2.1622 |
| Neutrophils segmented, Year 2, Week 40, n=262 | -0.236 ± 2.1413 |
| Neutrophils segmented, Year 2, Week 48, n=260 | -0.148 ± 2.1176 |
| Neutrophils segmented, Year 3, Week 8, n=260 | -0.333 ± 2.1308 |
| Neutrophils segmented, Year 3, Week 16, n=258 | -0.308 ± 2.2022 |
| Neutrophils segmented, Year 3, Week 24, n=242 | -0.129 ± 1.9829 |
| Neutrophils segmented, Year 3, Week 32, n=248 | -0.211 ± 2.2333 |
| Neutrophils segmented, Year 3, Week 40, n=242 | -0.161 ± 1.9939 |
| Neutrophils segmented, Year 3, Week 48, n=240 | -0.159 ± 2.1315 |
| Neutrophils segmented, Year 4, Week 8, n=234 | -0.119 ± 2.0635 |
| Neutrophils segmented, Year 4, Week 16, n=238 | -0.177 ± 2.1063 |
| Neutrophils segmented, Year 4, Week 24, n=227 | -0.136 ± 1.9402 |
| Neutrophils segmented, Year 4, Week 32, n=229 | -0.123 ± 2.2231 |
| Neutrophils segmented, Year 4, Week 40, n=216 | -0.119 ± 1.9639 |
| Neutrophils segmented, Year 4, Week 48, n=220 | -0.024 ± 2.2228 |
| Neutrophils segmented, Year 5, Week 8, n=215 | -0.169 ± 2.2107 |
| Neutrophils segmented, Year 5, Week 16, n=214 | -0.189 ± 2.0362 |
| Neutrophils segmented, Year 5, Week 24, n=207 | -0.120 ± 2.0997 |
| Neutrophils segmented, Year 5, Week 32, n=207 | -0.088 ± 2.1895 |
| Neutrophils segmented, Year 5, Week 40, n=196 | -0.064 ± 2.1536 |
| Neutrophils segmented, Year 5, Week 48, n=209 | 0.014 ± 2.0473 |
| Neutrophils segmented, Year 6, Week 8, n=206 | -0.097 ± 1.9542 |
| Neutrophils segmented, Year 6, Week 16, n=195 | -0.218 ± 2.2682 |
| Neutrophils segmented, Year 6, Week 24, n=192 | -0.226 ± 2.1749 |
| Neutrophils segmented, Year 6, Week 32, n=197 | -0.144 ± 2.0689 |
| Neutrophils segmented, Year 6, Week 40, n=183 | -0.359 ± 2.2241 |
| Neutrophils segmented, Year 6, Week 48, n=188 | -0.306 ± 2.1609 |
| Neutrophils segmented, Year 7, Week 8, n=180 | -0.371 ± 2.1016 |
| Neutrophils segmented, Year 7, Week 16, n=181 | -0.410 ± 2.0287 |
| Neutrophils segmented, Year 7, Week 24, n=176 | -0.363 ± 2.2018 |
| Neutrophils segmented, Year 7, Week 32, n=179 | -0.214 ± 2.2148 |
| Neutrophils segmented, Year 7, Week 40, n=177 | -0.360 ± 2.2393 |
| Neutrophils segmented, Year 7, Week 48, n=173 | -0.423 ± 2.1389 |
| Neutrophils segmented, Year 8, Week 8, n=172 | -0.387 ± 2.1621 |
| Neutrophils segmented, Year 8, Week 16, n=173 | -0.310 ± 2.1373 |
| Neutrophils segmented, Year 8, Week 24, n=170 | -0.152 ± 2.3134 |
| Neutrophils segmented, Year 8, Week 32, n=169 | -0.218 ± 2.1233 |
| Neutrophils segmented, Year 8, Week 40, n=162 | -0.281 ± 2.2042 |
| Neutrophils segmented, Year 8, Week 48, n=161 | -0.407 ± 2.2558 |
| Neutrophils segmented, Year 9, Week 8, n=164 | -0.161 ± 2.1968 |
| Neutrophils segmented, Year 9, Week 16, n=161 | -0.332 ± 2.0436 |
| Neutrophils segmented, Year 9, Week 24, n=163 | -0.240 ± 2.1439 |
| Neutrophils segmented, Year 9, Week 32, n=159 | -0.114 ± 2.3286 |
| Neutrophils segmented, Year 9, Week 40, n=156 | -0.252 ± 2.2301 |
| Neutrophils segmented, Year 9, Week 48, n=151 | -0.268 ± 2.4153 |
| Neutrophils segmented, Year 10, Week 8, n=149 | 0.049 ± 2.4409 |
| Neutrophils segmented, Year 10, Week 16, n=145 | 0.008 ± 2.7611 |
| Neutrophils segmented, Year 10, Week 24, n=147 | -0.166 ± 2.2970 |
| Neutrophils segmented, Year 10, Week 32, n=142 | -0.299 ± 2.1597 |
| Neutrophils segmented, Year 10, Week 40, n=137 | -0.051 ± 2.1023 |
| Neutrophils segmented, Year 10, Week 48, n=137 | -0.176 ± 2.0628 |
| Neutrophils segmented, Year 11, Week 8, n=137 | -0.077 ± 2.4456 |
| Neutrophils segmented, Year 11, Week 16, n=130 | -0.035 ± 2.3922 |
| Neutrophils segmented, Year 11, Week 24, n=130 | -0.031 ± 2.2826 |
| Neutrophils segmented, Year 11, Week 32, n=128 | 0.145 ± 2.4689 |
| Neutrophils segmented, Year 11, Week 40, n=122 | -0.043 ± 2.2994 |
| Neutrophils segmented, Year 11, Week 48, n=106 | -0.004 ± 2.5913 |
| Neutrophils segmented, Year 12, Week 8, n=109 | -0.011 ± 2.5216 |
| Neutrophils segmented, Year 12, Week 16, n=97 | -0.032 ± 2.6750 |
| Neutrophils segmented, Year 12, Week 24, n=86 | -0.126 ± 2.2583 |
| Neutrophils segmented, Year 12, Week 32, n=88 | -0.081 ± 2.5744 |
| Neutrophils segmented, Year 12, Week 40, n=83 | -0.293 ± 2.2448 |
| Neutrophils segmented, Year 12, Week 48, n=72 | -0.126 ± 2.9212 |
| Neutrophils segmented, Year 13, Week 8, n=53 | -0.747 ± 2.7599 |
| Neutrophils segmented, Year 13, Week 16, n=42 | 0.169 ± 2.5731 |
| Neutrophils segmented, Year 13, Week 24, n=20 | -0.121 ± 2.8499 |
| Neutrophils segmented, Year 13, Week 32, n=7 | -0.927 ± 2.9565 |
| Neutrophils segmented, Year 13, Week 40, n=1 | -0.680 ± NA |
| Neutrophils segmented, Exit, n=241 | 0.436 ± 2.6133 |
| Neutrophils segmented, 8-Week Follow-up, n=219 | 0.514 ± 3.6918 |
| Neutrophils segmented, 24-Week Follow-up, n=198 | 0.369 ± 2.6988 |
| Platelets, Year 1, Week ,8 n=279 | 3.7 ± 34.73 |
| Platelets, Year 1, Week 16, n=279 | 4.5 ± 34.48 |
| Platelets, Year 1, Week 24, n=286 | 7.9 ± 36.76 |
| Platelets, Year 1, Week 32, n=285 | 10.3 ± 41.03 |
| Platelets, Year 1, Week 40, n=283 | 13.1 ± 39.75 |
| Platelets, Year 1, Week 48, n=282 | 13.2 ± 46.13 |
| Platelets, Year 2, Week 8, n=280 | 18.1 ± 48.14 |
| Platelets, Year 2, Week 16, n=276 | 15.4 ± 45.99 |
| Platelets, Year 2, Week 24, n=273 | 16.7 ± 49.67 |
| Platelets, Year 2, Week 32, n=277 | 24.0 ± 50.04 |
| Platelets, Year 2, Week 40, n=259 | 21.9 ± 46.95 |
| Platelets, Year 2, Week 48, n=255 | 21.2 ± 50.63 |
| Platelets, Year 3, Week 8, n=256 | 22.0 ± 53.16 |
| Platelets, Year 3, Week 16, n=253 | 22.7 ± 55.76 |
| Platelets, Year 3, Week 24, n=239 | 18.4 ± 50.97 |
| Platelets, Year 3, Week 32, n=243 | 14.1 ± 50.03 |
| Platelets, Year 3, Week 40, n=240 | 14.3 ± 55.47 |
| Platelets, Year 3, Week 48, n=235 | 12.6 ± 56.20 |
| Platelets, Year 4, Week 8, n=230 | 11.5 ± 48.78 |
| Platelets, Year 4, Week 16, n=234 | 11.7 ± 54.46 |
| Platelets, Year 4, Week 24, n=226 | 11.7 ± 51.12 |
| Platelets, Year 4, Week 32, n=220 | 9.6 ± 55.85 |
| Platelets, Year 4, Week 40, n=214 | 5.6 ± 54.44 |
| Platelets, Year 4, Week 48, n=216 | 6.7 ± 56.74 |
| Platelets, Year 5, Week 8, n=211 | 4.6 ± 62.04 |
| Platelets, Year 5, Week 16, n=212 | -2.1 ± 54.06 |
| Platelets, Year 5, Week 24, n=206 | -3.0 ± 52.05 |
| Platelets, Year 5, Week 32, n=203 | -4.8 ± 53.16 |
| Platelets, Year 5, Week 40, n=194 | -7.7 ± 51.97 |
| Platelets, Year 5, Week 48, n=206 | -3.4 ± 54.93 |
| Platelets, Year 6, Week 8, n=203 | -10.8 ± 56.67 |
| Platelets, Year 6, Week 16, n=193 | -12.7 ± 56.99 |
| Platelets, Year 6, Week 24, n=190 | -15.6 ± 51.76 |
| Platelets, Year 6, Week 32, n=194 | -12.2 ± 52.69 |
| Platelets, Year 6, Week 40, n=182 | -15.8 ± 56.24 |
| Platelets, Year 6, Week 48, n=186 | -19.5 ± 52.68 |
| Platelets, Year 7, Week 8, n=179 | -17.3 ± 53.81 |
| Platelets, Year 7, Week 16, n=179 | -24.2 ± 49.52 |
| Platelets, Year 7, Week 24, n=175 | -22.0 ± 52.19 |
| Platelets, Year 7, Week 32, n=178 | -19.4 ± 59.77 |
| Platelets, Year 7, Week 40, n=176 | -16.6 ± 63.50 |
| Platelets, Year 7, Week 48, n=171 | -14.3 ± 60.69 |
| Platelets, Year 8, Week 8, n=168 | -11.5 ± 54.16 |
| Platelets, Year 8, Week 16, n=172 | -15.0 ± 58.24 |
| Platelets, Year 8, Week 24, n=169 | -11.0 ± 56.12 |
| Platelets, Year 8, Week 32, n=168 | -13.9 ± 55.53 |
| Platelets, Year 8, Week 40, n=161 | -12.0 ± 62.73 |
| Platelets, Year 8, Week 48, n=161 | -8.9 ± 80.44 |
| Platelets, Year 9, Week 8, n=162 | -8.4 ± 64.02 |
| Platelets, Year 9, Week 16, n=160 | -11.7 ± 68.06 |
| Platelets, Year 9, Week 24, n=162 | -13.6 ± 60.20 |
| Platelets, Year 9, Week 32, n=158 | -16.8 ± 62.14 |
| Platelets, Year 9, Week 40, n=156 | -13.4 ± 63.09 |
| Platelets, Year 9, Week 48, n=150 | -13.0 ± 65.20 |
| Platelets, Year 10, Week 8, n=149 | -10.9 ± 60.24 |
| Platelets, Year 10, Week 16, n=144 | -9.7 ± 62.61 |
| Platelets, Year 10, Week 24, n=146 | -9.7 ± 60.67 |
| Platelets, Year 10, Week 32, n=141 | -10.6 ± 62.35 |
| Platelets, Year 10, Week 40, n=136 | -9.5 ± 61.80 |
| Platelets, Year 10, Week 48, n=136 | -11.7 ± 61.81 |
| Platelets, Year 11, Week 8, n=136 | -8.4 ± 69.58 |
| Platelets, Year 11, Week 16, n=129 | -6.4 ± 63.81 |
| Platelets, Year 11, Week 24, n=129 | -6.7 ± 61.75 |
| Platelets, Year 11, Week 32, n=127 | -3.0 ± 65.54 |
| Platelets, Year 11, Week 40, n=121 | -5.8 ± 68.01 |
| Platelets, Year 11, Week 48, n=105 | -7.8 ± 62.13 |
| Platelets, Year 12, Week 8, n=108 | -4.1 ± 73.02 |
| Platelets, Year 12, Week 16, n=96 | -10.6 ± 68.02 |
| Platelets, Year 12, Week 24, n=84 | -11.5 ± 60.94 |
| Platelets, Year 12, Week 32, n=87 | -5.7 ± 70.98 |
| Platelets, Year 12, Week 40, n=82 | -10.7 ± 67.51 |
| Platelets, Year 12, Week 48, n=72 | -8.7 ± 80.99 |
| Platelets, Year 13, Week 8, n=53 | -8.6 ± 70.53 |
| Platelets, Year 13, Week 16, n=41 | -6.2 ± 61.57 |
| Platelets, Year 13, Week 24, n=20 | -7.1 ± 47.37 |
| Platelets, Year 13, Week 32, n=7 | -6.7 ± 51.61 |
| Platelets, Year 13, Week 40, n=1 | -29.0 ± NA |
| Platelets, Exit, n=236 | 8.4 ± 77.24 |
| Platelets, 8-Week Follow-up, n=217 | 8.2 ± 71.32 |
| Platelets, 24-Week Follow-up, n=194 | 4.0 ± 67.29 |
Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in erythrocytes is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
| 10^12 per liter | Belimumab 10 mg/kg IV |
|---|---|
| Erythrocytes, Year 1, Week 8, n=287 | 0.01 ± 0.313 |
| Erythrocytes, Year 1, Week 16, n=288 | 0.04 ± 0.361 |
| Erythrocytes, Year 1, Week 24, n=293 | 0.05 ± 0.309 |
| Erythrocytes, Year 1, Week 32, n=291 | 0.07 ± 0.301 |
| Erythrocytes, Year 1, Week 40, n=287 | 0.10 ± 0.321 |
| Erythrocytes, Year 1, Week 48, n=287 | 0.11 ± 0.338 |
| Erythrocytes, Year 2, Week 8, n=288 | 0.07 ± 0.339 |
| Erythrocytes, Year 2, Week 16, n=280 | 0.09 ± 0.320 |
| Erythrocytes, Year 2, Week 24, n=278 | 0.12 ± 0.331 |
| Erythrocytes, Year 2, Week 32, n=281 | 0.15 ± 0.331 |
| Erythrocytes, Year 2, Week 40, n=262 | 0.17 ± 0.330 |
| Erythrocytes, Year 2, Week 48, n=260 | 0.19 ± 0.336 |
| Erythrocytes, Year 3, Week 8, n=260 | 0.18 ± 0.331 |
| Erythrocytes, Year 3, Week 16, n=258 | 0.19 ± 0.347 |
| Erythrocytes, Year 3, Week 24, n=242 | 0.17 ± 0.384 |
| Erythrocytes, Year 3, Week 32, n=248 | 0.16 ± 0.356 |
| Erythrocytes, Year 3, Week 40, n=243 | 0.17 ± 0.369 |
| Erythrocytes, Year 3, Week 48, n=240 | 0.15 ± 0.368 |
| Erythrocytes, Year 4, Week 8, n=235 | 0.15 ± 0.392 |
| Erythrocytes, Year 4, Week 16, n=238 | 0.15 ± 0.367 |
| Erythrocytes, Year 4, Week 24, n=227 | 0.12 ± 0.363 |
| Erythrocytes, Year 4, Week 32, n=229 | 0.14 ± 0.394 |
| Erythrocytes, Year 4, Week 40, n=216 | 0.14 ± 0.383 |
| Erythrocytes, Year 4, Week 48, n=220 | 0.14 ± 0.420 |
| Erythrocytes, Year 5, Week 8, n=215 | 0.13 ± 0.435 |
| Erythrocytes, Year 5, Week 16, n=214 | 0.15 ± 0.432 |
| Erythrocytes, Year 5, Week 24, n=207 | 0.13 ± 0.426 |
| Erythrocytes, Year 5, Week 32, n=207 | 0.12 ± 0.430 |
| Erythrocytes, Year 5, Week 40, n=196 | 0.15 ± 0.417 |
| Erythrocytes, Year 5, Week 48, n=209 | 0.15 ± 0.420 |
| Erythrocytes, Year 6, Week 8, n=206 | 0.13 ± 0.441 |
| Erythrocytes, Year 6, Week 16, n=195 | 0.10 ± 0.448 |
| Erythrocytes, Year 6, Week 24, n=192 | 0.13 ± 0.380 |
| Erythrocytes, Year 6, Week 32, n=197 | 0.14 ± 0.420 |
| Erythrocytes, Year 6, Week 40, n=184 | 0.15 ± 0.430 |
| Erythrocytes, Year 6, Week 48, n=188 | 0.13 ± 0.401 |
| Erythrocytes, Year 7, Week 8, n=180 | 0.12 ± 0.397 |
| Erythrocytes, Year 7, Week 16, n=181 | 0.09 ± 0.407 |
| Erythrocytes, Year 7, Week 24, n=176 | 0.11 ± 0.390 |
| Erythrocytes, Year 7, Week 32, n=179 | 0.14 ± 0.395 |
| Erythrocytes, Year 7, Week 40, n=177 | 0.09 ± 0.391 |
| Erythrocytes, Year 7, Week 48, n=173 | 0.09 ± 0.394 |
| Erythrocytes, Year 8, Week 8, n=172 | 0.09 ± 0.378 |
| Erythrocytes, Year 8, Week 16, n=173 | 0.08 ± 0.368 |
| Erythrocytes, Year 8, Week 24, n=170 | 0.10 ± 0.388 |
| Erythrocytes, Year 8, Week 32, n=169 | 0.11 ± 0.373 |
| Erythrocytes, Year 8, Week 40, n=162 | 0.10 ± 0.415 |
| Erythrocytes, Year 8, Week 48, n=161 | 0.12 ± 0.411 |
| Erythrocytes, Year 9, Week 8, n=164 | 0.11 ± 0.402 |
| Erythrocytes, Year 9, Week 16, n=161 | 0.09 ± 0.396 |
| Erythrocytes, Year 9, Week 24, n=163 | 0.08 ± 0.387 |
| Erythrocytes, Year 9, Week 32, n=160 | 0.11 ± 0.409 |
| Erythrocytes, Year 9, Week 40, n=156 | 0.09 ± 0.407 |
| Erythrocytes, Year 9, Week 48, n=151 | 0.11 ± 0.431 |
| Erythrocytes, Year 10, Week 8, n=150 | 0.16 ± 0.442 |
| Erythrocytes, Year 10, Week 16, n=145 | 0.17 ± 0.411 |
| Erythrocytes, Year 10, Week 24, n=147 | 0.21 ± 0.427 |
| Erythrocytes, Year 10, Week 32, n=142 | 0.18 ± 0.419 |
| Erythrocytes, Year 10, Week 40, n=137 | 0.20 ± 0.417 |
| Erythrocytes, Year 10, Week 48, n=137 | 0.19 ± 0.429 |
| Erythrocytes, Year 11, Week 8, n=137 | 0.20 ± 0.430 |
| Erythrocytes, Year 11, Week 16, n=130 | 0.24 ± 0.422 |
| Erythrocytes, Year 11, Week 24, n=130 | 0.25 ± 0.436 |
| Erythrocytes, Year 11, Week 32, n=128 | 0.27 ± 0.410 |
| Erythrocytes, Year 11, Week 40, n=122 | 0.27 ± 0.426 |
| Erythrocytes, Year 11, Week 48, n=106 | 0.25 ± 0.426 |
| Erythrocytes, Year 12, Week 8, n=109 | 0.29 ± 0.422 |
| Erythrocytes, Year 12, Week 16, n=97 | 0.28 ± 0.435 |
| Erythrocytes, Year 12, Week 24, n=86 | 0.33 ± 0.483 |
| Erythrocytes, Year 12, Week 32, n=88 | 0.26 ± 0.512 |
| Erythrocytes, Year 12, Week 40, n=83 | 0.31 ± 0.428 |
| Erythrocytes, Year 12, Week 48, n=72 | 0.32 ± 0.467 |
| Erythrocytes, Year 13, Week 8, n=53 | 0.35 ± 0.400 |
| Erythrocytes, Year 13, Week 16, n=42 | 0.34 ± 0.387 |
| Erythrocytes, Year 13, Week 24, n=20 | 0.30 ± 0.407 |
| Erythrocytes, Year 13, Week 32, n=7 | 0.20 ± 0.379 |
| Erythrocytes, Year 13, Week 40, n=1 | 0.30 ± NA |
| Erythrocytes, Exit, n=241 | 0.27 ± 0.473 |
| Erythrocytes, 8-Week Follow-up, n=220 | 0.28 ± 0.478 |
| Erythrocytes, 24-Week Follow-up , n=198 | 0.33 ± 0.539 |
Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in hematocrit is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
| Percentage of blood by volume | Belimumab 10 mg/kg IV |
|---|---|
| Hematocrit, Year 1, Week 8, n=287 | 0.11 ± 2.908 |
| Hematocrit, Year 1, Week 16, n=288 | 0.23 ± 3.109 |
| Hematocrit, Year 1, Week 24, n=293 | 0.28 ± 2.917 |
| Hematocrit, Year 1, Week 32, n=291 | 0.44 ± 2.973 |
| Hematocrit, Year 1, Week 40, n=287 | 0.60 ± 3.199 |
| Hematocrit, Year 1, Week 48, n=287 | 0.84 ± 3.431 |
| Hematocrit, Year 2, Week 8, n=288 | 0.67 ± 3.415 |
| Hematocrit, Year 2, Week 16, n=280 | 0.93 ± 3.332 |
| Hematocrit, Year 2, Week 24, n=278 | 0.96 ± 3.435 |
| Hematocrit, Year 2, Week 32, n=281 | 1.34 ± 3.496 |
| Hematocrit, Year 2, Week 40, n=262 | 1.43 ± 3.476 |
| Hematocrit, Year 2, Week 48, n=260 | 1.65 ± 3.444 |
| Hematocrit, Year 3, Week 8, n=260 | 1.54 ± 3.453 |
| Hematocrit, Year 3, Week 16, n=258 | 1.76 ± 3.508 |
| Hematocrit, Year 3, Week 24, n=242 | 1.68 ± 3.709 |
| Hematocrit, Year 3, Week 32, n=248 | 1.55 ± 3.676 |
| Hematocrit, Year 3, Week 40, n=243 | 1.55 ± 3.703 |
| Hematocrit, Year 3, Week 48, n=240 | 1.26 ± 3.726 |
| Hematocrit, Year 4, Week 8, n=235 | 1.33 ± 3.908 |
| Hematocrit, Year 4, Week 16, n=238 | 1.37 ± 3.759 |
| Hematocrit, Year 4, Week 24, n=227 | 1.27 ± 3.680 |
| Hematocrit, Year 4, Week 32, n=229 | 1.34 ± 3.955 |
| Hematocrit, Year 4, Week 40, n=216 | 1.39 ± 3.779 |
| Hematocrit, Year 4, Week 48, n=220 | 1.37 ± 4.033 |
| Hematocrit, Year 5, Week 8, n=215 | 1.27 ± 4.031 |
| Hematocrit, Year 5, Week 16, n=214 | 1.58 ± 3.917 |
| Hematocrit, Year 5, Week 24, n=207 | 1.45 ± 3.905 |
| Hematocrit, Year 5, Week 32, n=207 | 1.39 ± 3.979 |
| Hematocrit, Year 5, Week 40, n=196 | 1.59 ± 4.031 |
| Hematocrit, Year 5, Week 48, n=209 | 1.35 ± 3.929 |
| Hematocrit, Year 6, Week 8, n=206 | 1.24 ± 4.128 |
| Hematocrit, Year 6, Week 16, n=195 | 1.07 ± 4.114 |
| Hematocrit, Year 6, Week 24, n=192 | 1.43 ± 3.648 |
| Hematocrit, Year 6, Week 32, n=197 | 1.77 ± 3.822 |
| Hematocrit, Year 6, Week 40, n=184 | 2.07 ± 4.089 |
| Hematocrit, Year 6, Week 48, n=188 | 2.02 ± 3.961 |
| Hematocrit, Year 7, Week 8, n=180 | 1.80 ± 3.808 |
| Hematocrit, Year 7, Week 16, n=181 | 1.50 ± 3.883 |
| Hematocrit, Year 7, Week 24, n=176 | 1.88 ± 3.840 |
| Hematocrit, Year 7, Week 32, n=179 | 2.25 ± 3.824 |
| Hematocrit, Year 7, Week 40, n=177 | 2.07 ± 3.907 |
| Hematocrit, Year 7, Week 48, n=173 | 1.97 ± 3.958 |
| Hematocrit, Year 8, Week 8, n=172 | 1.89 ± 3.909 |
| Hematocrit, Year 8, Week 16, n=173 | 1.87 ± 3.729 |
| Hematocrit, Year 8, Week 24, n=170 | 2.12 ± 4.065 |
| Hematocrit, Year 8, Week 32, n=169 | 2.20 ± 3.954 |
| Hematocrit, Year 8, Week 40, n=162 | 2.10 ± 4.122 |
| Hematocrit, Year 8, Week 48, n=161 | 2.18 ± 4.029 |
| Hematocrit, Year 9, Week 8, n=164 | 1.99 ± 3.995 |
| Hematocrit, Year 9, Week 16, n=161 | 1.76 ± 4.114 |
| Hematocrit, Year 9, Week 24, n=163 | 1.70 ± 4.020 |
| Hematocrit, Year 9, Week 32, n=160 | 1.95 ± 4.171 |
| Hematocrit, Year 9, Week 40, n=156 | 1.88 ± 4.302 |
| Hematocrit, Year 9, Week 48, n=151 | 2.32 ± 4.174 |
| Hematocrit, Year 10, Week 8, n=150 | 2.87 ± 4.087 |
| Hematocrit, Year 10, Week 16, n=145 | 2.80 ± 4.050 |
| Hematocrit, Year 10, Week 24, n=147 | 2.94 ± 4.046 |
| Hematocrit, Year 10, Week 32, n=142 | 2.78 ± 4.046 |
| Hematocrit, Year 10, Week 40, n=137 | 2.95 ± 3.884 |
| Hematocrit, Year 10, Week 48, n=137 | 3.00 ± 4.245 |
| Hematocrit, Year 11, Week 8, n=137 | 3.04 ± 4.176 |
| Hematocrit, Year 11, Week 16, n=130 | 3.20 ± 4.155 |
| Hematocrit, Year 11, Week 24, n=130 | 2.93 ± 4.331 |
| Hematocrit, Year 11, Week 32, n=128 | 3.06 ± 3.976 |
| Hematocrit, Year 11, Week 40, n=122 | 3.15 ± 4.098 |
| Hematocrit, Year 11, Week 48, n=106 | 2.93 ± 4.356 |
| Hematocrit, Year 12, Week 8, n=109 | 3.12 ± 4.223 |
| Hematocrit, Year 12, Week 16, n=97 | 3.43 ± 4.321 |
| Hematocrit, Year 12, Week 24, n=86 | 3.74 ± 4.867 |
| Hematocrit, Year 12, Week 32, n=88 | 2.99 ± 4.826 |
| Hematocrit, Year 12, Week 40, n=83 | 3.57 ± 4.377 |
| Hematocrit, Year 12, Week 48, n=72 | 3.88 ± 4.439 |
| Hematocrit, Year 13, Week 8, n=53 | 4.20 ± 3.776 |
| Hematocrit, Year 13, Week 16, n=42 | 4.26 ± 3.803 |
| Hematocrit, Year 13, Week 24, n=20 | 3.81 ± 3.930 |
| Hematocrit, Year 13, Week 32, n=7 | 3.26 ± 4.547 |
| Hematocrit, Year 13, Week 40, n=1 | 2.20 ± NA |
| Hematocrit, Exit, n=241 | 3.35 ± 4.596 |
| Hematocrit, 8-Week Follow-up, n=220 | 3.46 ± 4.690 |
| Hematocrit, 24-Week Follow-up , n=198 | 3.51 ± 4.627 |
Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in hemoglobin is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
| grams per liter | Belimumab 10 mg/kg IV |
|---|---|
| Hemoglobin, Year 1, Week 8, n=287 | 0.1 ± 9.42 |
| Hemoglobin, Year 1, Week 16, n=288 | 0.6 ± 10.60 |
| Hemoglobin, Year 1, Week 24, n=293 | 1.5 ± 9.86 |
| Hemoglobin, Year 1, Week 32, n=291 | 2.2 ± 10.37 |
| Hemoglobin, Year 1, Week 40, n=287 | 2.8 ± 10.84 |
| Hemoglobin, Year 1, Week 48, n=287 | 2.9 ± 11.39 |
| Hemoglobin, Year 2, Week 8, n=288 | 2.2 ± 11.62 |
| Hemoglobin, Year 2, Week 16, n=280 | 2.8 ± 11.54 |
| Hemoglobin, Year 2, Week 24, n=278 | 3.2 ± 12.20 |
| Hemoglobin, Year 2, Week 32, n=281 | 4.5 ± 12.19 |
| Hemoglobin, Year 2, Week 40, n=262 | 4.9 ± 12.15 |
| Hemoglobin, Year 2, Week 48, n=260 | 5.6 ± 12.10 |
| Hemoglobin, Year 3, Week 8, n=260 | 4.8 ± 12.01 |
| Hemoglobin, Year 3, Week 16, n=258 | 5.2 ± 12.15 |
| Hemoglobin, Year 3, Week 24, n=242 | 5.4 ± 12.47 |
| Hemoglobin, Year 3, Week 32, n=248 | 5.6 ± 12.59 |
| Hemoglobin, Year 3, Week 40, n=243 | 5.9 ± 12.90 |
| Hemoglobin, Year 3, Week 48, n=240 | 5.1 ± 12.97 |
| Hemoglobin, Year 4, Week 8, n=235 | 5.2 ± 13.49 |
| Hemoglobin, Year 4, Week 16, n=238 | 5.2 ± 13.11 |
| Hemoglobin, Year 4, Week 24, n=227 | 4.1 ± 13.05 |
| Hemoglobin, Year 4, Week 32, n=229 | 4.9 ± 13.64 |
| Hemoglobin, Year 4, Week 40, n=216 | 4.9 ± 13.25 |
| Hemoglobin, Year 4, Week 48, n=220 | 5.3 ± 13.94 |
| Hemoglobin, Year 5, Week 8, n=215 | 5.1 ± 14.20 |
| Hemoglobin, Year 5, Week 16, n=214 | 5.5 ± 13.44 |
| Hemoglobin, Year 5, Week 24, n=207 | 4.4 ± 13.73 |
| Hemoglobin, Year 5, Week 32, n=207 | 4.1 ± 13.39 |
| Hemoglobin, Year 5, Week 40, n=196 | 5.2 ± 14.31 |
| Hemoglobin, Year 5, Week 48, n=209 | 5.4 ± 14.20 |
| Hemoglobin, Year 6, Week 8, n=206 | 5.5 ± 14.72 |
| Hemoglobin, Year 6, Week 16, n=195 | 4.8 ± 14.82 |
| Hemoglobin, Year 6, Week 24, n=192 | 5.6 ± 12.80 |
| Hemoglobin, Year 6, Week 32, n=197 | 5.9 ± 13.12 |
| Hemoglobin, Year 6, Week 40, n=184 | 6.6 ± 13.96 |
| Hemoglobin, Year 6, Week 48, n=188 | 6.4 ± 13.78 |
| Hemoglobin, Year 7, Week 8, n=180 | 6.3 ± 13.58 |
| Hemoglobin, Year 7, Week 16, n=181 | 5.5 ± 13.83 |
| Hemoglobin, Year 7, Week 24, n=176 | 6.0 ± 13.51 |
| Hemoglobin, Year 7, Week 32, n=179 | 7.0 ± 13.37 |
| Hemoglobin, Year 7, Week 40, n=177 | 6.4 ± 13.61 |
| Hemoglobin, Year 7, Week 48, n=173 | 5.6 ± 13.91 |
| Hemoglobin, Year 8, Week 8, n=172 | 5.7 ± 13.69 |
| Hemoglobin, Year 8, Week 16, n=173 | 5.3 ± 13.09 |
| Hemoglobin, Year 8, Week 24, n=170 | 6.1 ± 14.13 |
| Hemoglobin, Year 8, Week 32, n=169 | 5.8 ± 13.33 |
| Hemoglobin, Year 8, Week 40, n=162 | 4.9 ± 13.93 |
| Hemoglobin, Year 8, Week 48, n=161 | 5.5 ± 13.95 |
| Hemoglobin, Year 9, Week 8, n=164 | 5.5 ± 13.79 |
| Hemoglobin, Year 9, Week 16, n=161 | 4.9 ± 14.60 |
| Hemoglobin, Year 9, Week 24, n=163 | 4.6 ± 14.32 |
| Hemoglobin, Year 9, Week 32, n=160 | 5.2 ± 14.39 |
| Hemoglobin, Year 9, Week 40, n=156 | 3.9 ± 15.20 |
| Hemoglobin, Year 9, Week 48, n=151 | 4.8 ± 14.50 |
| Hemoglobin, Year 10, Week 8, n=150 | 6.5 ± 14.46 |
| Hemoglobin, Year 10, Week 16, n=145 | 6.5 ± 14.05 |
| Hemoglobin, Year 10, Week 24, n=147 | 6.5 ± 14.20 |
| Hemoglobin, Year 10, Week 32, n=142 | 5.9 ± 14.02 |
| Hemoglobin, Year 10, Week 40, n=137 | 6.0 ± 13.29 |
| Hemoglobin, Year 10, Week 48, n=137 | 5.7 ± 14.86 |
| Hemoglobin, Year 11, Week 8, n=137 | 5.9 ± 14.40 |
| Hemoglobin, Year 11, Week 16, n=130 | 6.4 ± 14.50 |
| Hemoglobin, Year 11, Week 24, n=130 | 5.9 ± 15.02 |
| Hemoglobin, Year 11, Week 32, n=128 | 6.3 ± 13.79 |
| Hemoglobin, Year 11, Week 40, n=122 | 6.7 ± 14.03 |
| Hemoglobin, Year 11, Week 48, n=106 | 6.2 ± 14.95 |
| Hemoglobin, Year 12, Week 8, n=109 | 6.8 ± 14.55 |
| Hemoglobin, Year 12, Week 16, n=97 | 8.1 ± 15.12 |
| Hemoglobin, Year 12, Week 24, n=86 | 8.9 ± 16.83 |
| Hemoglobin, Year 12, Week 32, n=88 | 6.6 ± 17.18 |
| Hemoglobin, Year 12, Week 40, n=83 | 7.0 ± 15.41 |
| Hemoglobin, Year 12, Week 48, n=72 | 8.3 ± 14.80 |
| Hemoglobin, Year 13, Week 8, n=53 | 8.4 ± 12.37 |
| Hemoglobin, Year 13, Week 16, n=42 | 8.0 ± 12.81 |
| Hemoglobin, Year 13, Week 24, n=20 | 6.3 ± 12.01 |
| Hemoglobin, Year 13, Week 32, n=7 | 5.4 ± 14.27 |
| Hemoglobin, Year 13, Week 40, n=1 | 3.0 ± NA |
| Hemoglobin, Exit, n=241 | 7.4 ± 15.11 |
| Hemoglobin, 8-Week Follow-up, n=220 | 6.7 ± 15.46 |
| Hemoglobin, 24-Week Follow-up , n=198 | 6.8 ± 14.91 |
Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in albumin and protein is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
| grams/liter | Belimumab 10 mg/kg IV |
|---|---|
| Albumin, Year 1, Week 8, n=284 | 0.1 ± 2.36 |
| Albumin, Year 1, Week 16, n=286 | -0.2 ± 2.68 |
| Albumin, Year 1, Week 24, n=292 | 0.2 ± 2.74 |
| Albumin, Year 1, Week 32, n=287 | 0.1 ± 2.91 |
| Albumin, Year 1, Week 40, n=284 | 0.2 ± 3.06 |
| Albumin, Year 1, Week 48, n=287 | 0.3 ± 3.21 |
| Albumin, Year 2, Week 8, n=288 | 0.4 ± 2.84 |
| Albumin, Year 2, Week 16, n=278 | 0.4 ± 2.95 |
| Albumin, Year 2, Week 24, n=273 | 0.1 ± 3.17 |
| Albumin, Year 2, Week 32, n=284 | 0.7 ± 3.08 |
| Albumin, Year 2, Week 40, n=264 | 0.8 ± 2.92 |
| Albumin, Year 2, Week 48, n=269 | 1.1 ± 3.25 |
| Albumin, Year 3, Week 8, n=265 | 0.7 ± 3.39 |
| Albumin, Year 3, Week 16, n=260 | 1.0 ± 3.05 |
| Albumin, Year 3, Week 24, n=244 | 1.2 ± 3.23 |
| Albumin, Year 3, Week 32, n=249 | 1.3 ± 3.13 |
| Albumin, Year 3, Week 40, n=245 | 1.4 ± 3.11 |
| Albumin, Year 3, Week 48, n=244 | 1.5 ± 3.12 |
| Albumin, Year 4, Week 8, n=239 | 1.4 ± 3.36 |
| Albumin, Year 4, Week 16, n=238 | 1.3 ± 3.21 |
| Albumin, Year 4, Week 24, n=227 | 1.2 ± 3.15 |
| Albumin, Year 4, Week 32, n=233 | 1.3 ± 3.31 |
| Albumin, Year 4, Week 40, n=220 | 1.2 ± 3.29 |
| Albumin, Year 4, Week 48, n=218 | 1.6 ± 3.57 |
| Albumin, Year 5, Week 8, n=218 | 1.6 ± 3.37 |
| Albumin, Year 5, Week 16, n=214 | 1.5 ± 3.07 |
| Albumin, Year 5, Week 24, n=211 | 1.5 ± 3.36 |
| Albumin, Year 5, Week 32, n=211 | 1.9 ± 3.34 |
| Albumin, Year 5, Week 40, n=198 | 1.8 ± 3.40 |
| Albumin, Year 5, Week 48, n=207 | 1.7 ± 3.41 |
| Albumin, Year 6, Week 8, n=206 | 1.8 ± 3.27 |
| Albumin, Year 6, Week 16, n=198 | 1.5 ± 3.72 |
| Albumin, Year 6, Week 24, n=190 | 1.6 ± 3.32 |
| Albumin, Year 6, Week 32, n=193 | 2.0 ± 3.71 |
| Albumin, Year 6, Week 40, n=185 | 1.9 ± 3.52 |
| Albumin, Year 6, Week 48, n=186 | 1.9 ± 3.64 |
| Albumin, Year 7, Week 8, n=179 | 1.9 ± 3.36 |
| Albumin, Year 7, Week 16, n=179 | 1.7 ± 3.57 |
| Albumin, Year 7, Week 24, n=173 | 1.7 ± 3.88 |
| Albumin, Year 7, Week 32, n=180 | 1.9 ± 3.53 |
| Albumin, Year 7, Week 40, n=175 | 1.6 ± 3.41 |
| Albumin, Year 7, Week 48, n=175 | 1.6 ± 3.60 |
| Albumin, Year 8, Week 8, n=171 | 1.7 ± 3.61 |
| Albumin, Year 8, Week 16, n=170 | 1.5 ± 3.31 |
| Albumin, Year 8, Week 24, n=168 | 1.6 ± 3.47 |
| Albumin, Year 8, Week 32, n=168 | 1.7 ± 3.25 |
| Albumin, Year 8, Week 40, n=162 | 1.3 ± 3.46 |
| Albumin, Year 8, Week 48, n=159 | 1.7 ± 3.56 |
| Albumin, Year 9, Week 8, n=164 | 2.0 ± 3.97 |
| Albumin, Year 9, Week 16, n=162 | 1.9 ± 3.58 |
| Albumin, Year 9, Week 24, n=161 | 1.6 ± 3.38 |
| Albumin, Year 9, Week 32, n=163 | 1.9 ± 3.27 |
| Albumin, Year 9, Week 40, n=156 | 1.6 ± 3.54 |
| Albumin, Year 9, Week 48, n=151 | 1.9 ± 3.55 |
| Albumin, Year 10, Week 8, n=152 | 1.9 ± 3.64 |
| Albumin, Year 10, Week 16, n=143 | 2.1 ± 3.55 |
| Albumin, Year 10, Week 24, n=145 | 2.0 ± 3.85 |
| Albumin, Year 10, Week 32, n=142 | 2.1 ± 4.05 |
| Albumin, Year 10, Week 40, n=138 | 1.8 ± 3.78 |
| Albumin, Year 10, Week 48, n=135 | 2.0 ± 3.52 |
| Albumin, Year 11, Week 8, n=138 | 2.0 ± 3.74 |
| Albumin, Year 11, Week 16, n=128 | 2.2 ± 3.58 |
| Albumin, Year 11, Week 24, n=130 | 2.1 ± 3.87 |
| Albumin, Year 11, Week 32, n=125 | 1.8 ± 3.89 |
| Albumin, Year 11, Week 40, n=124 | 1.7 ± 3.69 |
| Albumin, Year 11, Week 48, n=108 | 1.8 ± 3.91 |
| Albumin, Year 12, Week 8, n=110 | 1.8 ± 3.43 |
| Albumin, Year 12, Week 16, n=97 | 1.9 ± 3.68 |
| Albumin, Year 12, Week 24, n=87 | 2.5 ± 4.01 |
| Albumin, Year 12, Week 32, n=84 | 1.9 ± 4.01 |
| Albumin, Year 12, Week 40, n=82 | 1.7 ± 3.76 |
| Albumin, Year 12, Week 48, n=72 | 2.1 ± 3.67 |
| Albumin, Year 13, Week 8, n=53 | 2.8 ± 3.68 |
| Albumin, Year 13, Week 16, n=42 | 2.3 ± 3.61 |
| Albumin, Year 13, Week 24, n=20 | 2.5 ± 3.30 |
| Albumin, Year 13, Week 32, n=7 | 1.1 ± 2.67 |
| Albumin, Year 13, Week 40, n=1 | 5.0 ± NA |
| Albumin, Exit, n=248 | 2.0 ± 4.02 |
| Albumin, 8-Week Follow-up, n=220 | 1.6 ± 3.92 |
| Albumin, 24-Week Follow-up , n=200 | 2.2 ± 4.24 |
| Protein, Year 1, Week 8, n=284 | -1.3 ± 4.31 |
| Protein, Year 1, Week 16, n=286 | -1.8 ± 4.63 |
| Protein, Year 1, Week 24, n=292 | -1.5 ± 4.76 |
| Protein, Year 1, Week 32, n=287 | -1.7 ± 4.69 |
| Protein, Year 1, Week 40, n=284 | -1.6 ± 5.0 |
| Protein, Year 1, Week 48, n=287 | -2.0 ± 5.01 |
| Protein, Year 2, Week 8, n=288 | -2.1 ± 4.74 |
| Protein, Year 2, Week 16, n=278 | -2.5 ± 4.66 |
| Protein, Year 2, Week 24, n=273 | -2.9 ± 5.07 |
| Protein, Year 2, Week 32, n=284 | -2.4 ± 5.13 |
| Protein, Year 2, Week 40, n=264 | -2.4 ± 4.87 |
| Protein, Year 2, Week 48, n=269 | -1.5 ± 5.18 |
| Protein, Year 3, Week 8, n=265 | -2.2 ± 5.49 |
| Protein, Year 3, Week 16, n=260 | -2.0 ± 5.19 |
| Protein, Year 3, Week 24, n=244 | -1.9 ± 5.63 |
| Protein, Year 3, Week 32, n=249 | -1.8 ± 5.19 |
| Protein, Year 3, Week 40, n=245 | -1.6 ± 5.34 |
| Protein, Year 3, Week 48, n=244 | -1.8 ± 5.16 |
| Protein, Year 4, Week 8, n=239 | -2.1 ± 5.27 |
| Protein, Year 4, Week 16, n=238 | -1.8 ± 4.93 |
| Protein, Year 4, Week 24, n=227 | -2.5 ± 5.06 |
| Protein, Year 4, Week 32, n=233 | -2.3 ± 5.02 |
| Protein, Year 4, Week 40, n=220 | -2.8 ± 4.97 |
| Protein, Year 4, Week 48, n=218 | -2.2 ± 5.44 |
| Protein, Year 5, Week 8, n=218 | -2.5 ± 5.34 |
| Protein, Year 5, Week 16, n=214 | -2.6 ± 5.09 |
| Protein, Year 5, Week 24, n=211 | -3.2 ± 5.22 |
| Protein, Year 5, Week 32, n=211 | -2.5 ± 5.05 |
| Protein, Year 5, Week 40, n=198 | -2.9 ± 5.47 |
| Protein, Year 5, Week 48, n=207 | -2.8 ± 5.67 |
| Protein, Year 6, Week 8, n=206 | -3.1 ± 5.39 |
| Protein, Year 6, Week 16, n=198 | -3.4 ± 5.75 |
| Protein, Year 6, Week 24, n=190 | -3.5 ± 5.6 |
| Protein, Year 6, Week 32, n=193 | -3.0 ± 5.77 |
| Protein, Year 6, Week 40, n=185 | -3.4 ± 5.84 |
| Protein, Year 6, Week 48, n=186 | -3.5 ± 6.0 |
| Protein, Year 7, Week 8, n=179 | -3.6 ± 5.52 |
| Protein, Year 7, Week 16, n=179 | -4.1 ± 5.87 |
| Protein, Year 7, Week 24, n=173 | -3.9 ± 5.96 |
| Protein, Year 7, Week 32, n=180 | -3.7 ± 5.68 |
| Protein, Year 7, Week 40, n=175 | -4.2 ± 5.39 |
| Protein, Year 7, Week 48, n=175 | -4.5 ± 5.6 |
| Protein, Year 8, Week 8, n=171 | -4.6 ± 5.75 |
| Protein, Year 8, Week 16, n=170 | -4.7 ± 5.37 |
| Protein, Year 8, Week 24, n=168 | -4.7 ± 5.54 |
| Protein, Year 8, Week 32, n=168 | -4.5 ± 5.46 |
| Protein, Year 8, Week 40, n=162 | -5.2 ± 5.36 |
| Protein, Year 8, Week 48, n=159 | -4.5 ± 5.3 |
| Protein, Year 9, Week 8, n=164 | -4.5 ± 5.75 |
| Protein, Year 9, Week 16, n=162 | -4.8 ± 5.34 |
| Protein, Year 9, Week 24, n=161 | -5.0 ± 5.32 |
| Protein, Year 9, Week 32, n=163 | -4.8 ± 5.18 |
| Protein, Year 9, Week 40, n=156 | -5.4 ± 5.51 |
| Protein, Year 9, Week 48, n=151 | -5.1 ± 5.6 |
| Protein, Year 10, Week 8, n=152 | -5.2 ± 5.86 |
| Protein, Year 10, Week 16, n=143 | -5.0 ± 5.79 |
| Protein, Year 10, Week 24, n=145 | -5.2 ± 5.88 |
| Protein, Year 10, Week 32, n=142 | -5.1 ± 5.98 |
| Protein, Year 10, Week 40, n=138 | -5.4 ± 5.98 |
| Protein, Year 10, Week 48, n=135 | -5.4 ± 5.62 |
| Protein, Year 11, Week 8, n=138 | -5.4 ± 6.15 |
| Protein, Year 11, Week 16, n=128 | -5.1 ± 5.51 |
| Protein, Year 11, Week 24, n=130 | -5.1 ± 6.15 |
| Protein, Year 11, Week 32, n=125 | -5.6 ± 6.12 |
| Protein, Year 11, Week 40, n=124 | -5.6 ± 5.81 |
| Protein, Year 11, Week 48, n=108 | -5.4 ± 6.42 |
| Protein, Year 12, Week 8, n=110 | -5.0 ± 5.65 |
| Protein, Year 12, Week 16, n=97 | -5.1 ± 5.86 |
| Protein, Year 12, Week 24, n=87 | -4.6 ± 6.26 |
| Protein, Year 12, Week 32, n=84 | -5.1 ± 5.82 |
| Protein, Year 12, Week 40, n=82 | -5.7 ± 5.35 |
| Protein, Year 12, Week 48, n=72 | -5.0 ± 5.86 |
| Protein, Year 13, Week 8, n=53 | -4.8 ± 6.0 |
| Protein, Year 13, Week 16, n=42 | -5.6 ± 6.04 |
| Protein, Year 13, Week 24, n=20 | -4.4 ± 6.3 |
| Protein, Year 13, Week 32, n=7 | -8.9 ± 5.08 |
| Protein, Year 13, Week 40, n=1 | 1.0 ± NA |
| Protein, Exit, n=248 | -3.2 ± 6.12 |
| Protein, 8-Week Follow-up, n=220 | -3.7 ± 6.39 |
| Protein, 24-Week Follow-up , n=200 | -2.6 ± 6.72 |
Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in BUN, glucose, calcium, carbon dioxide, chloride, magnesium, phosphate, potassium and sodium is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
| millimoles per liter | Belimumab 10 mg/kg IV |
|---|---|
| BUN, Year 1, Week 8, n=284 | 0.0189 ± 1.4412 |
| BUN, Year 1, Week 16, n=286 | -0.0836 ± 1.4928 |
| BUN, Year 1, Week 24, n=292 | -0.0281 ± 1.5612 |
| BUN, Year 1, Week 32, n=287 | -0.0199 ± 1.4020 |
| BUN, Year 1, Week 40, n=284 | -0.1823 ± 1.3626 |
| BUN, Year 1, Week 48, n=287 | 0.0224 ± 1.6607 |
| BUN, Year 2, Week 8, n=288 | -0.0607 ± 1.5714 |
| BUN, Year 2, Week 16, n=278 | -0.0796 ± 1.6220 |
| BUN, Year 2, Week 24, n=273 | -0.0850 ± 1.6900 |
| BUN, Year 2, Week 32, n=284 | -0.0779 ± 1.8263 |
| BUN, Year 2, Week 40, n=264 | -0.1136 ± 1.7293 |
| BUN, Year 2, Week 48, n=269 | -0.0571 ± 1.7035 |
| BUN, Year 3, Week 8, n=265 | -0.0620 ± 1.6580 |
| BUN, Year 3, Week 16, n=260 | -0.0357 ± 1.7963 |
| BUN, Year 3, Week 24, n=244 | 0.0775 ± 1.9949 |
| BUN, Year 3, Week 32, n=249 | 0.0129 ± 1.8758 |
| BUN, Year 3, Week 40, n=245 | 0.0903 ± 1.9922 |
| BUN, Year 3, Week 48, n=244 | 0.1346 ± 2.1131 |
| BUN, Year 4, Week 8, n=239 | 0.1658 ± 1.9076 |
| BUN, Year 4, Week 16, n=238 | 0.0900 ± 1.7799 |
| BUN, Year 4, Week 24, n=227 | 0.1258 ± 2.0386 |
| BUN, Year 4, Week 32, n=233 | 0.0812 ± 1.8611 |
| BUN, Year 4, Week 40, n=220 | 0.0325 ± 2.0164 |
| BUN, Year 4, Week 48, n=218 | 0.2948 ± 2.3008 |
| BUN, Year 5, Week 8, n=218 | 0.2047 ± 2.0007 |
| BUN, Year 5, Week 16, n=214 | 0.2669 ± 1.8316 |
| BUN, Year 5, Week 24, n=211 | 0.2064 ± 2.0558 |
| BUN, Year 5, Week 32, n=211 | 0.0558 ± 1.7962 |
| BUN, Year 5, Week 40, n=198 | 0.2632 ± 2.0944 |
| BUN, Year 5, Week 48, n=207 | 0.1794 ± 2.0505 |
| BUN, Year 6, Week 8, n=206 | 0.2773 ± 1.8758 |
| BUN, Year 6, Week 16, n=198 | 0.2632 ± 1.8983 |
| BUN, Year 6, Week 24, n=190 | 0.1447 ± 2.0291 |
| BUN, Year 6, Week 32, n=193 | 0.2960 ± 2.1213 |
| BUN, Year 6, Week 40, n=185 | 0.3184 ± 2.1795 |
| BUN, Year 6, Week 48, n=186 | 0.3647 ± 1.9359 |
| BUN, Year 7, Week 8, n=179 | 0.2852 ± 2.1528 |
| BUN, Year 7, Week 16, n=179 | 0.3191 ± 2.0398 |
| BUN, Year 7, Week 24, n=173 | 0.2683 ± 2.5539 |
| BUN, Year 7, Week 32, n=180 | 0.1686 ± 2.1547 |
| BUN, Year 7, Week 40, n=175 | 0.2285 ± 1.9007 |
| BUN, Year 7, Week 48, n=175 | 0.2326 ± 2.3098 |
| BUN, Year 8, Week 8, n=171 | 0.2234 ± 2.3330 |
| BUN, Year 8, Week 16, n=170 | 0.1932 ± 2.1219 |
| BUN, Year 8, Week 24, n=168 | 0.2189 ± 2.0413 |
| BUN, Year 8, Week 32, n=168 | 0.0680 ± 2.0995 |
| BUN, Year 8, Week 40, n=162 | 0.1234 ± 2.0504 |
| BUN, Year 8, Week 48, n=159 | 0.2560 ± 1.8494 |
| BUN, Year 9, Week 8, n=164 | 0.1197 ± 1.6667 |
| BUN, Year 9, Week 16, n=162 | 0.1719 ± 1.8226 |
| BUN, Year 9, Week 24, n=161 | 0.1397 ± 1.9255 |
| BUN, Year 9, Week 32, n=163 | 0.2979 ± 1.9020 |
| BUN, Year 9, Week 40, n=156 | 0.1304 ± 1.8027 |
| BUN, Year 9, Week 48, n=151 | 0.0804 ± 1.9432 |
| BUN, Year 10, Week 8, n=152 | 0.1973 ± 2.1517 |
| BUN, Year 10, Week 16, n=143 | 0.1098 ± 1.8916 |
| BUN, Year 10, Week 24, n=145 | 0.1847 ± 1.8330 |
| BUN, Year 10, Week 32, n=142 | 0.1911 ± 1.8808 |
| BUN, Year 10, Week 40, n=138 | -0.0440 ± 1.8103 |
| BUN, Year 10, Week 48, n=135 | 0.0926 ± 1.8219 |
| BUN, Year 11, Week 8, n=138 | 0.1837 ± 2.0925 |
| BUN, Year 11, Week 16, n=128 | 0.1060 ± 1.9866 |
| BUN, Year 11, Week 24, n=130 | 0.1291 ± 1.8654 |
| BUN, Year 11, Week 32, n=125 | 0.0029 ± 1.7563 |
| BUN, Year 11, Week 40, n=124 | 0.0576 ± 1.9364 |
| BUN, Year 11, Week 48, n=108 | -0.0926 ± 1.8134 |
| BUN, Year 12, Week 8, n=110 | 0.1266 ± 2.0325 |
| BUN, Year 12, Week 16, n=97 | 0.2687 ± 1.9561 |
| BUN, Year 12, Week 24, n=87 | 0.0780 ± 1.8996 |
| BUN, Year 12, Week 32, n=84 | -0.2167 ± 1.6336 |
| BUN, Year 12, Week 40, n=82 | -0.1741 ± 1.8725 |
| BUN, Year 12, Week 48, n=72 | -0.0992 ± 1.8146 |
| BUN, Year 13, Week 8, n=53 | 0.0808 ± 1.7244 |
| BUN, Year 13, Week 16, n=42 | 0.5695 ± 1.6690 |
| BUN, Year 13, Week 24, n=20 | 0.1964 ± 1.0708 |
| BUN, Year 13, Week 32, n=7 | -0.4590 ± 1.6961 |
| BUN, Year 13, Week 40, n=1 | -1.7850 ± NA |
| BUN, Exit, n=248 | 0.2519 ± 2.3492 |
| BUN, 8-Week Follow-up, n=220 | 0.0471 ± 2.3709 |
| BUN, 24-Week Follow-up , n=200 | -0.0268 ± 2.1652 |
| Glucose, Year 1, Week 8, n=284 | -0.0264 ± 1.4683 |
| Glucose, Year 1, Week 16, n=286 | 0.0314 ± 1.5221 |
| Glucose, Year 1, Week 24, n=292 | -0.0375 ± 1.6213 |
| Glucose, Year 1, Week 32, n=287 | -0.0265 ± 1.6241 |
| Glucose, Year 1, Week 40, n=284 | 0.0031 ± 1.4590 |
| Glucose, Year 1, Week 48, n=287 | 0.0232 ± 1.8176 |
| Glucose, Year 2, Week 8, n=288 | 0.0168 ± 1.6196 |
| Glucose, Year 2, Week 16, n=278 | 0.0327 ± 1.6027 |
| Glucose, Year 2, Week 24, n=273 | 0.1194 ± 1.6450 |
| Glucose, Year 2, Week 32, n=284 | 0.0510 ± 1.4905 |
| Glucose, Year 2, Week 40, n=264 | 0.0639 ± 1.5995 |
| Glucose, Year 2, Week 48, n=269 | 0.0017 ± 1.6178 |
| Glucose, Year 3, Week 8, n=265 | -0.0161 ± 1.3878 |
| Glucose, Year 3, Week 16, n=260 | -0.1223 ± 1.5965 |
| Glucose, Year 3, Week 24, n=244 | 0.0348 ± 1.9713 |
| Glucose, Year 3, Week 32, n=249 | -0.0887 ± 1.7057 |
| Glucose, Year 3, Week 40, n=245 | -0.0242 ± 1.3532 |
| Glucose, Year 3, Week 48, n=244 | -0.0271 ± 2.1535 |
| Glucose, Year 4, Week 8, n=239 | -0.0451 ± 1.6912 |
| Glucose, Year 4, Week 16, n=238 | -0.1199 ± 1.7495 |
| Glucose, Year 4, Week 24, n=227 | -0.1142 ± 1.8087 |
| Glucose, Year 4, Week 32, n=233 | 0.0741 ± 1.7592 |
| Glucose, Year 4, Week 40, n=220 | 0.1204 ± 2.0200 |
| Glucose, Year 4, Week 48, n=218 | -0.0410 ± 1.9212 |
| Glucose, Year 5, Week 8, n=218 | 0.1350 ± 1.8331 |
| Glucose, Year 5, Week 16, n=214 | 0.0999 ± 1.9373 |
| Glucose, Year 5, Week 24, n=211 | 0.2402 ± 1.7548 |
| Glucose, Year 5, Week 32, n=211 | -0.0873 ± 1.5258 |
| Glucose, Year 5, Week 40, n=198 | 0.0535 ± 1.7957 |
| Glucose, Year 5, Week 48, n=207 | -0.0107 ± 1.3758 |
| Glucose, Year 6, Week 8, n=206 | 0.0385 ± 2.0336 |
| Glucose, Year 6, Week 16, n=198 | 0.0112 ± 1.6676 |
| Glucose, Year 6, Week 24, n=190 | 0.0894 ± 2.1875 |
| Glucose, Year 6, Week 32, n=193 | 0.0380 ± 1.9025 |
| Glucose, Year 6, Week 40, n=185 | 0.0939 ± 1.9242 |
| Glucose, Year 6, Week 48, n=186 | -0.0176 ± 1.7507 |
| Glucose, Year 7, Week 8, n=179 | 0.1098 ± 1.9999 |
| Glucose, Year 7, Week 16, n=179 | 0.0558 ± 2.0164 |
| Glucose, Year 7, Week 24, n=173 | 0.2118 ± 2.3731 |
| Glucose, Year 7, Week 32, n=180 | 0.1588 ± 1.6939 |
| Glucose, Year 7, Week 40, n=175 | 0.1380 ± 2.1777 |
| Glucose, Year 7, Week 48, n=175 | 0.0698 ± 1.9178 |
| Glucose, Year 8, Week 8, n=171 | 0.0217 ± 2.0227 |
| Glucose, Year 8, Week 16, n=170 | 0.0307 ± 1.9951 |
| Glucose, Year 8, Week 24, n=168 | 0.0430 ± 1.5670 |
| Glucose, Year 8, Week 32, n=168 | 0.2029 ± 2.1886 |
| Glucose, Year 8, Week 40, n=162 | 0.3481 ± 1.8895 |
| Glucose, Year 8, Week 48, n=159 | 0.2821 ± 2.3294 |
| Glucose, Year 9, Week 8, n=164 | 0.2065 ± 2.3063 |
| Glucose, Year 9, Week 16, n=162 | 0.2457 ± 2.2362 |
| Glucose, Year 9, Week 24, n=161 | 0.2065 ± 2.3096 |
| Glucose, Year 9, Week 32, n=163 | 0.1437 ± 1.7266 |
| Glucose, Year 9, Week 40, n=156 | 0.2619 ± 2.4664 |
| Glucose, Year 9, Week 48, n=151 | 0.3110 ± 1.7497 |
| Glucose, Year 10, Week 8, n=152 | 0.2184 ± 2.5367 |
| Glucose, Year 10, Week 16, n=143 | 0.2713 ± 2.2189 |
| Glucose, Year 10, Week 24, n=145 | 0.2695 ± 1.9119 |
| Glucose, Year 10, Week 32, n=142 | 0.0192 ± 2.0309 |
| Glucose, Year 10, Week 40, n=138 | 0.2277 ± 1.8718 |
| Glucose, Year 10, Week 48, n=135 | 0.2919 ± 2.2420 |
| Glucose, Year 11, Week 8, n=138 | 0.3524 ± 2.4257 |
| Glucose, Year 11, Week 16, n=128 | 0.1778 ± 2.4430 |
| Glucose, Year 11, Week 24, n=130 | 0.2818 ± 1.9155 |
| Glucose, Year 11, Week 32, n=125 | 0.2203 ± 2.2945 |
| Glucose, Year 11, Week 40, n=124 | 0.0877 ± 2.0564 |
| Glucose, Year 11, Week 48, n=108 | 0.1778 ± 2.2984 |
| Glucose, Year 12, Week 8, n=110 | 0.2861 ± 2.5700 |
| Glucose, Year 12, Week 16, n=97 | 0.0830 ± 2.1347 |
| Glucose, Year 12, Week 24, n=87 | 0.1448 ± 1.8433 |
| Glucose, Year 12, Week 32, n=84 | -0.0886 ± 2.2813 |
| Glucose, Year 12, Week 40, n=82 | 0.3209 ± 1.4176 |
| Glucose, Year 12, Week 48, n=72 | 0.3870 ± 1.4519 |
| Glucose, Year 13, Week 8, n=53 | 0.3561 ± 1.1963 |
| Glucose, Year 13, Week 16, n=42 | 0.2498 ± 1.2196 |
| Glucose, Year 13, Week 24, n=20 | 0.4663 ± 1.6396 |
| Glucose, Year 13, Week 32, n=7 | 0.3727 ± 0.8144 |
| Glucose, Year 13, Week 40, n=1 | -0.8326 ± NA |
| Glucose, Exit, n=248 | 0.1744 ± 1.9656 |
| Glucose, 8-Week Follow-up, n=220 | 0.2707 ± 1.5879 |
| Glucose, 24-Week Follow-up , n=200 | 0.3295 ± 2.1561 |
| Calcium, Year 1, Week 8, n=281 | -0.0033 ± 0.1012 |
| Calcium, Year 1, Week 16, n=283 | -0.0025 ± 0.1175 |
| Calcium, Year 1, Week 24, n=287 | 0.0156 ± 0.1036 |
| Calcium, Year 1, Week 32, n=283 | 0.0159 ± 0.1067 |
| Calcium, Year 1, Week 40, n=282 | 0.0203 ± 0.1102 |
| Calcium, Year 1, Week 48, n=284 | 0.0011 ± 0.1193 |
| Calcium, Year 2, Week 8, n=288 | 0.0010 ± 0.1093 |
| Calcium, Year 2, Week 16, n=276 | -0.0080 ± 0.1104 |
| Calcium, Year 2, Week 24, n=269 | -0.0180 ± 0.1171 |
| Calcium, Year 2, Week 32, n=284 | -0.0131 ± 0.1120 |
| Calcium, Year 2, Week 40, n=261 | -0.0071 ± 0.1091 |
| Calcium, Year 2, Week 48, n=267 | -0.0081 ± 0.1158 |
| Calcium, Year 3, Week 8, n=262 | -0.0273 ± 0.1291 |
| Calcium, Year 3, Week 16, n=258 | -0.0189 ± 0.1102 |
| Calcium, Year 3, Week 24, n=241 | -0.0205 ± 0.1165 |
| Calcium, Year 3, Week 32, n=245 | -0.0205 ± 0.1044 |
| Calcium, Year 3, Week 40, n=242 | -0.0121 ± 0.1122 |
| Calcium, Year 3, Week 48, n=239 | -0.0156 ± 0.1112 |
| Calcium, Year 4, Week 8, n=237 | -0.0183 ± 0.1147 |
| Calcium, Year 4, Week 16, n=235 | -0.0264 ± 0.1118 |
| Calcium, Year 4, Week 24, n=225 | -0.0250 ± 0.1140 |
| Calcium, Year 4, Week 32, n=230 | -0.0221 ± 0.1074 |
| Calcium, Year 4, Week 40, n=218 | -0.0220 ± 0.1105 |
| Calcium, Year 4, Week 48, n=214 | -0.0192 ± 0.1162 |
| Calcium, Year 5, Week 8, n=217 | -0.0297 ± 0.1112 |
| Calcium, Year 5, Week 16, n=213 | -0.0274 ± 0.1149 |
| Calcium, Year 5, Week 24, n=206 | -0.0292 ± 0.1179 |
| Calcium, Year 5, Week 32, n=211 | -0.0104 ± 0.1132 |
| Calcium, Year 5, Week 40, n=196 | -0.0140 ± 0.1166 |
| Calcium, Year 5, Week 48, n=207 | -0.0036 ± 0.1133 |
| Calcium, Year 6, Week 8, n=205 | -0.0127 ± 0.1086 |
| Calcium, Year 6, Week 16, n=198 | -0.0263 ± 0.1269 |
| Calcium, Year 6, Week 24, n=189 | -0.0037 ± 0.1155 |
| Calcium, Year 6, Week 32, n=192 | -0.0044 ± 0.1150 |
| Calcium, Year 6, Week 40, n=181 | -0.0123 ± 0.1068 |
| Calcium, Year 6, Week 48, n=186 | -0.0025 ± 0.1107 |
| Calcium, Year 7, Week 8, n=177 | -0.0162 ± 0.1076 |
| Calcium, Year 7, Week 16, n=178 | -0.0175 ± 0.1217 |
| Calcium, Year 7, Week 24, n=171 | -0.0163 ± 0.1169 |
| Calcium, Year 7, Week 32, n=179 | -0.0114 ± 0.1097 |
| Calcium, Year 7, Week 40, n=172 | -0.0144 ± 0.1111 |
| Calcium, Year 7, Week 48, n=175 | -0.0234 ± 0.1058 |
| Calcium, Year 8, Week 8, n=170 | -0.0203 ± 0.1144 |
| Calcium, Year 8, Week 16, n=169 | -0.0176 ± 0.1099 |
| Calcium, Year 8, Week 24, n=167 | -0.0121 ± 0.1047 |
| Calcium, Year 8, Week 32, n=166 | -0.0153 ± 0.1015 |
| Calcium, Year 8, Week 40, n=161 | -0.0254 ± 0.1111 |
| Calcium, Year 8, Week 48, n=159 | -0.0210 ± 0.1138 |
| Calcium, Year 9, Week 8, n=163 | -0.0167 ± 0.1283 |
| Calcium, Year 9, Week 16, n=160 | -0.0198 ± 0.1181 |
| Calcium, Year 9, Week 24, n=160 | -0.0253 ± 0.1231 |
| Calcium, Year 9, Week 32, n=162 | -0.0205 ± 0.1150 |
| Calcium, Year 9, Week 40, n=156 | -0.0157 ± 0.1246 |
| Calcium, Year 9, Week 48, n=150 | -0.0075 ± 0.1116 |
| Calcium, Year 10, Week 8, n=151 | -0.0114 ± 0.1050 |
| Calcium, Year 10, Week 16, n=143 | 0.0026 ± 0.1015 |
| Calcium, Year 10, Week 24, n=145 | -0.0067 ± 0.1115 |
| Calcium, Year 10, Week 32, n=140 | -0.0066 ± 0.1109 |
| Calcium, Year 10, Week 40, n=137 | -0.0067 ± 0.1157 |
| Calcium, Year 10, Week 48, n=135 | -0.0033 ± 0.1268 |
| Calcium, Year 11, Week 8, n=138 | -0.0043 ± 0.1185 |
| Calcium, Year 11, Week 16, n=128 | -0.0033 ± 0.1078 |
| Calcium, Year 11, Week 24, n=129 | -0.0116 ± 0.1304 |
| Calcium, Year 11, Week 32, n=124 | -0.0131 ± 0.1131 |
| Calcium, Year 11, Week 40, n=124 | -0.0093 ± 0.1157 |
| Calcium, Year 11, Week 48, n=107 | -0.0061 ± 0.1238 |
| Calcium, Year 12, Week 8, n=109 | -0.0153 ± 0.1214 |
| Calcium, Year 12, Week 16, n=97 | -0.0005 ± 0.1189 |
| Calcium, Year 12, Week 24, n=85 | 0.0220 ± 0.1251 |
| Calcium, Year 12, Week 32, n=84 | 0.0009 ± 0.1265 |
| Calcium, Year 12, Week 40, n=82 | -0.0103 ± 0.1247 |
| Calcium, Year 12, Week 48, n=72 | -0.0028 ± 0.1206 |
| Calcium, Year 13, Week 8, n=53 | -0.0151 ± 0.1402 |
| Calcium, Year 13, Week 16, n=42 | -0.0154 ± 0.1595 |
| Calcium, Year 13, Week 24, n=20 | 0.0037 ± 0.1435 |
| Calcium, Year 13, Week 32, n=7 | -0.0784 ± 0.1234 |
| Calcium, Year 13, Week 40, n=1 | 0.0000 ± NA |
| Calcium, Exit, n=248 | 0.0141 ± 0.1239 |
| Calcium, 8-Week Follow-up, n=220 | 0.0082 ± 0.1152 |
| Calcium, 24-Week Follow-up , n=200 | 0.0181 ± 0.1211 |
| Carbon dioxide, Year 1, Week 8, n=281 | 0.2 ± 2.54 |
| Carbon dioxide, Year 1, Week 16, n=283 | 0.7 ± 2.73 |
| Carbon dioxide, Year 1, Week 24, n=287 | 0.9 ± 2.78 |
| Carbon dioxide, Year 1, Week 32, n=283 | 1.0 ± 2.51 |
| Carbon dioxide, Year 1, Week 40, n=282 | 1.0 ± 2.75 |
| Carbon dioxide, Year 1, Week 48, n=284 | 1.3 ± 2.71 |
| Carbon dioxide, Year 2, Week 8, n=288 | 1.0 ± 2.74 |
| Carbon dioxide, Year 2, Week 16, n=275 | 1.2 ± 2.74 |
| Carbon dioxide, Year 2, Week 24, n=269 | 1.2 ± 2.96 |
| Carbon dioxide, Year 2, Week 32, n=284 | 1.3 ± 2.77 |
| Carbon dioxide, Year 2, Week 40, n=261 | 1.1 ± 2.72 |
| Carbon dioxide, Year 2, Week 48, n=267 | 1.7 ± 3.02 |
| Carbon dioxide, Year 3, Week 8, n=262 | 1.3 ± 2.83 |
| Carbon dioxide, Year 3, Week 16, n=258 | 1.5 ± 2.95 |
| Carbon dioxide, Year 3, Week 24, n=241 | 1.0 ± 2.81 |
| Carbon dioxide, Year 3, Week 32, n=245 | 1.1 ± 2.96 |
| Carbon dioxide, Year 3, Week 40, n=242 | 1.0 ± 2.94 |
| Carbon dioxide, Year 3, Week 48, n=239 | 1.3 ± 3.29 |
| Carbon dioxide, Year 4, Week 8, n=237 | 1.1 ± 2.81 |
| Carbon dioxide, Year 4, Week 16, n=235 | 1.3 ± 3.04 |
| Carbon dioxide, Year 4, Week 24, n=225 | 1.0 ± 2.84 |
| Carbon dioxide, Year 4, Week 32, n=230 | 1.1 ± 2.90 |
| Carbon dioxide, Year 4, Week 40, n=218 | 1.2 ± 3.11 |
| Carbon dioxide, Year 4, Week 48, n=214 | 1.6 ± 3.17 |
| Carbon dioxide, Year 5, Week 8, n=217 | 1.4 ± 2.93 |
| Carbon dioxide, Year 5, Week 16, n=213 | 1.7 ± 2.93 |
| Carbon dioxide, Year 5, Week 24, n=206 | 1.4 ± 2.82 |
| Carbon dioxide, Year 5, Week 32, n=211 | 1.5 ± 2.98 |
| Carbon dioxide, Year 5, Week 40, n=196 | 1.5 ± 2.91 |
| Carbon dioxide, Year 5, Week 48, n=207 | 1.7 ± 2.82 |
| Carbon dioxide, Year 6, Week 8, n=205 | 1.8 ± 3.10 |
| Carbon dioxide, Year 6, Week 16, n=198 | 1.8 ± 2.94 |
| Carbon dioxide, Year 6, Week 24, n=189 | 1.7 ± 2.77 |
| Carbon dioxide, Year 6, Week 32, n=192 | 1.7 ± 2.82 |
| Carbon dioxide, Year 6, Week 40, n=181 | 1.8 ± 3.07 |
| Carbon dioxide, Year 6, Week 48, n=186 | 1.9 ± 2.97 |
| Carbon dioxide, Year 7, Week 8, n=177 | 1.8 ± 3.12 |
| Carbon dioxide, Year 7, Week 16, n=178 | 1.6 ± 3.11 |
| Carbon dioxide, Year 7, Week 24, n=171 | 1.6 ± 3.08 |
| Carbon dioxide, Year 7, Week 32, n=179 | 1.6 ± 3.10 |
| Carbon dioxide, Year 7, Week 40, n=172 | 1.6 ± 2.83 |
| Carbon dioxide, Year 7, Week 48, n=175 | 1.6 ± 2.97 |
| Carbon dioxide, Year 8, Week 8, n=170 | 1.5 ± 3.00 |
| Carbon dioxide, Year 8, Week 16, n=169 | 1.5 ± 3.17 |
| Carbon dioxide, Year 8, Week 24, n=167 | 1.5 ± 3.08 |
| Carbon dioxide, Year 8, Week 32, n=166 | 1.5 ± 3.27 |
| Carbon dioxide, Year 8, Week 40, n=161 | 1.6 ± 3.32 |
| Carbon dioxide, Year 8, Week 48, n=159 | 1.5 ± 3.25 |
| Carbon dioxide, Year 9, Week 8, n=163 | 1.1 ± 3.26 |
| Carbon dioxide, Year 9, Week 16, n=160 | 1.4 ± 3.08 |
| Carbon dioxide, Year 9, Week 24, n=160 | 1.1 ± 2.93 |
| Carbon dioxide, Year 9, Week 32, n=162 | 1.4 ± 3.13 |
| Carbon dioxide, Year 9, Week 40, n=156 | 1.0 ± 3.30 |
| Carbon dioxide, Year 9, Week 48, n=150 | 1.0 ± 3.16 |
| Carbon dioxide, Year 10, Week 8, n=151 | 1.1 ± 2.95 |
| Carbon dioxide, Year 10, Week 16, n=143 | 1.2 ± 3.14 |
| Carbon dioxide, Year 10, Week 24, n=145 | 1.0 ± 3.14 |
| Carbon dioxide, Year 10, Week 32, n=140 | 1.5 ± 3.12 |
| Carbon dioxide, Year 10, Week 40, n=137 | 1.5 ± 3.21 |
| Carbon dioxide, Year 10, Week 48, n=135 | 1.3 ± 3.03 |
| Carbon dioxide, Year 11, Week 8, n=138 | 1.0 ± 3.13 |
| Carbon dioxide, Year 11, Week 16, n=128 | 1.5 ± 3.04 |
| Carbon dioxide, Year 11, Week 24, n=129 | 1.5 ± 3.13 |
| Carbon dioxide, Year 11, Week 32, n=124 | 1.6 ± 2.99 |
| Carbon dioxide, Year 11, Week 40, n=124 | 1.7 ± 3.03 |
| Carbon dioxide, Year 11, Week 48, n=107 | 1.7 ± 3.10 |
| Carbon dioxide, Year 12, Week 8, n=109 | 1.1 ± 3.12 |
| Carbon dioxide, Year 12, Week 16, n=97 | 2.1 ± 3.05 |
| Carbon dioxide, Year 12, Week 24, n=85 | 2.0 ± 3.12 |
| Carbon dioxide, Year 12, Week 32, n=84 | 2.3 ± 3.58 |
| Carbon dioxide, Year 12, Week 40, n=82 | 2.0 ± 3.26 |
| Carbon dioxide, Year 12, Week 48, n=72 | 1.7 ± 3.39 |
| Carbon dioxide, Year 13, Week 8, n=53 | 1.6 ± 2.90 |
| Carbon dioxide, Year 13, Week 16, n=42 | 2.0 ± 2.76 |
| Carbon dioxide, Year 13, Week 24, n=20 | 2.5 ± 3.19 |
| Carbon dioxide, Year 13, Week 32, n=7 | 1.3 ± 3.59 |
| Carbon dioxide, Year 13, Week 40, n=1 | 4.0 ± NA |
| Carbon dioxide, Exit, n=248 | 1.8 ± 2.93 |
| Carbon dioxide, 8-Week Follow-up, n=220 | 1.8 ± 3.26 |
| Carbon dioxide, 24-Week Follow-up , n=200 | 1.8 ± 3.25 |
| Chloride, Year 1, Week 8, n=284 | 0.1 ± 2.52 |
| Chloride, Year 1, Week 16, n=286 | 0.4 ± 2.76 |
| Chloride, Year 1, Week 24, n=292 | 0.0 ± 2.64 |
| Chloride, Year 1, Week 32, n=287 | 0.0 ± 2.66 |
| Chloride, Year 1, Week 40, n=284 | 0.0 ± 2.74 |
| Chloride, Year 1, Week 48, n=287 | 0.4 ± 2.90 |
| Chloride, Year 2, Week 8, n=288 | 0.2 ± 2.77 |
| Chloride, Year 2, Week 16, n=278 | 0.4 ± 2.95 |
| Chloride, Year 2, Week 24, n=273 | 0.6 ± 2.82 |
| Chloride, Year 2, Week 32, n=284 | 0.4 ± 2.80 |
| Chloride, Year 2, Week 40, n=264 | 0.3 ± 3.05 |
| Chloride, Year 2, Week 48, n=269 | 0.2 ± 2.94 |
| Chloride, Year 3, Week 8, n=265 | 0.3 ± 3.07 |
| Chloride, Year 3, Week 16, n=260 | 0.0 ± 2.91 |
| Chloride, Year 3, Week 24, n=244 | 0.1 ± 2.93 |
| Chloride, Year 3, Week 32, n=249 | -0.1 ± 2.99 |
| Chloride, Year 3, Week 40, n=245 | -0.2 ± 2.87 |
| Chloride, Year 3, Week 48, n=244 | -0.3 ± 3.29 |
| Chloride, Year 4, Week 8, n=239 | -0.2 ± 2.93 |
| Chloride, Year 4, Week 16, n=238 | -0.2 ± 3.16 |
| Chloride, Year 4, Week 24, n=227 | 0.1 ± 2.85 |
| Chloride, Year 4, Week 32, n=233 | -0.3 ± 3.12 |
| Chloride, Year 4, Week 40, n=220 | -0.4 ± 2.94 |
| Chloride, Year 4, Week 48, n=218 | -0.3 ± 3.15 |
| Chloride, Year 5, Week 8, n=218 | -0.1 ± 3.20 |
| Chloride, Year 5, Week 16, n=214 | 0.1 ± 2.80 |
| Chloride, Year 5, Week 24, n=211 | 0.2 ± 3.05 |
| Chloride, Year 5, Week 32, n=211 | -0.2 ± 3.08 |
| Chloride, Year 5, Week 40, n=198 | 0.1 ± 2.97 |
| Chloride, Year 5, Week 48, n=207 | -0.3 ± 3.00 |
| Chloride, Year 6, Week 8, n=206 | -0.2 ± 3.11 |
| Chloride, Year 6, Week 16, n=198 | -0.2 ± 3.23 |
| Chloride, Year 6, Week 24, n=190 | -0.2 ± 3.11 |
| Chloride, Year 6, Week 32, n=193 | -0.4 ± 3.31 |
| Chloride, Year 6, Week 40, n=185 | -0.3 ± 3.25 |
| Chloride, Year 6, Week 48, n=186 | -0.4 ± 3.07 |
| Chloride, Year 7, Week 8, n=179 | -0.3 ± 2.95 |
| Chloride, Year 7, Week 16, n=179 | -0.3 ± 3.10 |
| Chloride, Year 7, Week 24, n=173 | -0.2 ± 3.18 |
| Chloride, Year 7, Week 32, n=180 | -0.3 ± 4.06 |
| Chloride, Year 7, Week 40, n=175 | -0.4 ± 3.32 |
| Chloride, Year 7, Week 48, n=175 | -0.4 ± 3.24 |
| Chloride, Year 8, Week 8, n=171 | -0.3 ± 3.46 |
| Chloride, Year 8, Week 16, n=170 | -0.5 ± 3.75 |
| Chloride, Year 8, Week 24, n=168 | -0.5 ± 3.37 |
| Chloride, Year 8, Week 32, n=168 | -0.6 ± 3.30 |
| Chloride, Year 8, Week 40, n=162 | -0.4 ± 3.26 |
| Chloride, Year 8, Week 48, n=159 | -0.4 ± 3.49 |
| Chloride, Year 9, Week 8, n=164 | -0.7 ± 3.36 |
| Chloride, Year 9, Week 16, n=162 | -0.7 ± 3.26 |
| Chloride, Year 9, Week 24, n=161 | -0.3 ± 3.21 |
| Chloride, Year 9, Week 32, n=163 | -0.6 ± 3.43 |
| Chloride, Year 9, Week 40, n=156 | -0.3 ± 3.72 |
| Chloride, Year 9, Week 48, n=151 | -0.6 ± 3.76 |
| Chloride, Year 10, Week 8, n=152 | -0.6 ± 3.61 |
| Chloride, Year 10, Week 16, n=143 | -0.7 ± 3.59 |
| Chloride, Year 10, Week 24, n=145 | -0.3 ± 3.87 |
| Chloride, Year 10, Week 32, n=142 | -0.3 ± 3.72 |
| Chloride, Year 10, Week 40, n=138 | -0.2 ± 3.18 |
| Chloride, Year 10, Week 48, n=135 | -0.2 ± 3.48 |
| Chloride, Year 11, Week 8, n=138 | -0.1 ± 3.28 |
| Chloride, Year 11, Week 16, n=128 | -0.4 ± 3.41 |
| Chloride, Year 11, Week 24, n=130 | -0.5 ± 3.39 |
| Chloride, Year 11, Week 32, n=125 | -0.7 ± 3.69 |
| Chloride, Year 11, Week 40, n=124 | -0.4 ± 3.22 |
| Chloride, Year 11, Week 48, n=108 | -0.4 ± 3.33 |
| Chloride, Year 12, Week 8, n=110 | -0.3 ± 3.51 |
| Chloride, Year 12, Week 16, n=97 | -0.6 ± 3.23 |
| Chloride, Year 12, Week 24, n=87 | -0.3 ± 3.18 |
| Chloride, Year 12, Week 32, n=84 | -0.4 ± 3.01 |
| Chloride, Year 12, Week 40, n=82 | -0.4 ± 3.32 |
| Chloride, Year 12, Week 48, n=72 | -1.3 ± 3.09 |
| Chloride, Year 13, Week 8, n=53 | -0.8 ± 3.31 |
| Chloride, Year 13, Week 16, n=42 | -0.8 ± 3.00 |
| Chloride, Year 13, Week 24, n=20 | 0.0 ± 3.03 |
| Chloride, Year 13, Week 32, n=7 | 1.1 ± 3.13 |
| Chloride, Year 13, Week 40, n=1 | 0.0 ± NA |
| Chloride, Exit, n=248 | -0.8 ± 3.38 |
| Chloride, 8-Week Follow-up, n=220 | -0.8 ± 3.33 |
| Chloride, 24-Week Follow-up, n=200 | -0.8 ± 3.52 |
| Magnesium, Year 1, Week 8, n=284 | -0.003 ± 0.0646 |
| Magnesium, Year 1, Week 16, n=286 | -0.006 ± 0.0707 |
| Magnesium, Year 1, Week 24, n=292 | -0.002 ± 0.0660 |
| Magnesium, Year 1, Week 32, n=287 | -0.007 ± 0.0680 |
| Magnesium, Year 1, Week 40, n=284 | -0.007 ± 0.0657 |
| Magnesium, Year 1, Week 48, n=287 | -0.017 ± 0.0724 |
| Magnesium, Year 2, Week 8, n=288 | -0.016 ± 0.0694 |
| Magnesium, Year 2, Week 16, n=278 | -0.015 ± 0.0723 |
| Magnesium, Year 2, Week 24, n=273 | -0.020 ± 0.0704 |
| Magnesium, Year 2, Week 32, n=284 | -0.018 ± 0.0642 |
| Magnesium, Year 2, Week 40, n=264 | -0.018 ± 0.0699 |
| Magnesium, Year 2, Week 48, n=269 | -0.021 ± 0.0720 |
| Magnesium, Year 3, Week 8, n=265 | -0.029 ± 0.0709 |
| Magnesium, Year 3, Week 16, n=260 | -0.027 ± 0.0672 |
| Magnesium, Year 3, Week 24, n=244 | -0.040 ± 0.0646 |
| Magnesium, Year 3, Week 32, n=249 | -0.042 ± 0.0742 |
| Magnesium, Year 3, Week 40, n=245 | -0.054 ± 0.0712 |
| Magnesium, Year 3, Week 48, n=244 | -0.051 ± 0.0724 |
| Magnesium, Year 4, Week 8, n=239 | -0.052 ± 0.0692 |
| Magnesium, Year 4, Week 16, n=238 | -0.049 ± 0.0764 |
| Magnesium, Year 4, Week 24, n=227 | -0.046 ± 0.0720 |
| Magnesium, Year 4, Week 32, n=233 | -0.049 ± 0.0709 |
| Magnesium, Year 4, Week 40, n=220 | -0.053 ± 0.0702 |
| Magnesium, Year 4, Week 48, n=218 | -0.050 ± 0.0757 |
| Magnesium, Year 5, Week 8, n=218 | -0.052 ± 0.0676 |
| Magnesium, Year 5, Week 16, n=214 | -0.054 ± 0.0633 |
| Magnesium, Year 5, Week 24, n=211 | -0.062 ± 0.0648 |
| Magnesium, Year 5, Week 32, n=211 | -0.068 ± 0.0700 |
| Magnesium, Year 5, Week 40, n=198 | -0.063 ± 0.0709 |
| Magnesium, Year 5, Week 48, n=207 | -0.067 ± 0.0754 |
| Magnesium, Year 6, Week 8, n=206 | -0.059 ± 0.0724 |
| Magnesium, Year 6, Week 16, n=198 | -0.067 ± 0.0786 |
| Magnesium, Year 6, Week 24, n=190 | -0.065 ± 0.0724 |
| Magnesium, Year 6, Week 32, n=193 | -0.063 ± 0.0712 |
| Magnesium, Year 6, Week 40, n=185 | -0.060 ± 0.0750 |
| Magnesium, Year 6, Week 48, n=186 | -0.068 ± 0.0721 |
| Magnesium, Year 7, Week 8, n=179 | -0.052 ± 0.0746 |
| Magnesium, Year 7, Week 16, n=179 | -0.058 ± 0.0711 |
| Magnesium, Year 7, Week 24, n=173 | -0.056 ± 0.0712 |
| Magnesium, Year 7, Week 32, n=180 | -0.054 ± 0.0747 |
| Magnesium, Year 7, Week 40, n=175 | -0.050 ± 0.0826 |
| Magnesium, Year 7, Week 48, n=175 | -0.057 ± 0.0772 |
| Magnesium, Year 8, Week 8, n=171 | -0.052 ± 0.0761 |
| Magnesium, Year 8, Week 16, n=170 | -0.060 ± 0.0748 |
| Magnesium, Year 8, Week 24, n=168 | -0.051 ± 0.0739 |
| Magnesium, Year 8, Week 32, n=168 | -0.055 ± 0.0777 |
| Magnesium, Year 8, Week 40, n=162 | -0.050 ± 0.0737 |
| Magnesium, Year 8, Week 48, n=159 | -0.047 ± 0.0788 |
| Magnesium, Year 9, Week 8, n=164 | -0.049 ± 0.0793 |
| Magnesium, Year 9, Week 16, n=162 | -0.047 ± 0.0776 |
| Magnesium, Year 9, Week 24, n=161 | -0.052 ± 0.0825 |
| Magnesium, Year 9, Week 32, n=163 | -0.052 ± 0.0771 |
| Magnesium, Year 9, Week 40, n=156 | -0.048 ± 0.0840 |
| Magnesium, Year 9, Week 48, n=151 | -0.056 ± 0.0771 |
| Magnesium, Year 10, Week 8, n=152 | -0.050 ± 0.0795 |
| Magnesium, Year 10, Week 16, n=143 | -0.054 ± 0.0772 |
| Magnesium, Year 10, Week 24, n=145 | -0.055 ± 0.0770 |
| Magnesium, Year 10, Week 32, n=142 | -0.050 ± 0.0750 |
| Magnesium, Year 10, Week 40, n=138 | -0.055 ± 0.0798 |
| Magnesium, Year 10, Week 48, n=135 | -0.055 ± 0.0825 |
| Magnesium, Year 11, Week 8, n=138 | -0.057 ± 0.0823 |
| Magnesium, Year 11, Week 16, n=128 | -0.055 ± 0.0809 |
| Magnesium, Year 11, Week 24, n=130 | -0.055 ± 0.0810 |
| Magnesium, Year 11, Week 32, n=125 | -0.055 ± 0.0889 |
| Magnesium, Year 11, Week 40, n=124 | -0.044 ± 0.0842 |
| Magnesium, Year 11, Week 48, n=108 | -0.057 ± 0.0800 |
| Magnesium, Year 12, Week 8, n=110 | -0.041 ± 0.0855 |
| Magnesium, Year 12, Week 16, n=97 | -0.047 ± 0.0797 |
| Magnesium, Year 12, Week 24, n=87 | -0.040 ± 0.0846 |
| Magnesium, Year 12, Week 32, n=84 | -0.056 ± 0.0808 |
| Magnesium, Year 12, Week 40, n=82 | -0.049 ± 0.0909 |
| Magnesium, Year 12, Week 48, n=72 | -0.047 ± 0.0809 |
| Magnesium, Year 13, Week 8, n=53 | -0.045 ± 0.0834 |
| Magnesium, Year 13, Week 16, n=42 | -0.046 ± 0.0752 |
| Magnesium, Year 13, Week 24, n=20 | -0.055 ± 0.0776 |
| Magnesium, Year 13, Week 32, n=7 | -0.050 ± 0.0500 |
| Magnesium, Year 13, Week 40, n=1 | 0.050 ± NA |
| Magnesium, Exit, n=248 | -0.037 ± 0.0793 |
| Magnesium, 8-Week Follow-up, n=220 | -0.037 ± 0.0794 |
| Magnesium, 24-Week Follow-up , n=200 | -0.040 ± 0.0790 |
| Phosphate, Year 1, Week 8, n=284 | -0.0259 ± 0.1980 |
| Phosphate, Year 1, Week 16, n=286 | -0.0215 ± 0.1849 |
| Phosphate, Year 1, Week 24, n=292 | -0.0001 ± 0.2023 |
| Phosphate, Year 1, Week 32, n=287 | -0.0154 ± 0.1983 |
| Phosphate, Year 1, Week 40, n=284 | -0.0024 ± 0.1913 |
| Phosphate, Year 1, Week 48, n=287 | -0.0234 ± 0.1926 |
| Phosphate, Year 2, Week 8, n=288 | -0.0185 ± 0.1959 |
| Phosphate, Year 2, Week 16, n=278 | -0.0194 ± 0.2003 |
| Phosphate, Year 2, Week 24, n=273 | -0.0209 ± 0.1991 |
| Phosphate, Year 2, Week 32, n=284 | -0.0318 ± 0.2122 |
| Phosphate, Year 2, Week 40, n=264 | -0.0297 ± 0.2103 |
| Phosphate, Year 2, Week 48, n=269 | -0.0116 ± 0.2050 |
| Phosphate, Year 3, Week 8, n=265 | -0.04112 ± 0.2073 |
| Phosphate, Year 3, Week 16, n=260 | -0.0451 ± 0.2059 |
| Phosphate, Year 3, Week 24, n=244 | -0.0639 ± 0.2068 |
| Phosphate, Year 3, Week 32, n=249 | -0.0484 ± 0.2139 |
| Phosphate, Year 3, Week 40, n=245 | -0.0583 ± 0.2190 |
| Phosphate, Year 3, Week 48, n=244 | -0.0658 ± 0.2179 |
| Phosphate, Year 4, Week 8, n=239 | -0.0621 ± 0.2103 |
| Phosphate, Year 4, Week 16, n=238 | -0.0532 ± 0.2217 |
| Phosphate, Year 4, Week 24, n=227 | -0.0700 ± 0.2106 |
| Phosphate, Year 4, Week 32, n=233 | -0.0601 ± 0.2034 |
| Phosphate, Year 4, Week 40, n=220 | -0.0710 ± 0.2098 |
| Phosphate, Year 4, Week 48, n=218 | -0.0400 ± 0.2213 |
| Phosphate, Year 5, Week 8, n=218 | -0.0529 ± 0.2222 |
| Phosphate, Year 5, Week 16, n=214 | -0.0429 ± 0.2240 |
| Phosphate, Year 5, Week 24, n=211 | -0.0502 ± 0.1996 |
| Phosphate, Year 5, Week 32, n=211 | -0.0435 ± 0.2313 |
| Phosphate, Year 5, Week 40, n=198 | -0.0452 ± 0.2147 |
| Phosphate, Year 5, Week 48, n=207 | -0.0323 ± 0.2167 |
| Phosphate, Year 6, Week 8, n=206 | -0.0417 ± 0.2246 |
| Phosphate, Year 6, Week 16, n=198 | -0.0354 ± 0.2253 |
| Phosphate, Year 6, Week 24, n=190 | -0.0262 ± 0.2326 |
| Phosphate, Year 6, Week 32, n=193 | -0.0341 ± 0.2154 |
| Phosphate, Year 6, Week 40, n=185 | -0.0086 ± 0.2179 |
| Phosphate, Year 6, Week 48, n=186 | -0.0085 ± 0.2256 |
| Phosphate, Year 7, Week 8, n=179 | -0.0316 ± 0.2254 |
| Phosphate, Year 7, Week 16, n=179 | -0.0372 ± 0.1999 |
| Phosphate, Year 7, Week 24, n=173 | -0.0390 ± 0.2099 |
| Phosphate, Year 7, Week 32, n=180 | -0.0321 ± 0.2099 |
| Phosphate, Year 7, Week 40, n=175 | -0.0138 ± 0.2146 |
| Phosphate, Year 7, Week 48, n=175 | -0.0400 ± 0.2031 |
| Phosphate, Year 8, Week 8, n=171 | -0.0453 ± 0.2135 |
| Phosphate, Year 8, Week 16, n=170 | -0.0319 ± 0.2088 |
| Phosphate, Year 8, Week 24, n=168 | -0.0450 ± 0.2136 |
| Phosphate, Year 8, Week 32, n=168 | -0.0530 ± 0.2073 |
| Phosphate, Year 8, Week 40, n=162 | -0.0429 ± 0.2341 |
| Phosphate, Year 8, Week 48, n=159 | -0.0266 ± 0.2158 |
| Phosphate, Year 9, Week 8, n=164 | -0.0329 ± 0.2133 |
| Phosphate, Year 9, Week 16, n=162 | -0.0255 ± 0.2140 |
| Phosphate, Year 9, Week 24, n=161 | -0.0327 ± 0.2372 |
| Phosphate, Year 9, Week 32, n=163 | -0.0487 ± 0.2039 |
| Phosphate, Year 9, Week 40, n=156 | -0.0230 ± 0.2123 |
| Phosphate, Year 9, Week 48, n=151 | -0.0385 ± 0.2170 |
| Phosphate, Year 10, Week 8, n=152 | -0.0310 ± 0.2136 |
| Phosphate, Year 10, Week 16, n=143 | -0.0458 ± 0.2087 |
| Phosphate, Year 10, Week 24, n=145 | -0.0307 ± 0.2130 |
| Phosphate, Year 10, Week 32, n=142 | -0.0241 ± 0.2227 |
| Phosphate, Year 10, Week 40, n=138 | -0.0459 ± 0.2184 |
| Phosphate, Year 10, Week 48, n=135 | -0.0335 ± 0.2158 |
| Phosphate, Year 11, Week 8, n=138 | -0.0314 ± 0.2311 |
| Phosphate, Year 11, Week 16, n=128 | -0.0560 ± 0.2327 |
| Phosphate, Year 11, Week 24, n=130 | -0.0365 ± 0.2371 |
| Phosphate, Year 11, Week 32, n=125 | -0.0302 ± 0.2140 |
| Phosphate, Year 11, Week 40, n=124 | -0.0370 ± 0.2215 |
| Phosphate, Year 11, Week 48, n=108 | -0.0287 ± 0.2361 |
| Phosphate, Year 12, Week 8, n=110 | -0.0470 ± 0.2230 |
| Phosphate, Year 12, Week 16, n=97 | -0.0333 ± 0.2264 |
| Phosphate, Year 12, Week 24, n=87 | -0.0238 ± 0.2169 |
| Phosphate, Year 12, Week 32, n=84 | -0.0488 ± 0.2235 |
| Phosphate, Year 12, Week 40, n=82 | -0.0555 ± 0.2188 |
| Phosphate, Year 12, Week 48, n=72 | -0.0341 ± 0.2213 |
| Phosphate, Year 13, Week 8, n=53 | -0.0804 ± 0.2002 |
| Phosphate, Year 13, Week 16, n=42 | -0.0461 ± 0.2669 |
| Phosphate, Year 13, Week 24, n=20 | 0.0533 ± 0.1881 |
| Phosphate, Year 13, Week 32, n=7 | 0.0784 ± 0.2075 |
| Phosphate, Year 13, Week 40, n=1 | -0.1615 ± NA |
| Phosphate, Exit, n=248 | -0.0328 ± 0.2385 |
| Phosphate, 8-Week Follow-up, n=220 | -0.0631 ± 0.2221 |
| Phosphate, 24-Week Follow-up , n=200 | -0.0375 ± 0.2183 |
| Potassium, Year 1, Week 8, n=281 | -0.01 ± 0.354 |
| Potassium, Year 1, Week 16, n=283 | 0.04 ± 0.394 |
| Potassium, Year 1, Week 24, n=287 | 0.04 ± 0.406 |
| Potassium, Year 1, Week 32, n=283 | 0.01 ± 0.381 |
| Potassium, Year 1, Week 40, n=282 | 0.03 ± 0.378 |
| Potassium, Year 1, Week 48, n=284 | 0.00 ± 0.406 |
| Potassium, Year 2, Week 8, n=288 | 0.00 ± 0.370 |
| Potassium, Year 2, Week 16, n=275 | 0.03 ± 0.385 |
| Potassium, Year 2, Week 24, n=269 | 0.02 ± 0.398 |
| Potassium, Year 2, Week 32, n=284 | 0.00 ± 0.397 |
| Potassium, Year 2, Week 40, n=261 | 0.04 ± 0.378 |
| Potassium, Year 2, Week 48, n=267 | 0.01 ± 0.386 |
| Potassium, Year 3, Week 8, n=262 | 0.00 ± 0.415 |
| Potassium, Year 3, Week 16, n=258 | 0.02 ± 0.413 |
| Potassium, Year 3, Week 24, n=241 | 0.02 ± 0.407 |
| Potassium, Year 3, Week 32, n=245 | -0.02 ± 0.406 |
| Potassium, Year 3, Week 40, n=242 | 0.02 ± 0.428 |
| Potassium, Year 3, Week 48, n=239 | 0.00 ± 0.400 |
| Potassium, Year 4, Week 8, n=237 | 0.03 ± 0.414 |
| Potassium, Year 4, Week 16, n=236 | 0.00 ± 0.423 |
| Potassium, Year 4, Week 24, n=225 | 0.03 ± 0.400 |
| Potassium, Year 4, Week 32, n=230 | 0.02 ± 0.383 |
| Potassium, Year 4, Week 40, n=218 | -0.02 ± 0.396 |
| Potassium, Year 4, Week 48, n=214 | 0.02 ± 0.391 |
| Potassium, Year 5, Week 8, n=217 | 0.01 ± 0.413 |
| Potassium, Year 5, Week 16, n=213 | 0.00 ± 0.390 |
| Potassium, Year 5, Week 24, n=206 | 0.03 ± 0.420 |
| Potassium, Year 5, Week 32, n=211 | -0.01 ± 0.393 |
| Potassium, Year 5, Week 40, n=196 | 0.03 ± 0.416 |
| Potassium, Year 5, Week 48, n=207 | -0.01 ± 0.375 |
| Potassium, Year 6, Week 8, n=205 | -0.02 ± 0.424 |
| Potassium, Year 6, Week 16, n=198 | -0.04 ± 0.429 |
| Potassium, Year 6, Week 24, n=189 | 0.00 ± 0.411 |
| Potassium, Year 6, Week 32, n=192 | -0.02 ± 0.395 |
| Potassium, Year 6, Week 40, n=181 | 0.03 ± 0.435 |
| Potassium, Year 6, Week 48, n=186 | -0.01 ± 0.388 |
| Potassium,Year 7, Week 8, n=177 | 0.00 ± 0.424 |
| Potassium, Year 7, Week 16, n=178 | -0.02 ± 0.412 |
| Potassium, Year 7, Week 24, n=171 | 0.03 ± 0.388 |
| Potassium, Year 7, Week 32, n=179 | 0.02 ± 0.406 |
| Potassium, Year 7, Week 40, n=172 | 0.03 ± 0.453 |
| Potassium, Year 7, Week 48, n=175 | -0.03 ± 0.403 |
| Potassium, Year 8, Week 8, n=170 | -0.05 ± 0.426 |
| Potassium, Year 8, Week 16, n=169 | -0.05 ± 0.455 |
| Potassium, Year 8, Week 24, n=167 | 0.00 ± 0.386 |
| Potassium, Year 8, Week 32, n=166 | -0.06 ± 0.382 |
| Potassium, Year 8, Week 40, n=161 | 0.00 ± 0.401 |
| Potassium, Year 8, Week 48, n=159 | -0.07 ± 0.377 |
| Potassium, Year 9, Week 8, n=163 | -0.02 ± 0.448 |
| Potassium, Year 9, Week 16, n=160 | -0.02 ± 0.385 |
| Potassium, Year 9, Week 24, n=160 | -0.03 ± 0.391 |
| Potassium, Year 9, Week 32, n=162 | -0.05 ± 0.391 |
| Potassium, Year 9, Week 40, n=156 | -0.04 ± 0.447 |
| Potassium, Year 9, Week 48, n=150 | -0.04 ± 0.432 |
| Potassium, Year 10, Week 8, n=151 | -0.03 ± 0.417 |
| Potassium, Year 10, Week 16, n=143 | -0.05 ± 0.415 |
| Potassium, Year 10, Week 24, n=145 | 0.00 ± 0.428 |
| Potassium, Year 10, Week 32, n=140 | -0.03 ± 0.452 |
| Potassium, Year 10, Week 40, n=137 | -0.02 ± 0.433 |
| Potassium, Year 10, Week 48, n=135 | -0.02 ± 0.442 |
| Potassium, Year 11, Week 8, n=138 | -0.03 ± 0.438 |
| Potassium, Year 11, Week 16, n=128 | -0.04 ± 0.395 |
| Potassium, Year 11, Week 24, n=129 | 0.02 ± 0.433 |
| Potassium, Year 11, Week 32, n=124 | -0.08 ± 0.399 |
| Potassium, Year 11, Week 40, n=124 | -0.01 ± 0.383 |
| Potassium, Year 11, Week 48, n=107 | 0.01 ± 0.413 |
| Potassium, Year 12, Week 8, n=109 | 0.01 ± 0.422 |
| Potassium, Year 12, Week 16, n=97 | -0.02 ± 0.433 |
| Potassium, Year 12, Week 24, n=85 | 0.00 ± 0.447 |
| Potassium, Year 12, Week 32, n=84 | -0.06 ± 0.443 |
| Potassium, Year 12, Week 40, n=82 | -0.02 ± 0.411 |
| Potassium, Year 12, Week 48, n=72 | -0.06 ± 0.527 |
| Potassium, Year 13, Week 8, n=53 | -0.14 ± 0.401 |
| Potassium, Year 13, Week 16, n=42 | -0.09 ± 0.416 |
| Potassium, Year 13, Week 24, n=20 | 0.01 ± 0.525 |
| Potassium, Year 13, Week 32, n=7 | -0.19 ± 0.389 |
| Potassium, Year 13, Week 40, n=1 | 0.60 ± NA |
| Potassium, Exit, n=248 | 0.03 ± 0.409 |
| Potassium, 8-Week Follow-up, n=220 | 0.01 ± 0.415 |
| Potassium, 24-Week Follow-up , n=200 | 0.02 ± 0.411 |
| Sodium, Year 1, Week 8, n=284 | 0.1 ± 2.76 |
| Sodium, Year 1, Week 16, n=286 | 0.2 ± 2.91 |
| Sodium, ,Year 1, Week 24, n=292 | 0.0 ± 2.78 |
| Sodium, Year 1, Week 32, n=287 | 0.0 ± 2.83 |
| Sodium, Year 1, Week 40, n=284 | -0.2 ± 2.64 |
| Sodium, Year 1, Week 48, n=287 | -0.1 ± 2.75 |
| Sodium, Year 2, Week 8, n=288 | 0.0 ± 2.64 |
| Sodium, Year 2, Week 16, n=278 | 0.1 ± 2.74 |
| Sodium, Year 2, Week 24, n=273 | 0.1 ± 2.72 |
| Sodium, Year 2, Week 32, n=284 | -0.3 ± 2.79 |
| Sodium, Year 2, Week 40, n=264 | -0.2 ± 2.67 |
| Sodium, Year 2, Week 48, n=269 | -0.1 ± 2.86 |
| Sodium, Year 3, Week 8, n=265 | -0.3 ± 2.81 |
| Sodium, Year 3, Week 16, n=260 | -0.3 ± 2.90 |
| Sodium, Year 3, Week 24, n=244 | -0.2 ± 2.76 |
| Sodium, Year 3, Week 32, n=249 | -0.2 ± 2.74 |
| Sodium, Year 3, Week 40, n=245 | -0.2 ± 2.77 |
| Sodium, Year 3, Week 48, n=244 | -0.3 ± 2.91 |
| Sodium, Year 4, Week 8, n=239 | -0.2 ± 2.72 |
| Sodium, Year 4, Week 16, n=238 | -0.2 ± 2.71 |
| Sodium, Year 4, Week 24, n=227 | -0.1 ± 2.64 |
| Sodium, Year 4, Week 32, n=233 | -0.2 ± 2.57 |
| Sodium, Year 4, Week 40, n=220 | -0.1 ± 2.55 |
| Sodium, Year 4, Week 48, n=218 | -0.1 ± 2.64 |
| Sodium, Year 5, Week 8, n=218 | -0.1 ± 2.85 |
| Sodium, Year 5, Week 16, n=214 | -0.1 ± 2.60 |
| Sodium, Year 5, Week 24, n=211 | 0.0 ± 2.92 |
| Sodium, Year 5, Week 32, n=211 | -0.1 ± 2.74 |
| Sodium, Year 5, Week 40, n=198 | 0.1 ± 3.04 |
| Sodium, Year 5, Week 48, n=207 | -0.3 ± 2.90 |
| Sodium, Year 6, Week 8, n=206 | -0.1 ± 2.96 |
| Sodium, Year 6, Week 16, n=198 | -0.3 ± 2.85 |
| Sodium, Year 6, Week 24, n=190 | -0.3 ± 2.90 |
| Sodium, Year 6, Week 32, n=193 | -0.3 ± 2.90 |
| Sodium, Year 6, Week 40, n=185 | -0.3 ± 2.91 |
| Sodium, Year 6, Week 48, n=186 | -0.4 ± 2.77 |
| Sodium,Year 7, Week 8, n=179 | -0.4 ± 2.90 |
| Sodium, Year 7, Week 16, n=179 | -0.5 ± 2.86 |
| Sodium, Year 7, Week 24, n=173 | -0.5 ± 2.86 |
| Sodium, Year 7, Week 32, n=180 | -0.4 ± 4.24 |
| Sodium, Year 7, Week 40, n=175 | -0.2 ± 2.98 |
| Sodium, Year 7, Week 48, n=175 | -0.5 ± 3.01 |
| Sodium, Year 8, Week 8, n=171 | -0.2 ± 2.96 |
| Sodium, Year 8, Week 16, n=170 | -0.3 ± 3.22 |
| Sodium, Year 8, Week 24, n=168 | -0.3 ± 2.79 |
| Sodium, Year 8, Week 32, n=168 | -0.5 ± 3.01 |
| Sodium, Year 8, Week 40, n=162 | -0.3 ± 2.94 |
| Sodium, Year 8, Week 48, n=159 | -0.3 ± 2.88 |
| Sodium, Year 9, Week 8, n=164 | -0.4 ± 2.94 |
| Sodium, Year 9, Week 16, n=162 | -0.4 ± 3.14 |
| Sodium, Year 9, Week 24, n=161 | -0.3 ± 3.05 |
| Sodium, Year 9, Week 32, n=163 | -0.7 ± 2.94 |
| Sodium, Year 9, Week 40, n=156 | -0.4 ± 3.13 |
| Sodium, Year 9, Week 48, n=151 | -0.6 ± 3.22 |
| Sodium, Year 10, Week 8, n=152 | -0.5 ± 3.25 |
| Sodium, Year 10, Week 16, n=143 | -0.3 ± 3.31 |
| Sodium, Year 10, Week 24, n=145 | -0.4 ± 3.56 |
| Sodium, Year 10, Week 32, n=142 | -0.2 ± 3.15 |
| Sodium, Year 10, Week 40, n=138 | -0.1 ± 2.80 |
| Sodium, Year 10, Week 48, n=135 | -0.4 ± 3.26 |
| Sodium, Year 11, Week 8, n=138 | -0.2 ± 3.21 |
| Sodium, Year 11, Week 16, n=128 | -0.5 ± 3.30 |
| Sodium, Year 11, Week 24, n=130 | -0.4 ± 3.27 |
| Sodium, Year 11, Week 32, n=125 | -0.6 ± 3.19 |
| Sodium, Year 11, Week 40, n=124 | -0.5 ± 3.25 |
| Sodium, Year 11, Week 48, n=108 | -0.7 ± 3.16 |
| Sodium, Year 12, Week 8, n=110 | -0.9 ± 3.07 |
| Sodium, Year 12, Week 16, n=97 | -0.7 ± 3.12 |
| Sodium, Year 12, Week 24, n=87 | -0.1 ± 3.26 |
| Sodium, Year 12, Week 32, n=84 | -0.3 ± 2.91 |
| Sodium, Year 12, Week 40, n=82 | -0.5 ± 3.18 |
| Sodium, Year 12, Week 48, n=72 | -1.1 ± 2.98 |
| Sodium, Year 13, Week 8, n=53 | -0.3 ± 3.04 |
| Sodium, Year 13, Week 16, n=42 | -0.3 ± 2.68 |
| Sodium, Year 13, Week 24, n=20 | 0.2 ± 3.47 |
| Sodium, Year 13, Week 32, n=7 | 0.0 ± 3.21 |
| Sodium, Year 13, Week 40, n=1 | 2.0 ± NA |
| Sodium, Exit, n=248 | -0.7 ± 2.96 |
| Sodium, 8-Week Follow-up, n=220 | -0.5 ± 3.06 |
| Sodium, 24-Week Follow-up , n=200 | -0.3 ± 3.16 |
Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in creatinine, urate, and bilirubin is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value.
| micromoles per liter | Belimumab 10 mg/kg IV |
|---|---|
| Creatinine, Year 1, Week 8, n=284 | 0.436 ± 11.3838 |
| Creatinine, Year 1, Week 16, n=286 | 0.464 ± 12.4820 |
| Creatinine, Year 1, Week 24, n=292 | 1.211 ± 12.9503 |
| Creatinine, Year 1, Week 32, n=287 | 1.047 ± 12.5885 |
| Creatinine, Year 1, Week 40, n=284 | 0.965 ± 12.0245 |
| Creatinine, Year 1, Week 48, n=287 | 0.955 ± 12.4760 |
| Creatinine, Year 2, Week 8, n=288 | 0.583 ± 11.9874 |
| Creatinine, Year 2, Week 16, n=278 | 1.558 ± 11.7857 |
| Creatinine, Year 2, Week 24, n=273 | 1.036 ± 13.7310 |
| Creatinine, Year 2, Week 32, n=284 | 0.716 ± 14.1894 |
| Creatinine, Year 2, Week 40, n=264 | 1.976 ± 15.7590 |
| Creatinine, Year 2, Week 48, n=269 | 1.413 ± 13.7896 |
| Creatinine, Year 3, Week 8, n=265 | -1.268 ± 14.8256 |
| Creatinine, Year 3, Week 16, n=260 | -2.006 ± 14.6735 |
| Creatinine, Year 3, Week 24, n=244 | -2.464 ± 15.3328 |
| Creatinine, Year 3, Week 32, n=249 | -3.089 ± 14.8793 |
| Creatinine, Year 3, Week 40, n=245 | -3.320 ± 18.5589 |
| Creatinine, Year 3, Week 48, n=244 | -3.297 ± 17.3222 |
| Creatinine, Year 4, Week 8, n=239 | -3.440 ± 14.6181 |
| Creatinine, Year 4, Week 16, n=238 | -3.417 ± 17.3832 |
| Creatinine, Year 4, Week 24, n=227 | -3.271 ± 15.7446 |
| Creatinine, Year 4, Week 32, n=233 | -2.238 ± 15.9372 |
| Creatinine, Year 4, Week 40, n=220 | -2.331 ± 15.0967 |
| Creatinine, Year 4, Week 48, n=218 | -1.987 ± 18.0028 |
| Creatinine, Year 5, Week 8, n=218 | -2.514 ± 16.1511 |
| Creatinine, Year 5, Week 16, n=214 | -2.602 ± 16.0764 |
| Creatinine, Year 5, Week 24, n=211 | -1.843 ± 16.8703 |
| Creatinine, Year 5, Week 32, n=211 | -1.634 ± 17.1000 |
| Creatinine, Year 5, Week 40, n=198 | -2.456 ± 17.8333 |
| Creatinine, Year 5, Week 48, n=207 | -3.203 ± 17.3533 |
| Creatinine, Year 6, Week 8, n=206 | -3.562 ± 16.8131 |
| Creatinine, Year 6, Week 16, n=198 | -2.634 ± 26.0097 |
| Creatinine, Year 6, Week 24, n=190 | -4.373 ± 15.1824 |
| Creatinine, Year 6, Week 32, n=193 | -3.527 ± 18.6685 |
| Creatinine, Year 6, Week 40, n=185 | -3.488 ± 19.8547 |
| Creatinine, Year 6, Week 48, n=186 | -3.565 ± 18.7328 |
| Creatinine, Year 7, Week 8, n=179 | -4.198 ± 19.0041 |
| Creatinine, Year 7, Week 16, n=179 | -5.185 ± 20.4159 |
| Creatinine, Year 7, Week 24, n=173 | -6.438 ± 20.9087 |
| Creatinine, Year 7, Week 32, n=180 | -7.907 ± 19.4999 |
| Creatinine, Year 7, Week 40, n=175 | -8.486 ± 15.0558 |
| Creatinine, Year 7, Week 48, n=175 | -8.789 ± 17.9447 |
| Creatinine, Year 8, Week 8, n=171 | -9.202 ± 17.7671 |
| Creatinine, Year 8, Week 16, n=170 | -8.008 ± 19.5492 |
| Creatinine, Year 8, Week 24, n=168 | -8.630 ± 19.0791 |
| Creatinine, Year 8, Week 32, n=168 | -8.682 ± 19.2383 |
| Creatinine, Year 8, Week 40, n=162 | -8.349 ± 21.3658 |
| Creatinine, Year 8, Week 48, n=159 | -8.228 ± 18.9524 |
| Creatinine, Year 9, Week 8, n=164 | -8.517 ± 14.5862 |
| Creatinine, Year 9, Week 16, n=162 | -7.585 ± 20.0682 |
| Creatinine, Year 9, Week 24, n=161 | -8.291 ± 21.4197 |
| Creatinine, Year 9, Week 32, n=163 | -7.593 ± 18.2143 |
| Creatinine, Year 9, Week 40, n=156 | -7.763 ± 18.4432 |
| Creatinine, Year 9, Week 48, n=151 | -8.430 ± 15.7255 |
| Creatinine, Year 10, Week 8, n=152 | -8.258 ± 19.3747 |
| Creatinine, Year 10, Week 16, n=143 | -9.273 ± 14.3973 |
| Creatinine, Year 10, Week 24, n=145 | -7.986 ± 17.3492 |
| Creatinine, Year 10, Week 32, n=142 | -8.217 ± 17.1597 |
| Creatinine, Year 10, Week 40, n=138 | -9.417 ± 16.4848 |
| Creatinine, Year 10, Week 48, n=135 | -8.120 ± 15.7637 |
| Creatinine, Year 11, Week 8, n=138 | -8.584 ± 16.5792 |
| Creatinine, Year 11, Week 16, n=128 | -9.254 ± 16.0322 |
| Creatinine, Year 11, Week 24, n=130 | -8.500 ± 16.4151 |
| Creatinine, Year 11, Week 32, n=125 | -8.699 ± 15.1035 |
| Creatinine, Year 11, Week 40, n=124 | -7.058 ± 19.1292 |
| Creatinine, Year 11, Week 48, n=108 | -7.858 ± 15.6339 |
| Creatinine, Year 12, Week 8, n=110 | -7.715 ± 14.5236 |
| Creatinine, Year 12, Week 16, n=97 | -6.744 ± 13.1845 |
| Creatinine, Year 12, Week 24, n=87 | -7.316 ± 13.4273 |
| Creatinine, Year 12, Week 32, n=84 | -7.998 ± 14.5624 |
| Creatinine, Year 12, Week 40, n=82 | -7.331 ± 14.9482 |
| Creatinine, Year 12, Week 48, n=72 | -8.103 ± 14.0558 |
| Creatinine, Year 13, Week 8, n=53 | -7.672 ± 12.1403 |
| Creatinine, Year 13, Week 16, n=42 | -6.104 ± 9.8570 |
| Creatinine, Year 13, Week 24, n=20 | -9.282 ± 9.7155 |
| Creatinine, Year 13, Week 32, n=7 | -3.789 ± 15.1893 |
| Creatinine, Year 13, Week 40, n=1 | -8.840 ± NA |
| Creatinine, Exit, n=248 | -3.707 ± 21.7147 |
| Creatinine, 8-Week Follow-up, n=220 | -4.058 ± 21.6587 |
| Creatinine, 24-Week Follow-up , n=200 | -5.216 ± 19.0936 |
| Urate, Year 1, Week 8, n=284 | 1.8849 ± 44.3384 |
| Urate, Year 1, Week 16, n=286 | -2.8076 ± 47.4812 |
| Urate, Year 1, Week 24, n=292 | -2.6888 ± 47.8723 |
| Urate, Year 1, Week 32, n=287 | -4.9739 ± 51.9503 |
| Urate, Year 1, Week 40, n=284 | -10.2415 ± 52.6846 |
| Urate, Year 1, Week 48, n=287 | -9.6785 ± 52.9454 |
| Urate, Year 2, Week 8, n=288 | -5.8034 ± 54.3409 |
| Urate, Year 2, Week 16, n=278 | -2.2679 ± 55.1544 |
| Urate, Year 2, Week 24, n=273 | -2.5709 ± 59.5925 |
| Urate, Year 2, Week 32, n=284 | -2.1153 ± 62.2559 |
| Urate, Year 2, Week 40, n=264 | 0.8111 ± 59.7227 |
| Urate, Year 2, Week 48, n=269 | 2.1448 ± 60.1246 |
| Urate, Year 3, Week 8, n=265 | 2.1772 ± 66.2923 |
| Urate, Year 3, Week 16, n=260 | 8.6246 ± 60.1972 |
| Urate, Year 3, Week 24, n=244 | 17.1614 ± 64.9072 |
| Urate, Year 3, Week 32, n=249 | 20.6627 ± 69.7507 |
| Urate, Year 3, Week 40, n=245 | 15.5862 ± 64.9204 |
| Urate, Year 3, Week 48, n=244 | 17.2346 ± 69.9632 |
| Urate, Year 4, Week 8, n=239 | 18.8644 ± 69.2770 |
| Urate, Year 4, Week 16, n=238 | 17.0443 ± 65.9764 |
| Urate, Year 4, Week 24, n=227 | 22.1150 ± 73.0409 |
| Urate, Year 4, Week 32, n=233 | 27.1872 ± 67.0773 |
| Urate, Year 4, Week 40, n=220 | 20.6017 ± 77.3509 |
| Urate, Year 4, Week 48, n=218 | 27.3663 ± 74.9898 |
| Urate, Year 5, Week 8, n=218 | 26.3294 ± 73.0884 |
| Urate, Year 5, Week 16, n=214 | 26.4325 ± 75.1583 |
| Urate, Year 5, Week 24, n=211 | 25.6525 ± 73.5651 |
| Urate, Year 5, Week 32, n=211 | 32.0515 ± 75.9635 |
| Urate, Year 5, Week 40, n=198 | 26.8862 ± 77.2803 |
| Urate, Year 5, Week 48, n=207 | 24.9126 ± 79.1890 |
| Urate, Year 6, Week 8, n=206 | 26.3329 ± 80.0258 |
| Urate, Year 6, Week 16, n=198 | 27.2166 ± 79.2525 |
| Urate, Year 6, Week 24, n=190 | 32.5888 ± 81.4485 |
| Urate, Year 6, Week 32, n=193 | 32.3904 ± 81.4550 |
| Urate, Year 6, Week 40, n=185 | 34.4019 ± 75.0211 |
| Urate, Year 6, Week 48, n=186 | 39.1737 ± 75.6743 |
| Urate, Year 7, Week 8, n=179 | 34.0930 ± 75.0241 |
| Urate, Year 7, Week 16, n=179 | 35.0566 ± 77.2918 |
| Urate, Year 7, Week 24, n=173 | 34.7941 ± 80.7184 |
| Urate, Year 7, Week 32, n=180 | 32.8792 ± 75.6337 |
| Urate, Year 7, Week 40, n=175 | 31.7453 ± 81.9889 |
| Urate, Year 7, Week 48, n=175 | 31.9832 ± 78.3131 |
| Urate, Year 8, Week 8, n=171 | 26.6790 ± 79.7678 |
| Urate, Year 8, Week 16, n=170 | 30.7197 ± 83.1681 |
| Urate, Year 8, Week 24, n=168 | 25.4560 ± 83.0349 |
| Urate, Year 8, Week 32, n=168 | 30.0940 ± 81.9997 |
| Urate, Year 8, Week 40, n=162 | 29.4096 ± 76.1203 |
| Urate, Year 8, Week 48, n=159 | 29.9270 ± 82.9390 |
| Urate, Year 9, Week 8, n=164 | 37.6828 ± 78.7998 |
| Urate, Year 9, Week 16, n=162 | 27.2066 ± 79.3972 |
| Urate, Year 9, Week 24, n=161 | 25.9717 ± 78.7793 |
| Urate, Year 9, Week 32, n=163 | 26.1639 ± 78.0704 |
| Urate, Year 9, Week 40, n=156 | 24.7833 ± 81.4956 |
| Urate, Year 9, Week 48, n=151 | 21.9012 ± 82.0174 |
| Urate, Year 10, Week 8, n=152 | 24.8486 ± 75.5325 |
| Urate, Year 10, Week 16, n=143 | 17.5528 ± 82.4129 |
| Urate, Year 10, Week 24, n=145 | 17.6389 ± 88.8154 |
| Urate, Year 10, Week 32, n=142 | 16.9644 ± 84.0128 |
| Urate, Year 10, Week 40, n=138 | 16.0768 ± 88.6943 |
| Urate, Year 10, Week 48, n=135 | 20.9722 ± 92.2400 |
| Urate, Year 11, Week 8, n=138 | 16.3354 ± 88.7370 |
| Urate, Year 11, Week 16, n=128 | 19.0057 ± 80.9138 |
| Urate, Year 11, Week 24, n=129 | 13.8326 ± 91.9844 |
| Urate, Year 11, Week 32, n=125 | 14.4180 ± 81.6362 |
| Urate, Year 11, Week 40, n=124 | 17.8920 ± 97.1467 |
| Urate, Year 11, Week 48, n=108 | 15.9164 ± 86.7371 |
| Urate, Year 12, Week 8, n=110 | 18.3307 ± 92.3013 |
| Urate, Year 12, Week 16, n=97 | 15.3912 ± 85.1873 |
| Urate, Year 12, Week 24, n=87 | 15.3828 ± 87.1985 |
| Urate, Year 12, Week 32, n=84 | 16.7817 ± 89.8376 |
| Urate, Year 12, Week 40, n=82 | 12.2587 ± 83.5304 |
| Urate, Year 12, Week 48, n=72 | 9.9133 ± 85.1185 |
| Urate, Year 13, Week 8, n=53 | 32.4334 ± 79.1035 |
| Urate, Year 13, Week 16, n=42 | 42.6273 ± 74.2314 |
| Urate, Year 13, Week 24, n=20 | 25.5764 ± 56.8583 |
| Urate, Year 13, Week 32, n=7 | 64.5783 ± 59.0251 |
| Urate, Year 13, Week 40, n=1 | 53.5320 ± NA |
| Urate, Exit, n=248 | 18.5635 ± 89.4280 |
| Urate, 8-Week Follow-up, n=220 | 19.6014 ± 89.9097 |
| Urate, 24-Week Follow-up , n=200 | 17.5763 ± 82.1420 |
| Bilirubin, Year 1, Week 8, n=283 | 0.145 ± 2.2995 |
| Bilirubin, Year 1, Week 16, n=285 | 0.168 ± 2.3476 |
| Bilirubin, Year 1, Week 24, n=292 | 0.287 ± 2.4529 |
| Bilirubin, Year 1, Week 32, n=287 | 0.346 ± 2.6100 |
| Bilirubin, Year 1, Week 40, n=283 | 0.236 ± 2.3829 |
| Bilirubin, Year 1, Week 48, n=286 | 0.293 ± 2.5315 |
| Bilirubin, Year 2, Week 8, n=288 | 0.243 ± 2.6498 |
| Bilirubin, Year 2, Week 16, n=277 | 0.019 ± 2.5896 |
| Bilirubin, Year 2, Week 24, n=272 | 0.176 ± 2.5041 |
| Bilirubin, Year 2, Week 32, n=284 | 0.331 ± 2.6475 |
| Bilirubin, Year 2, Week 40, n=262 | 0.398 ± 2.9233 |
| Bilirubin, Year 2, Week 48, n=269 | 0.464 ± 2.5138 |
| Bilirubin, Year 3, Week 8, n=264 | 0.343 ± 2.6599 |
| Bilirubin, Year 3, Week 16, n=258 | 0.252 ± 2.8788 |
| Bilirubin, Year 3, Week 24, n=243 | 0.274 ± 3.0754 |
| Bilirubin, Year 3, Week 32, n=249 | 0.494 ± 2.5860 |
| Bilirubin, Year 3, Week 40, n=244 | 0.182 ± 2.8589 |
| Bilirubin, Year 3, Week 48, n=243 | 0.267 ± 3.0780 |
| Bilirubin, Year 4, Week 8, n=239 | 0.336 ± 2.7639 |
| Bilirubin, Year 4, Week 16, n=238 | 0.481 ± 2.8625 |
| Bilirubin, Year 4, Week 24, n=227 | 0.309 ± 2.8038 |
| Bilirubin, Year 4, Week 32, n=231 | 0.326 ± 2.9524 |
| Bilirubin, Year 4, Week 40, n=220 | -0.023 ± 2.5236 |
| Bilirubin, Year 4, Week 48, n=218 | 0.157 ± 2.8815 |
| Bilirubin, Year 5, Week 8, n=218 | 0.329 ± 2.4013 |
| Bilirubin, Year 5, Week 16, n=214 | 0.304 ± 2.6180 |
| Bilirubin, Year 5, Week 24, n=211 | 0.259 ± 2.5450 |
| Bilirubin, Year 5, Week 32, n=211 | 0.575 ± 2.6520 |
| Bilirubin, Year 5, Week 40, n=198 | 0.544 ± 2.6496 |
| Bilirubin, Year 5, Week 48, n=207 | 0.322 ± 2.5320 |
| Bilirubin, Year 6, Week 8, n=206 | 0.282 ± 2.5233 |
| Bilirubin, Year 6, Week 16, n=198 | 0.138 ± 2.6093 |
| Bilirubin, Year 6, Week 24, n=190 | 0.099 ± 2.7600 |
| Bilirubin, Year 6, Week 32, n=193 | 0.284 ± 2.6431 |
| Bilirubin, Year 6, Week 40, n=185 | 0.296 ± 2.8314 |
| Bilirubin, Year 6, Week 48, n=186 | 0.248 ± 3.0097 |
| Bilirubin, Year 7, Week 8, n=179 | 0.258 ± 2.6974 |
| Bilirubin, Year 7, Week 16, n=179 | 0.143 ± 2.6134 |
| Bilirubin, Year 7, Week 24, n=173 | 0.287 ± 2.6082 |
| Bilirubin, Year 7, Week 32, n=180 | 0.313 ± 2.9727 |
| Bilirubin, Year 7, Week 40, n=175 | 0.137 ± 2.7527 |
| Bilirubin, Year 7, Week 48, n=175 | 0.156 ± 2.9747 |
| Bilirubin, Year 8, Week 8, n=171 | 0.020 ± 2.9559 |
| Bilirubin, Year 8, Week 16, n=170 | -0.050 ± 2.6856 |
| Bilirubin, Year 8, Week 24, n=168 | 0.010 ± 2.4720 |
| Bilirubin, Year 8, Week 32, n=168 | -0.336 ± 2.5471 |
| Bilirubin, Year 8, Week 40, n=162 | -0.032 ± 2.8934 |
| Bilirubin, Year 8, Week 48, n=159 | -0.097 ± 3.2550 |
| Bilirubin, Year 9, Week 8, n=164 | -0.125 ± 2.7616 |
| Bilirubin, Year 9, Week 16, n=162 | -0.095 ± 2.9603 |
| Bilirubin, Year 9, Week 24, n=161 | -0.234 ± 3.1385 |
| Bilirubin, Year 9, Week 32, n=163 | -0.126 ± 2.7175 |
| Bilirubin, Year 9, Week 40, n=156 | -0.296 ± 3.3709 |
| Bilirubin, Year 9, Week 48, n=151 | 0.057 ± 2.8231 |
| Bilirubin, Year 10, Week 8, n=152 | -0.158 ± 3.0763 |
| Bilirubin, Year 10, Week 16, n=143 | -0.179 ± 3.1616 |
| Bilirubin, Year 10, Week 24, n=145 | -0.024 ± 2.8853 |
| Bilirubin, Year 10, Week 32, n=142 | 0.120 ± 3.3068 |
| Bilirubin, Year 10, Week 40, n=138 | -0.248 ± 3.0684 |
| Bilirubin, Year 10, Week 48, n=135 | 0.190 ± 3.0751 |
| Bilirubin, Year 11, Week 8, n=138 | 0.050 ± 2.9936 |
| Bilirubin, Year 11, Week 16, n=128 | 0.281 ± 2.9640 |
| Bilirubin, Year 11, Week 24, n=130 | 0.026 ± 2.8004 |
| Bilirubin, Year 11, Week 32, n=125 | 0.192 ± 2.5160 |
| Bilirubin, Year 11, Week 40, n=124 | 0.193 ± 3.2650 |
| Bilirubin, Year 11, Week 48, n=108 | 0.538 ± 2.9261 |
| Bilirubin, Year 12, Week 8, n=110 | 0.311 ± 2.8762 |
| Bilirubin, Year 12, Week 16, n=97 | 0.776 ± 3.0231 |
| Bilirubin, Year 12, Week 24, n=87 | 0.511 ± 3.4508 |
| Bilirubin, Year 12, Week 32, n=84 | 1.282 ± 3.3563 |
| Bilirubin, Year 12, Week 40, n=82 | 0.542 ± 3.2454 |
| Bilirubin, Year 12, Week 48, n=72 | 0.570 ± 3.8398 |
| Bilirubin, Year 13, Week 8, n=53 | 0.129 ± 2.8623 |
| Bilirubin, Year 13, Week 16, n=42 | -0.244 ± 3.1046 |
| Bilirubin, Year 13, Week 24, n=20 | -0.513 ± 2.0080 |
| Bilirubin, Year 13, Week 32, n=7 | -0.244 ± 2.5032 |
| Bilirubin, Year 13, Week 40, n=1 | 0.000 ± NA |
| Bilirubin, Exit, n=248 | 0.510 ± 3.0619 |
| Bilirubin, 8-Week Follow-up, n=220 | 0.389 ± 2.7311 |
| Bilirubin, 24-Week Follow-up , n=200 | 0.650 ± 3.3222 |
Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in BUN/creatinine is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
| Ratio | Belimumab 10 mg/kg IV |
|---|---|
| BUN/Creatinine, Year 1, Week 8, n=284 | -0.1 ± 4.13 |
| BUN/Creatinine, Year 1, Week 16, n=286 | -0.4 ± 4.31 |
| BUN/Creatinine, Year 1, Week 24, n=292 | -0.4 ± 4.67 |
| BUN/Creatinine, Year 1, Week 32, n=287 | -0.4 ± 4.07 |
| BUN/Creatinine, Year 1, Week 40, n=284 | -0.8 ± 4.26 |
| BUN/Creatinine, Year 1, Week 48, n=287 | -0.3 ± 4.80 |
| BUN/Creatinine, Year 2, Week 8, n=288 | -0.4 ± 4.91 |
| BUN/Creatinine, Year 2, Week 16, n=278 | -0.6 ± 4.95 |
| BUN/Creatinine, Year 2, Week 24, n=273 | -0.6 ± 5.00 |
| BUN/Creatinine, Year 2, Week 32, n=284 | -0.4 ± 4.82 |
| BUN/Creatinine, Year 2, Week 40, n=264 | -0.8 ± 4.80 |
| BUN/Creatinine, Year 2, Week 48, n=269 | -0.5 ± 4.90 |
| BUN/Creatinine, Year 3, Week 8, n=265 | 0.2 ± 4.81 |
| BUN/Creatinine, Year 3, Week 16, n=260 | 0.2 ± 4.95 |
| BUN/Creatinine, Year 3, Week 24, n=244 | 0.6 ± 4.93 |
| BUN/Creatinine, Year 3, Week 32, n=249 | 0.5 ± 5.16 |
| BUN/Creatinine, Year 3, Week 40, n=245 | 0.9 ± 4.83 |
| BUN/Creatinine, Year 3, Week 48, n=244 | 0.8 ± 4.99 |
| BUN/Creatinine, Year 4, Week 8, n=239 | 1.1 ± 4.99 |
| BUN/Creatinine, Year 4, Week 16, n=238 | 0.8 ± 4.86 |
| BUN/Creatinine, Year 4, Week 24, n=227 | 0.9 ± 5.15 |
| BUN/Creatinine, Year 4, Week 32, n=233 | 0.5 ± 4.93 |
| BUN/Creatinine, Year 4, Week 40, n=220 | 0.3 ± 4.81 |
| BUN/Creatinine, Year 4, Week 48, n=218 | 1.1 ± 5.35 |
| BUN/Creatinine, Year 5, Week 8, n=218 | 0.8 ± 5.34 |
| BUN/Creatinine, Year 5, Week 16, n=214 | 1.2 ± 5.03 |
| BUN/Creatinine, Year 5, Week 24, n=211 | 0.8 ± 5.01 |
| BUN/Creatinine, Year 5, Week 32, n=211 | 0.3 ± 4.93 |
| BUN/Creatinine, Year 5, Week 40, n=198 | 1.2 ± 5.04 |
| BUN/Creatinine, Year 5, Week 48, n=207 | 0.9 ± 5.11 |
| BUN/Creatinine, Year 6, Week 8, n=206 | 1.4 ± 5.04 |
| BUN/Creatinine, Year 6, Week 16, n=198 | 1.3 ± 5.03 |
| BUN/Creatinine, Year 6, Week 24, n=190 | 1.2 ± 5.37 |
| BUN/Creatinine, Year 6, Week 32, n=193 | 1.6 ± 5.76 |
| BUN/Creatinine, Year 6, Week 40, n=185 | 1.5 ± 4.73 |
| BUN/Creatinine, Year 6, Week 48, n=186 | 1.8 ± 5.08 |
| BUN/Creatinine, Year 7, Week 8, n=179 | 1.6 ± 5.07 |
| BUN/Creatinine, Year 7, Week 16, n=179 | 2.1 ± 5.04 |
| BUN/Creatinine, Year 7, Week 24, n=173 | 2.1 ± 5.55 |
| BUN/Creatinine, Year 7, Week 32, n=180 | 2.3 ± 5.39 |
| BUN/Creatinine, Year 7, Week 40, n=175 | 2.6 ± 5.19 |
| BUN/Creatinine, Year 7, Week 48, n=175 | 2.6 ± 5.31 |
| BUN/Creatinine, Year 8, Week 8, n=171 | 2.7 ± 5.65 |
| BUN/Creatinine, Year 8, Week 16, n=170 | 2.5 ± 5.54 |
| BUN/Creatinine, Year 8, Week 24, n=168 | 2.6 ± 5.37 |
| BUN/Creatinine, Year 8, Week 32, n=168 | 2.2 ± 5.11 |
| BUN/Creatinine, Year 8, Week 40, n=162 | 2.3 ± 5.36 |
| BUN/Creatinine, Year 8, Week 48, n=159 | 2.9 ± 5.20 |
| BUN/Creatinine, Year 9, Week 8, n=164 | 2.4 ± 5.26 |
| BUN/Creatinine, Year 9, Week 16, n=162 | 2.5 ± 6.15 |
| BUN/Creatinine, Year 9, Week 24, n=161 | 2.4 ± 5.89 |
| BUN/Creatinine, Year 9, Week 32, n=163 | 2.7 ± 5.54 |
| BUN/Creatinine, Year 9, Week 40, n=156 | 2.4 ± 5.90 |
| BUN/Creatinine, Year 9, Week 48, n=151 | 2.2 ± 6.01 |
| BUN/Creatinine, Year 10, Week 8, n=152 | 2.6 ± 5.98 |
| BUN/Creatinine, Year 10, Week 16, n=143 | 2.6 ± 6.13 |
| BUN/Creatinine, Year 10, Week 24, n=145 | 2.5 ± 5.72 |
| BUN/Creatinine, Year 10, Week 32, n=142 | 2.8 ± 6.03 |
| BUN/Creatinine, Year 10, Week 40, n=138 | 2.0 ± 5.87 |
| BUN/Creatinine, Year 10, Week 48, n=135 | 2.4 ± 6.07 |
| BUN/Creatinine, Year 11, Week 8, n=138 | 2.7 ± 6.13 |
| BUN/Creatinine, Year 11, Week 16, n=128 | 2.6 ± 6.28 |
| BUN/Creatinine, Year 11, Week 24, n=130 | 2.8 ± 6.12 |
| BUN/Creatinine, Year 11, Week 32, n=125 | 2.2 ± 6.10 |
| BUN/Creatinine, Year 11, Week 40, n=124 | 2.3 ± 6.68 |
| BUN/Creatinine, Year 11, Week 48, n=108 | 1.7 ± 5.65 |
| BUN/Creatinine, Year 12, Week 8, n=110 | 2.4 ± 6.36 |
| BUN/Creatinine, Year 12, Week 16, n=97 | 2.4 ± 6.38 |
| BUN/Creatinine, Year 12, Week 24, n=87 | 2.2 ± 6.62 |
| BUN/Creatinine, Year 12, Week 32, n=84 | 1.5 ± 5.75 |
| BUN/Creatinine, Year 12, Week 40, n=82 | 1.4 ± 6.50 |
| BUN/Creatinine, Year 12, Week 48, n=72 | 1.6 ± 6.42 |
| BUN/Creatinine, Year 13, Week 8, n=53 | 2.1 ± 5.44 |
| BUN/Creatinine, Year 13, Week 16, n=42 | 3.5 ± 6.22 |
| BUN/Creatinine, Year 13, Week 24, n=20 | 3.6 ± 4.36 |
| BUN/Creatinine, Year 13, Week 32, n=7 | 0.3 ± 2.93 |
| BUN/Creatinine, Year 13, Week 40, n=1 | -6.0 ± NA |
| BUN/Creatinine, Exit, n=248 | 1.6 ± 5.66 |
| BUN/Creatinine, 8-Week Follow-up, n=220 | 1.1 ± 5.88 |
| BUN/Creatinine, 24-Week Follow-up , n=200 | 1.3 ± 5.53 |
Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in ALT, AP, AST, GGT and LD are summarized. Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.
| International units per liter | Belimumab 10 mg/kg IV |
|---|---|
| ALT, Year 1, Week 8, n=284 | -0.7 ± 12.05 |
| ALT, Year 1, Week 16, n=286 | 0.2 ± 17.32 |
| ALT, Year 1, Week 24, n=292 | 0.9 ± 17.04 |
| ALT, Year 1, Week 32, n=287 | -0.6 ± 12.36 |
| ALT, Year 1, Week 40, n=284 | -0.6 ± 14.15 |
| ALT, Year 1, Week 48, n=287 | -1.3 ± 11.56 |
| ALT, Year 2, Week 8, n=288 | -0.7 ± 13.36 |
| ALT, Year 2, Week 16, n=278 | -1.2 ± 11.44 |
| ALT, Year 2, Week 24, n=273 | 0.3 ± 13.35 |
| ALT, Year 2, Week 32, n=284 | 0.1 ± 15.85 |
| ALT, Year 2, Week 40, n=264 | 0.0 ± 14.02 |
| ALT, Year 2, Week 48, n=269 | 0.9 ± 15.65 |
| ALT, Year 3, Week 8, n=265 | 0.5 ± 14.46 |
| ALT, Year 3, Week 16, n=260 | 1.3 ± 21.94 |
| ALT, Year 3, Week 24, n=244 | -0.1 ± 13.95 |
| ALT, Year 3, Week 32, n=249 | 0.0 ± 12.55 |
| ALT, Year 3, Week 40, n=245 | -0.3 ± 13.08 |
| ALT, Year 3, Week 48, n=244 | -0.4 ± 13.62 |
| ALT, Year 4, Week 8, n=239 | -0.5 ± 10.97 |
| ALT, Year 4, Week 16, n=238 | -1.3 ± 14.28 |
| ALT, Year 4, Week 24, n=227 | -1.3 ± 13.29 |
| ALT, Year 4, Week 32, n=233 | -0.4 ± 13.60 |
| ALT, Year 4, Week 40, n=220 | -1.6 ± 12.83 |
| ALT, Year 4, Week 48, n=218 | -1.3 ± 12.45 |
| ALT, Year 5, Week 8, n=218 | 0.1 ± 12.76 |
| ALT, Year 5, Week 16, n=214 | -0.5 ± 12.67 |
| ALT, Year 5, Week 24, n=211 | -0.9 ± 14.68 |
| ALT, Year 5, Week 32, n=211 | -1.5 ± 13.23 |
| ALT, Year 5, Week 40, n=198 | -1.3 ± 13.90 |
| ALT, Year 5, Week 48, n=207 | -0.1 ± 17.16 |
| ALT, Year 6, Week 8, n=206 | -1.4 ± 12.09 |
| ALT, Year 6, Week 16, n=198 | -1.4 ± 13.55 |
| ALT, Year 6, Week 24, n=190 | -1.6 ± 13.87 |
| ALT, Year 6, Week 32, n=193 | -1.4 ± 13.58 |
| ALT, Year 6, Week 40, n=185 | -1.4 ± 14.78 |
| ALT, Year 6, Week 48, n=186 | -0.9 ± 14.98 |
| ALT, Year 7, Week 8, n=179 | -0.4 ± 14.50 |
| ALT, Year 7, Week 16, n=179 | 0.5 ± 15.78 |
| ALT, Year 7, Week 24, n=173 | 0.1 ± 16.09 |
| ALT, Year 7, Week 32, n=180 | -0.2 ± 14.71 |
| ALT, Year 7, Week 40, n=175 | -0.1 ± 16.43 |
| ALT, Year 7, Week 48, n=175 | -0.4 ± 16.15 |
| ALT, Year 8, Week 8, n=171 | 0.9 ± 16.58 |
| ALT, Year 8, Week 16, n=170 | -0.2 ± 17.74 |
| ALT, Year 8, Week 24, n=168 | -0.2 ± 15.62 |
| ALT, Year 8, Week 32, n=168 | -0.4 ± 14.82 |
| ALT, Year 8, Week 40, n=162 | -0.7 ± 14.79 |
| ALT, Year 8, Week 48, n=159 | -0.7 ± 15.14 |
| ALT, Year 9, Week 8, n=164 | 1.5 ± 21.38 |
| ALT, Year 9, Week 16, n=162 | -0.8 ± 14.31 |
| ALT, Year 9, Week 24, n=161 | -1.5 ± 14.35 |
| ALT, Year 9, Week 32, n=163 | 0.0 ± 15.62 |
| ALT, Year 9, Week 40, n=156 | -0.5 ± 14.61 |
| ALT, Year 9, Week 48, n=151 | -0.2 ± 15.69 |
| ALT, Year 10, Week 8, n=152 | -0.6 ± 14.25 |
| ALT, Year 10, Week 16, n=143 | -0.3 ± 13.88 |
| ALT, Year 10, Week 24, n=145 | -1.1 ± 15.71 |
| ALT, Year 10, Week 32, n=142 | -0.8 ± 15.97 |
| ALT, Year 10, Week 40, n=138 | -1.9 ± 15.56 |
| ALT, Year 10, Week 48, n=135 | -0.7 ± 19.61 |
| ALT, Year 11, Week 8, n=138 | -1.9 ± 15.75 |
| ALT, Year 11, Week 16, n=128 | -1.3 ± 16.74 |
| ALT, Year 11, Week 24, n=130 | -2.5 ± 15.11 |
| ALT, Year 11, Week 32, n=125 | -3.2 ± 14.71 |
| ALT, Year 11, Week 40, n=124 | -2.8 ± 15.31 |
| ALT, Year 11, Week 48, n=108 | -1.7 ± 18.29 |
| ALT, Year 12, Week 8, n=110 | -1.9 ± 16.30 |
| ALT, Year 12, Week 16, n=97 | -2.9 ± 12.74 |
| ALT, Year 12, Week 24, n=87 | -2.0 ± 13.47 |
| ALT, Year 12, Week 32, n=84 | -2.4 ± 13.39 |
| ALT, Year 12, Week 40, n=82 | -2.3 ± 14.74 |
| ALT, Year 12, Week 48, n=72 | -3.6 ± 14.92 |
| ALT, Year 13, Week 8, n=53 | -5.3 ± 16.58 |
| LT, Year 13, Week 16, n=42 | -5.7 ± 20.42 |
| ALT, Year 13, Week 24, n=20 | -1.0 ± 6.55 |
| ALT, Year 13, Week 32, n=7 | -0.6 ± 9.14 |
| ALT, Year 13, Week 40, n=1 | 3.0 ± NA |
| ALT, Exit, n=248 | -1.2 ± 13.39 |
| ALT, 8-Week Follow-up, n=220 | -0.6 ± 15.74 |
| ALT, 24-Week Follow-up , n=200 | 1.5 ± 36.52 |
| AP, Year 1, Week 8, n=284 | -0.1 ± 11.43 |
| AP, Year 1, Week 16, n=286 | 0.9 ± 14.08 |
| AP, Year 1, Week 24, n=292 | 0.7 ± 13.87 |
| AP, Year 1, Week 32, n=287 | 0.6 ± 14.03 |
| AP, Year 1, Week 40, n=284 | 1.1 ± 14.61 |
| AP, Year 1, Week 48, n=287 | 0.5 ± 16.94 |
| AP, Year 2, Week 8, n=288 | 1.2 ± 17.67 |
| AP, Year 2, Week 16, n=278 | 0.2 ± 15.87 |
| AP, Year 2, Week 24, n=273 | 1.3 ± 16.91 |
| AP, Year 2, Week 32, n=284 | 2.5 ± 17.17 |
| AP, Year 2, Week 40, n=264 | 3.5 ± 19.55 |
| AP, Year 2, Week 48, n=269 | 5.6 ± 23.81 |
| AP, Year 3, Week 8, n=265 | 4.0 ± 18.04 |
| AP, Year 3, Week 16, n=260 | 3.2 ± 19.53 |
| AP, Year 3, Week 24, n=244 | 2.0 ± 19.26 |
| AP, Year 3, Week 32, n=249 | 3.7 ± 21.48 |
| AP, Year 3, Week 40, n=245 | 3.4 ± 18.62 |
| AP, Year 3, Week 48, n=244 | 3.4 ± 19.32 |
| AP, Year 4, Week 8, n=239 | 2.5 ± 19.33 |
| AP, Year 4, Week 16, n=238 | 2.8 ± 17.37 |
| AP, Year 4, Week 24, n=227 | 2.5 ± 21.94 |
| AP, Year 4, Week 32, n=233 | 3.7 ± 21.17 |
| AP, Year 4, Week 40, n=220 | 2.9 ± 20.93 |
| AP, Year 4, Week 48, n=218 | 3.7 ± 22.97 |
| AP, Year 5, Week 8, n=218 | 4.9 ± 24.65 |
| AP, Year 5, Week 16, n=214 | 4.1 ± 23.87 |
| AP, Year 5, Week 24, n=211 | 4.0 ± 20.17 |
| AP, Year 5, Week 32, n=211 | 5.7 ± 20.68 |
| AP, Year 5, Week 40, n=198 | 5.5 ± 21.34 |
| AP, Year 5, Week 48, n=207 | 6.6 ± 21.74 |
| AP, Year 6, Week 8, n=206 | 7.1 ± 23.65 |
| AP, Year 6, Week 16, n=198 | 7.5 ± 21.41 |
| AP, Year 6, Week 24, n=190 | 7.5 ± 22.41 |
| AP, Year 6, Week 32, n=193 | 14.0 ± 67.61 |
| AP, Year 6, Week 40, n=185 | 10.2 ± 24.43 |
| AP, Year 6, Week 48, n=186 | 9.1 ± 22.93 |
| AP, Year 7, Week 8, n=179 | 9.0 ± 24.52 |
| AP, Year 7, Week 16, n=179 | 9.6 ± 25.70 |
| AP, Year 7, Week 24, n=173 | 9.9 ± 25.38 |
| AP, Year 7, Week 32, n=180 | 11.5 ± 27.02 |
| AP, Year 7, Week 40, n=175 | 9.6 ± 25.13 |
| AP, Year 7, Week 48, n=175 | 11.1 ± 24.96 |
| AP, Year 8, Week 8, n=171 | 10.0 ± 23.29 |
| AP, Year 8, Week 16, n=170 | 10.1 ± 27.16 |
| AP, Year 8, Week 24, n=168 | 10.4 ± 26.44 |
| AP, Year 8, Week 32, n=168 | 12.9 ± 27.45 |
| AP, Year 8, Week 40, n=162 | 11.1 ± 25.66 |
| AP, Year 8, Week 48, n=159 | 11.5 ± 30.97 |
| AP, Year 9, Week 8, n=164 | 12.0 ± 25.38 |
| AP, Year 9, Week 16, n=162 | 10.9 ± 25.48 |
| AP, Year 9, Week 24, n=161 | 10.5 ± 22.81 |
| AP, Year 9, Week 32, n=163 | 10.4 ± 24.05 |
| AP, Year 9, Week 40, n=156 | 9.5 ± 24.43 |
| AP, Year 9, Week 48, n=151 | 10.2 ± 22.77 |
| AP, Year 10, Week 8, n=152 | 10.6 ± 24.51 |
| AP, Year 10, Week 16, n=143 | 11.9 ± 29.31 |
| AP, Year 10, Week 24, n=145 | 13.0 ± 22.92 |
| AP, Year 10, Week 32, n=142 | 14.4 ± 24.55 |
| AP, Year 10, Week 40, n=138 | 13.7 ± 23.20 |
| AP, Year 10, Week 48, n=135 | 12.5 ± 23.89 |
| AP, Year 11, Week 8, n=138 | 13.3 ± 26.11 |
| AP, Year 11, Week 16, n=128 | 14.2 ± 26.05 |
| AP, Year 11, Week 24, n=130 | 12.9 ± 23.22 |
| AP, Year 11, Week 32, n=125 | 13.3 ± 23.74 |
| AP, Year 11, Week 40, n=124 | 13.3 ± 23.05 |
| AP, Year 11, Week 48, n=108 | 11.9 ± 25.59 |
| AP, Year 12, Week 8, n=110 | 12.3 ± 25.69 |
| AP, Year 12, Week 16, n=97 | 10.2 ± 22.48 |
| AP, Year 12, Week 24, n=87 | 11.5 ± 20.69 |
| AP, Year 12, Week 32, n=84 | 10.7 ± 19.91 |
| AP, Year 12, Week 40, n=82 | 10.8 ± 21.35 |
| AP, Year 12, Week 48, n=72 | 11.6 ± 21.77 |
| AP, Year 13, Week 8, n=53 | 12.2 ± 19.25 |
| AP, Year 13, Week 16, n=42 | 16.9 ± 37.69 |
| AP, Year 13, Week 24, n=20 | 20.7 ± 23.57 |
| AP, Year 13, Week 32, n=7 | 18.1 ± 21.47 |
| AP, Year 13, Week 40, n=1 | 15.0 ± NA |
| AP, Exit, n=248 | 8.3 ± 26.49 |
| AP, 8-Week Follow-up, n=220 | 10.3 ± 42.15 |
| AP, 24-Week Follow-up , n=200 | 10.7 ± 32.86 |
| AST, Year 1, Week 8, n=281 | -0.3 ± 8.68 |
| AST, Year 1, Week 16, n=283 | 2.0 ± 22.78 |
| AST, Year 1, Week 24, n=287 | 2.3 ± 26.94 |
| AST, Year 1, Week 32, n=283 | 0.5 ± 12.19 |
| AST, Year 1, Week 40, n=282 | -0.1 ± 9.63 |
| AST, Year 1, Week 48, n=284 | -1.2 ± 6.98 |
| AST, Year 2, Week 8, n=288 | -0.8 ± 9.15 |
| AST, Year 2, Week 16, n=275 | -1.2 ± 8.51 |
| AST, Year 2, Week 24, n=269 | -0.3 ± 9.04 |
| AST, Year 2, Week 32, n=284 | 0.2 ± 13.80 |
| AST, Year 2, Week 40, n=261 | -0.2 ± 10.44 |
| AST, Year 2, Week 48, n=267 | 0.7 ± 10.95 |
| AST, Year 3, Week 8, n=262 | 0.3 ± 10.81 |
| AST, Year 3, Week 16, n=258 | 1.0 ± 11.84 |
| AST, Year 3, Week 24, n=241 | 0.4 ± 10.36 |
| AST, Year 3, Week 32, n=245 | 1.3 ± 11.19 |
| AST, Year 3, Week 40, n=242 | 0.2 ± 10.99 |
| AST, Year 3, Week 48, n=239 | 0.6 ± 10.60 |
| AST, Year 4, Week 8, n=237 | 0.5 ± 7.73 |
| AST, Year 4, Week 16, n=235 | -0.2 ± 12.78 |
| AST, Year 4, Week 24, n=226 | 0.4 ± 11.45 |
| AST, Year 4, Week 32, n=230 | 0.8 ± 9.26 |
| AST, Year 4, Week 40, n=218 | -0.3 ± 9.44 |
| AST, Year 4, Week 48, n=214 | -0.2 ± 9.48 |
| AST, Year 5, Week 8, n=217 | 0.3 ± 12.79 |
| AST, Year 5, Week 16, n=213 | 0.8 ± 15.76 |
| AST, Year 5, Week 24, n=206 | -0.5 ± 11.36 |
| AST, Year 5, Week 32, n=211 | -0.8 ± 10.64 |
| AST, Year 5, Week 40, n=197 | 0.3 ± 14.39 |
| AST, Year 5, Week 48, n=207 | 0.0 ± 11.58 |
| AST, Year 6, Week 8, n=205 | -0.4 ± 9.04 |
| AST, Year 6, Week 16, n=198 | -0.7 ± 9.83 |
| AST, Year 6, Week 24, n=189 | -0.9 ± 11.35 |
| AST, Year 6, Week 32, n=192 | -0.6 ± 11.04 |
| AST, Year 6, Week 40, n=181 | -0.7 ± 10.56 |
| AST, Year 6, Week 48, n=186 | 0.1 ± 12.21 |
| AST, Year 7, Week 8, n=177 | -0.2 ± 10.76 |
| AST, Year 7, Week 16, n=178 | 1.0 ± 12.91 |
| AST, Year 7, Week 24, n=171 | 1.5 ± 14.44 |
| AST, Year 7, Week 32, n=179 | 0.5 ± 10.56 |
| AST, Year 7, Week 40, n=172 | 0.4 ± 14.51 |
| AST, Year 7, Week 48, n=175 | 0.2 ± 11.15 |
| AST, Year 8, Week 8, n=170 | 1.0 ± 16.78 |
| AST, Year 8, Week 16, n=169 | 1.0 ± 21.12 |
| AST, Year 8, Week 24, n=167 | 0.5 ± 13.61 |
| AST, Year 8, Week 32, n=166 | 0.7 ± 14.74 |
| AST, Year 8, Week 40, n=161 | 1.4 ± 16.28 |
| AST, Year 8, Week 48, n=159 | 0.2 ± 11.00 |
| AST, Year 9, Week 8, n=163 | 1.6 ± 16.09 |
| AST, Year 9, Week 16, n=160 | 0.8 ± 13.55 |
| AST, Year 9, Week 24, n=160 | 0.3 ± 12.60 |
| AST, Year 9, Week 32, n=162 | 1.3 ± 17.39 |
| AST, Year 9, Week 40, n=156 | 1.0 ± 14.17 |
| AST, Year 9, Week 48, n=150 | 1.5 ± 15.79 |
| AST, Year 10, Week 8, n=151 | 0.0 ± 11.05 |
| AST, Year 10, Week 16, n=143 | 0.1 ± 13.75 |
| AST, Year 10, Week 24, n=145 | 0.1 ± 13.80 |
| AST, Year 10, Week 32, n=140 | 0.5 ± 13.90 |
| AST, Year 10, Week 40, n=137 | -0.4 ± 13.30 |
| AST, Year 10, Week 48, n=135 | 0.9 ± 14.71 |
| AST, Year 11, Week 8, n=138 | -0.2 ± 12.04 |
| AST, Year 11, Week 16, n=128 | -0.1 ± 12.72 |
| AST, Year 11, Week 24, n=129 | -0.3 ± 12.69 |
| AST, Year 11, Week 32, n=124 | -1.0 ± 10.03 |
| AST, Year 11, Week 40, n=124 | 0.1 ± 14.28 |
| AST, Year 11, Week 48, n=107 | 1.3 ± 17.70 |
| AST, Year 12, Week 8, n=109 | 0.1 ± 16.11 |
| AST, Year 12, Week 16, n=97 | -0.5 ± 7.74 |
| AST, Year 12, Week 24, n=85 | 1.0 ± 13.58 |
| AST, Year 12, Week 32, n=84 | 0.5 ± 11.11 |
| AST, Year 12, Week 40, n=82 | 0.2 ± 11.60 |
| AST, Year 12, Week 48, n=72 | -1.0 ± 12.48 |
| AST, Year 13, Week 8, n=53 | -2.5 ± 10.00 |
| AST, Year 13, Week 16, n=42 | -3.4 ± 14.32 |
| AST, Year 13, Week 24, n=20 | 0.1 ± 7.94 |
| AST, Year 13, Week 32, n=7 | 0.3 ± 4.96 |
| AST, Year 13, Week 40, n=1 | 1.0 ± NA |
| AST, Exit, n=248 | -0.9 ± 10.19 |
| AST, 8-Week Follow-up, n=220 | -0.3 ± 11.02 |
| AST, 24-Week Follow-up , n=200 | 3.3 ± 52.99 |
| GGT, Year 1, Week 8, n=284 | 0.6 ± 23.57 |
| GGT, Year 1, Week 16, n=286 | 5.0 ± 32.94 |
| GGT, Year 1, Week 24, n=292 | 6.3 ± 48.10 |
| GGT, Year 1, Week 32, n=287 | 4.9 ± 46.96 |
| GGT, Year 1, Week 40, n=284 | 6.7 ± 55.51 |
| GGT, Year 1, Week 48, n=287 | 5.2 ± 58.66 |
| GGT, Year 2, Week 8, n=288 | 4.6 ± 50.82 |
| GGT, Year 2, Week 16, n=278 | 2.9 ± 37.57 |
| GGT, Year 2, Week 24, n=273 | 4.5 ± 42.01 |
| GGT, Year 2, Week 32, n=284 | 3.8 ± 38.55 |
| GGT, Year 2, Week 40, n=264 | 4.2 ± 41.34 |
| GGT, Year 2, Week 48, n=269 | 5.7 ± 48.48 |
| GGT, Year 3, Week 8, n=265 | 3.9 ± 33.83 |
| GGT, Year 3, Week 16, n=260 | 5.3 ± 44.46 |
| GGT, Year 3, Week 24, n=244 | 4.0 ± 51.58 |
| GGT, Year 3, Week 32, n=249 | 6.7 ± 57.32 |
| GGT, Year 3, Week 40, n=245 | 3.7 ± 29.97 |
| GGT, Year 3, Week 48, n=244 | 1.7 ± 39.47 |
| GGT, Year 4, Week 8, n=239 | 3.1 ± 53.57 |
| GGT, Year 4, Week 16, n=238 | 1.2 ± 36.22 |
| GGT, Year 4, Week 24, n=226 | 3.0 ± 55.72 |
| GGT, Year 4, Week 32, n=233 | 3.4 ± 47.24 |
| GGT, Year 4, Week 40, n=220 | 2.0 ± 40.20 |
| GGT, Year 4, Week 48, n=218 | 2.6 ± 39.26 |
| GGT, Year 5, Week 8, n=218 | 4.8 ± 40.08 |
| GGT, Year 5, Week 16, n=214 | 1.6 ± 41.04 |
| GGT, Year 5, Week 24, n=211 | 3.0 ± 39.90 |
| GGT, Year 5, Week 32, n=211 | 1.7 ± 36.58 |
| GGT, Year 5, Week 40, n=198 | 1.4 ± 41.74 |
| GGT, Year 5, Week 48, n=207 | 3.6 ± 46.10 |
| GGT, Year 6, Week 8, n=206 | 1.9 ± 48.45 |
| GGT, Year 6, Week 16, n=198 | 1.8 ± 37.61 |
| GGT, Year 6, Week 24, n=190 | 1.6 ± 43.58 |
| GGT, Year 6, Week 32, n=193 | 5.9 ± 55.25 |
| GGT, Year 6, Week 40, n=185 | 2.0 ± 34.66 |
| GGT, Year 6, Week 48, n=186 | 2.2 ± 38.05 |
| GGT, Year 7, Week 8, n=179 | 2.3 ± 36.39 |
| GGT, Year 7, Week 16, n=179 | 3.8 ± 43.49 |
| GGT, Year 7, Week 24, n=173 | 4.5 ± 33.15 |
| GGT, Year 7, Week 32, n=180 | 4.6 ± 41.12 |
| GGT, Year 7, Week 40, n=175 | 4.9 ± 36.94 |
| GGT, Year 7, Week 48, n=175 | 4.9 ± 40.27 |
| GGT, Year 8, Week 8, n=171 | 7.0 ± 41.53 |
| GGT, Year 8, Week 16, n=170 | 6.8 ± 41.70 |
| GGT, Year 8, Week 24, n=168 | 8.5 ± 48.16 |
| GGT, Year 8, Week 32, n=168 | 8.5 ± 44.76 |
| GGT, Year 8, Week 40, n=162 | 3.5 ± 38.79 |
| GGT, Year 8, Week 48, n=159 | 7.3 ± 37.89 |
| GGT, Year 9, Week 8, n=164 | 7.1 ± 39.19 |
| GGT, Year 9, Week 16, n=162 | 5.0 ± 37.32 |
| GGT, Year 9, Week 24, n=161 | 2.6 ± 33.54 |
| GGT, Year 9, Week 32, n=163 | 2.4 ± 29.43 |
| GGT, Year 9, Week 40, n=156 | 2.9 ± 32.70 |
| GGT, Year 9, Week 48, n=151 | 4.5 ± 33.25 |
| GGT, Year 10, Week 8, n=152 | 2.7 ± 28.57 |
| GGT, Year 10, Week 16, n=143 | 4.5 ± 33.50 |
| GGT, Year 10, Week 24, n=145 | 3.0 ± 31.51 |
| GGT, Year 10, Week 32, n=142 | 4.2 ± 31.74 |
| GGT, Year 10, Week 40, n=138 | 2.9 ± 31.64 |
| GGT, Year 10, Week 48, n=135 | 5.9 ± 29.18 |
| GGT, Year 11, Week 8, n=138 | 3.8 ± 33.68 |
| GGT, Year 11, Week 16, n=128 | 4.8 ± 32.72 |
| GGT, Year 11, Week 24, n=130 | 3.4 ± 26.42 |
| GGT, Year 11, Week 32, n=125 | 2.8 ± 29.33 |
| GGT, Year 11, Week 40, n=124 | 2.5 ± 28.02 |
| GGT, Year 11, Week 48, n=108 | 7.0 ± 37.14 |
| GGT, Year 12, Week 8, n=110 | 7.9 ± 37.22 |
| GGT, Year 12, Week 16, n=97 | 2.3 ± 19.42 |
| GGT, Year 12, Week 24, n=87 | 5.2 ± 32.26 |
| GGT, Year 12, Week 32, n=84 | 4.4 ± 26.44 |
| GGT, Year 12, Week 40, n=82 | 2.0 ± 27.54 |
| GGT, Year 12, Week 48, n=72 | 1.6 ± 18.01 |
| GGT, Year 13, Week 8, n=53 | 2.4 ± 18.65 |
| GGT, Year 13, Week 16, n=42 | 8.8 ± 57.73 |
| GGT, Year 13, Week 24, n=20 | 10.5 ± 40.97 |
| GGT, Year 13, Week 32, n=7 | 6.1 ± 19.07 |
| GGT, Year 13, Week 40, n=1 | 3.0 ± NA |
| GGT, Exit, n=248 | 1.8 ± 53.15 |
| GGT, 8-Week Follow-up, n=220 | 3.3 ± 24.91 |
| GGT, 24-Week Follow-up , n=200 | 3.1 ± 55.20 |
| LD, Year 1, Week 8, n=281 | -0.4 ± 23.41 |
| LD, Year 1, Week 16, n=283 | -0.4 ± 29.97 |
| LD, Year 1, Week 24, n=287 | -0.8 ± 31.43 |
| LD, Year 1, Week 32, n=283 | -5.1 ± 26.19 |
| LD, Year 1, Week 40, n=282 | -3.6 ± 27.97 |
| LD, Year 1, Week 48, n=284 | -4.5 ± 28.66 |
| LD, Year 2, Week 8, n=288 | -1.7 ± 28.26 |
| LD, Year 2, Week 16, n=275 | -0.3 ± 30.16 |
| LD, Year 2, Week 24, n=269 | -0.4 ± 29.91 |
| LD, Year 2, Week 32, n=284 | -2.1 ± 34.05 |
| LD, Year 2, Week 40, n=261 | -4.7 ± 29.69 |
| LD, Year 2, Week 48, n=267 | -1.9 ± 29.81 |
| LD, Year 3, Week 8, n=262 | -5.1 ± 29.71 |
| LD, Year 3, Week 16, n=258 | -2.9 ± 31.27 |
| LD, Year 3, Week 24, n=241 | 1.0 ± 32.12 |
| LD, Year 3, Week 32, n=245 | 0.9 ± 36.26 |
| LD, Year 3, Week 40, n=242 | 1.3 ± 34.00 |
| LD, Year 3, Week 48, n=239 | 4.5 ± 35.46 |
| LD, Year 4, Week 8, n=237 | 3.9 ± 36.59 |
| LD, Year 4, Week 16, n=235 | 4.2 ± 38.16 |
| LD, Year 4, Week 24, n=225 | 3.8 ± 38.59 |
| LD, Year 4, Week 32, n=230 | 6.3 ± 37.05 |
| LD, Year 4, Week 40, n=218 | 2.0 ± 37.75 |
| LD, Year 4, Week 48, n=214 | 8.5 ± 39.80 |
| LD, Year 5, Week 8, n=217 | 6.7 ± 39.42 |
| LD, Year 5, Week 16, n=213 | 7.9 ± 42.94 |
| LD, Year 5, Week 24, n=206 | 7.6 ± 40.54 |
| LD, Year 5, Week 32, n=211 | 7.0 ± 36.84 |
| LD, Year 5, Week 40, n=196 | 5.0 ± 40.29 |
| LD, Year 5, Week 48, n=207 | 6.1 ± 37.15 |
| LD, Year 6, Week 8, n=205 | 8.4 ± 36.82 |
| LD, Year 6, Week 16, n=198 | 6.4 ± 36.98 |
| LD, Year 6, Week 24, n=189 | 5.2 ± 38.41 |
| LD, Year 6, Week 32, n=192 | 6.1 ± 34.07 |
| LD, Year 6, Week 40, n=181 | 6.0 ± 39.60 |
| LD, Year 6, Week 48, n=186 | 2.9 ± 39.20 |
| LD, Year 7, Week 8, n=177 | 4.8 ± 37.46 |
| LD, Year 7, Week 16, n=178 | 3.3 ± 37.02 |
| LD, Year 7, Week 24, n=171 | 8.9 ± 39.81 |
| LD, Year 7, Week 32, n=179 | 4.7 ± 40.87 |
| LD, Year 7, Week 40, n=172 | 6.8 ± 39.49 |
| LD, Year 7, Week 48, n=175 | 3.5 ± 37.36 |
| LD, Year 8, Week 8, n=170 | 3.0 ± 36.88 |
| LD, Year 8, Week 16, n=169 | 2.4 ± 36.06 |
| LD, Year 8, Week 24, n=167 | 2.4 ± 37.06 |
| LD, Year 8, Week 32, n=166 | 7.4 ± 36.86 |
| LD, Year 8, Week 40, n=161 | 2.1 ± 35.04 |
| LD, Year 8, Week 48, n=159 | 6.6 ± 39.01 |
| LD, Year 9, Week 8, n=163 | 4.5 ± 36.82 |
| LD, Year 9, Week 16, n=160 | 1.8 ± 36.46 |
| LD, Year 9, Week 24, n=160 | 3.9 ± 35.65 |
| LD, Year 9, Week 32, n=162 | 3.8 ± 37.69 |
| LD, Year 9, Week 40, n=156 | 7.5 ± 39.97 |
| LD, Year 9, Week 48, n=150 | 5.8 ± 39.05 |
| LD, Year 10, Week 8, n=151 | 4.5 ± 42.02 |
| LD, Year 10, Week 16, n=143 | 2.5 ± 34.44 |
| LD, Year 10, Week 24, n=145 | 2.1 ± 38.80 |
| LD, Year 10, Week 32, n=140 | 5.4 ± 41.37 |
| LD, Year 10, Week 40, n=137 | 7.6 ± 37.07 |
| LD, Year 10, Week 48, n=135 | 5.4 ± 37.12 |
| LD, Year 11, Week 8, n=138 | 6.1 ± 45.90 |
| LD, Year 11, Week 16, n=128 | 2.4 ± 38.69 |
| LD, Year 11, Week 24, n=129 | 5.5 ± 42.10 |
| LD, Year 11, Week 32, n=124 | 0.8 ± 44.21 |
| LD, Year 11, Week 40, n=124 | 2.1 ± 41.89 |
| LD, Year 11, Week 48, n=107 | 8.8 ± 40.94 |
| LD, Year 12, Week 8, n=109 | 5.9 ± 51.46 |
| LD, Year 12, Week 16, n=97 | 5.2 ± 45.81 |
| LD, Year 12, Week 24, n=85 | 6.6 ± 47.18 |
| LD, Year 12, Week 32, n=84 | 2.0 ± 47.59 |
| LD, Year 12, Week 40, n=82 | 2.2 ± 47.71 |
| LD, Year 12, Week 48, n=72 | 1.9 ± 61.71 |
| LD, Year 13, Week 8, n=53 | -0.3 ± 31.81 |
| LD, Year 13, Week 16, n=42 | -6.3 ± 38.99 |
| LD, Year 13, Week 24, n=20 | 0.3 ± 51.57 |
| LD, Year 13, Week 32, n=7 | -27.3 ± 63.45 |
| LD, Year 13, Week 40, n=1 | 26.0 ± NA |
| LD, Exit, n=248 | 6.4 ± 44.59 |
| LD, 8-Week Follow-up, n=220 | 7.7 ± 51.21 |
| LD, 24-Week Follow-up , n=200 | 6.5 ± 49.90 |
SRI response was assessed at Week 16, 32, and 48 during Year 1 to 12 and Week 16 and 32 during Year 13. Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. SRI response is defined as:\>=4 point reduction from the Baseline in safety of estrogen in lupus national assessment (SELENA) SLE disease activity index (SLEDAI) score and no worsening (increase of \<0.30 points from the Baseline) in Physician's Global Assessment (PGA), and no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with the Baseline at the time of assessment.
| Percentage of participants | Belimumab 10 mg/kg IV |
|---|---|
| Year 1 , Week 16, n=268 | 32.8 |
| Year 1 , Week 32, n=269 | 41.6 |
| Year 1 , Week 48, n=266 | 47.0 |
| Year 2 , Week 16, n=266 | 50.8 |
| Year 2, Week 32, n=262 | 56.5 |
| Year 2, Week 48, n=251 | 57.0 |
| Year 3, Week 16, n=245 | 59.2 |
| Year 3, Week 32, n=235 | 54.5 |
| Year 3, Week 48, n=225 | 57.8 |
| Year 4, Week 16, n=225 | 56.9 |
| Year 4, Week 32, n=212 | 56.6 |
| Year 4, Week 48, n=206 | 59.7 |
| Year 5, Week 16, n=198 | 65.7 |
| Year 5, Week 32, n=194 | 64.4 |
| Year 5, Week 48, n=192 | 62.5 |
| Year 6, Week 16, n=182 | 64.8 |
| Year 6, Week 32, n=181 | 65.7 |
| Year 6, Week 48, n=176 | 63.6 |
| Year 7, Week 16, n=169 | 63.9 |
| Year 7, Week 32, n=173 | 69.4 |
| Year 7, Week 48, n=162 | 69.1 |
| Year 8, Week 16, n=161 | 68.3 |
| Year 8, Week 32, n=158 | 67.7 |
| Year 8, Week 48, n=149 | 62.4 |
| Year 9, Week 16, n=151 | 64.2 |
| Year 9, Week 32, n=148 | 66.2 |
| Year 9, Week 48, n=142 | 66.2 |
| Year 10, Week 16, n=141 | 66.0 |
| Year 10, Week 32, n=135 | 66.7 |
| Year 10, Week 48, n=126 | 65.1 |
| Year 11, Week 16, n=125 | 73.6 |
| Year 11, Week 32, n=120 | 64.2 |
| Year 11, Week 48, n=109 | 65.1 |
| Year 12, Week 16, n=100 | 69.0 |
| Year 12, Week 32, n=90 | 75.6 |
| Year 12, Week 48, n=71 | 71.8 |
| Year 13, Week 16, n=42 | 73.8 |
| Year 13, Week 32, n=7 | 57.1 |
Anti-double stranded DNA levels in participants positive at Baseline were assessed at Baseline, Week 16, 32, and 48 during Year 1 to 11, Week 16 and 32 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study.
| International units (IU)/milliliter (mL) | Belimumab 10 mg/kg IV |
|---|---|
| Baseline, n=149 | 147.00 (31.0 to 418.0) |
| Year 1 , Week 16, n=147 | 114.00 (6.0 to 418.0) |
| Year 1 , Week 32, n=147 | 113.00 (5.0 to 349.0) |
| Year 1 , Week 48, n=144 | 106.50 (5.0 to 464.0) |
| Year 2 , Week 16, n=144 | 93.50 (3.0 to 328.0) |
| Year 2, Week 32, n=143 | 85.00 (5.0 to 271.0) |
| Year 2, Week 48, n=128 | 83.50 (5.0 to 271.0) |
| Year 3, Week 16, n=134 | 83.50 (5.0 to 271.0) |
| Year 3, Week 32, n=127 | 76.00 (5.0 to 271.0) |
| Year 3, Week 48, n=125 | 73.00 (5.0 to 271.0) |
| Year 4, Week 16, n=124 | 80.00 (5.0 to 271.0) |
| Year 4, Week 32, n=120 | 72.00 (5.0 to 271.0) |
| Year 4, Week 48, n=116 | 66.50 (5.0 to 271.0) |
| Year 5, Week 16, n=112 | 54.00 (5.0 to 271.0) |
| Year 5, Week 32, n=111 | 61.00 (5.0 to 271.0) |
| Year 5, Week 48, n=108 | 49.50 (5.0 to 271.0) |
| Year 6, Week 16, n=105 | 41.00 (5.0 to 271.0) |
| Year 6, Week 32, n=101 | 44.00 (5.0 to 271.0) |
| Year 6, Week 48, n=99 | 36.00 (5.0 to 271.0) |
| Year 7, Week 16, n=89 | 41.00 (5.0 to 271.0) |
| Year 7, Week 32, n=94 | 36.50 (5.0 to 271.0) |
| Year 7, Week 48, n=89 | 38.00 (5.0 to 586.0) |
| Year 8, Week 16, n=87 | 30.00 (5.0 to 468.0) |
| Year 8, Week 32, n=89 | 43.00 (5.0 to 890.0) |
| Year 8, Week 48, n=80 | 27.50 (5.0 to 1826.0) |
| Year 9, Week 16, n=85 | 32.00 (5.0 to 745.0) |
| Year 9, Week 32, n=83 | 20.00 (5.0 to 2120.0) |
| Year 9, Week 48, n=77 | 16.00 (5.0 to 423.0) |
| Year 10, Week 16, n=77 | 18.00 (5.0 to 593.0) |
| Year 10, Week 32, n=75 | 22.00 (5.0 to 607.0) |
| Year 10, Week 48, n=71 | 18.00 (5.0 to 500.0) |
| Year 11, Week 16, n=67 | 17.00 (5.0 to 445.0) |
| Year 11, Week 32, n=66 | 15.00 (5.0 to 611.0) |
| Year 11, Week 48, n=63 | 11.00 (5.0 to 546.0) |
| Year 12, Week 16, n=54 | 11.00 (5.0 to 330.0) |
| Year 12, Week 32, n=47 | 8.00 (5.0 to 219.0) |
| Year 12, Week 48, n=39 | 14.00 (5.0 to 402.0) |
| Year 13, Week 16, n=20 | 13.50 (5.0 to 549.0) |
| Year 13, Week 32, n=3 | 7.00 (5.0 to 8.0) |
| Exit, n=124 | 31.00 (5.0 to 1073.0) |
Anti-double stranded DNA levels for participants positive at Baseline were assessed at Baseline, Week 16, 32, and 48 during Year 1 to 11, Week 16 and 32 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value.
| Percent change | Belimumab 10 mg/kg IV |
|---|---|
| Year 1 , Week 16, n=147 | -16.26 (-87.5 to 252.1) |
| Year 1 , Week 32, n=147 | -25.57 (-93.8 to 168.8) |
| Year 1 , Week 48, n=144 | -30.17 (-93.4 to 177.1) |
| Year 2 , Week 16, n=144 | -30.26 (-96.3 to 344.3) |
| Year 2, Week 32, n=143 | -31.25 (-90.0 to 224.6) |
| Year 2, Week 48, n=128 | -41.63 (-93.8 to 133.6) |
| Year 3, Week 16, n=134 | -41.10 (-94.1 to 232.4) |
| Year 3, Week 32, n=127 | -44.44 (-94.8 to 208.3) |
| Year 3, Week 48, n=125 | -45.29 (-95.4 to 133.6) |
| Year 4, Week 16, n=124 | -47.33 (-95.2 to 243.0) |
| Year 4, Week 32, n=120 | -48.53 (-95.4 to 243.0) |
| Year 4, Week 48, n=116 | -48.45 (-96.7 to 243.0) |
| Year 5, Week 16, n=112 | -53.97 (-96.1 to 243.0) |
| Year 5, Week 32, n=111 | -47.27 (-96.7 to 411.3) |
| Year 5, Week 48, n=108 | -57.76 (-96.7 to 453.1) |
| Year 6, Week 16, n=105 | -60.00 (-97.4 to 361.2) |
| Year 6, Week 32, n=101 | -65.38 (-96.8 to 411.3) |
| Year 6, Week 48, n=99 | -66.42 (-97.7 to 243.0) |
| Year 7, Week 16, n=89 | -64.14 (-97.2 to 243.0) |
| Year 7, Week 32, n=94 | -68.93 (-96.7 to 243.0) |
| Year 7, Week 48, n=89 | -68.63 (-98.1 to 182.3) |
| Year 8, Week 16, n=87 | -73.77 (-98.1 to 111.7) |
| Year 8, Week 32, n=89 | -71.02 (-98.3 to 249.0) |
| Year 8, Week 48, n=80 | -76.62 (-98.1 to 1326.6) |
| Year 9, Week 16, n=85 | -75.00 (-97.4 to 1452.1) |
| Year 9, Week 32, n=83 | -80.13 (-98.1 to 4316.7) |
| Year 9, Week 48, n=77 | -81.38 (-97.7 to 152.1) |
| Year 10, Week 16, n=77 | -81.25 (-97.4 to 363.3) |
| Year 10, Week 32, n=75 | -78.11 (-98.1 to 175.0) |
| Year 10, Week 48, n=71 | -81.13 (-98.4 to 124.2) |
| Year 11, Week 16, n=67 | -82.86 (-98.4 to 99.6) |
| Year 11, Week 32, n=66 | -85.39 (-97.7 to 377.3) |
| Year 11, Week 48, n=63 | -85.29 (-98.4 to 326.6) |
| Year 12, Week 16, n=54 | -85.39 (-97.8 to 132.8) |
| Year 12, Week 32, n=47 | -88.52 (-98.4 to 71.1) |
| Year 12, Week 48, n=39 | -87.76 (-98.4 to 135.2) |
| Year 13, Week 16, n=20 | -86.87 (-98.4 to 192.0) |
| Year 13, Week 32, n=3 | -91.49 (-98.4 to -86.8) |
| Exit, n=124 | -75.68 (-98.4 to 257.7) |
Complement C3 and C4 levels were assessed in participants low at Baseline at Baseline, Week 16, 32, and 48 during Year 1 to 12, Week 16 and 32 during Year 13, and Exit visit. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study.
| grams per liter | Belimumab 10 mg/kg IV |
|---|---|
| C3, Baseline, n=88 | 0.77 (0.4 to 0.9) |
| C3, Year 1, Week 16, n=86 | 0.81 (0.5 to 1.3) |
| C3, Year 1, Week 32, n=88 | 0.81 (0.2 to 1.5) |
| C3, Year 1, Week 48, n=86 | 0.82 (0.5 to 1.3) |
| C3, Year 2, Week 16, n=83 | 0.82 (0.6 to 1.4) |
| C3, Year 2, Week 32, n=83 | 0.84 (0.5 to 1.4) |
| C3, Year 2, Week 48, n=76 | 0.88 (0.5 to 1.3) |
| C3, Year 3, Week 16, n=75 | 0.88 (0.3 to 1.3) |
| C3, Year 3, Week 32, n=75 | 0.90 (0.5 to 1.4) |
| C3, Year 3, Week 48, n=73 | 0.90 (0.3 to 1.5) |
| C3, Year 4, Week 16, n=74 | 0.93 (0.5 to 1.4) |
| C3, Year 4, Week 32, n=72 | 0.96 (0.4 to 1.3) |
| C3, Year 4, Week 48, n=67 | 0.93 (0.5 to 1.4) |
| C3, Year 5, Week 16, n=65 | 0.94 (0.4 to 1.5) |
| C3, Year 5, Week 32, n=65 | 0.97 (0.4 to 1.5) |
| C3, Year 5, Week 48, n=65 | 1.01 (0.4 to 1.5) |
| C3, Year 6, Week 16, n=61 | 1.02 (0.4 to 1.4) |
| C3, Year 6, Week 32, n=59 | 1.03 (0.5 to 1.5) |
| C3, Year 6, Week 48, n=57 | 1.00 (0.4 to 1.5) |
| C3, Year 7, Week 16, n=50 | 0.94 (0.5 to 1.6) |
| C3, Year 7, Week 32, n=54 | 0.99 (0.2 to 1.5) |
| C3, Year 7, Week 48, n=52 | 0.98 (0.3 to 1.7) |
| C3, Year 8, Week 16, n=46 | 0.98 (0.3 to 1.6) |
| C3, Year 8, Week 32, n=48 | 1.01 (0.5 to 1.6) |
| C3, Year 8, Week 48, n=45 | 1.01 (0.6 to 2.0) |
| C3, Year 9, Week 16, n=49 | 1.02 (0.5 to 2.1) |
| C3, Year 9, Week 32, n=46 | 0.95 (0.5 to 2.0) |
| C3, Year 9, Week 48, n=47 | 0.98 (0.5 to 1.9) |
| C3, Year 10, Week 16, n=43 | 0.91 (0.4 to 1.6) |
| C3, Year 10, Week 32, n=45 | 0.99 (0.3 to 2.0) |
| C3, Year 10, Week 48, n=44 | 0.90 (0.5 to 1.9) |
| C3, Year 11, Week 16, n=43 | 0.97 (0.4 to 1.7) |
| C3, Year 11, Week 32, n=42 | 0.99 (0.6 to 1.9) |
| C3, Year 11, Week 48, n=37 | 0.88 (0.5 to 1.7) |
| C3, Year 12, Week 16, n=31 | 0.92 (0.5 to 1.9) |
| C3, Year 12, Week 32, n=28 | 0.94 (0.5 to 1.7) |
| C3, Year 12, Week 48, n=28 | 0.84 (0.4 to 1.6) |
| C3, Year 13, Week 16, n=12 | 0.95 (0.6 to 1.6) |
| C3, Year 13, Week 32, n=2 | 0.99 (0.8 to 1.2) |
| C3, Exit, n=74 | 0.98 (0.4 to 1.6) |
| C4, Baseline, n=116 | 0.10 (0.0 to 0.2) |
| C4, Year 1, Week 16, n=112 | 0.12 (0.0 to 0.4) |
| C4, Year 1, Week 32, n=113 | 0.13 (0.0 to 0.3) |
| C4, Year 1, Week 48, n=112 | 0.14 (0.0 to 0.3) |
| C4, Year 2, Week 16, n=110 | 0.15 (0.0 to 0.3) |
| C4, Year 2, Week 32, n=110 | 0.15 (0.0 to 0.3) |
| C4, Year 2, Week 48, n=103 | 0.17 (0.0 to 0.5) |
| C4, Year 3, Week 16, n=101 | 0.16 (0.0 to 0.4) |
| C4, Year 3, Week 32, n=100 | 0.17 (0.0 to 0.5) |
| C4, Year 3, Week 48, n=97 | 0.17 (0.0 to 0.5) |
| C4, Year 4, Week 16, n=97 | 0.17 (0.0 to 0.4) |
| C4, Year 4, Week 32, n=93 | 0.17 (0.0 to 0.4) |
| C4, Year 4, Week 48, n=90 | 0.18 (0.0 to 0.4) |
| C4, Year 5, Week 16, n=83 | 0.18 (0.0 to 0.4) |
| C4, Year 5, Week 32, n=81 | 0.19 (0.0 to 0.4) |
| C4, Year 5, Week 48, n=81 | 0.19 (0.0 to 0.4) |
| C4, Year 6, Week 16, n=78 | 0.20 (0.0 to 0.4) |
| C4, Year 6, Week 32, n=74 | 0.19 (0.0 to 0.4) |
| C4, Year 6, Week 48, n=71 | 0.19 (0.0 to 0.4) |
| C4, Year 7, Week 16, n=66 | 0.19 (0.0 to 0.4) |
| C4, Year 7, Week 32, n=67 | 0.20 (0.0 to 0.4) |
| C4, Year 7, Week 48, n=65 | 0.20 (0.0 to 0.5) |
| C4, Year 8, Week 16, n=61 | 0.20 (0.0 to 0.4) |
| C4, Year 8, Week 32, n=62 | 0.20 (0.0 to 0.4) |
| C4, Year 8, Week 48, n=56 | 0.20 (0.1 to 0.6) |
| C4, Year 9, Week 16, n=62 | 0.20 (0.0 to 0.5) |
| C4, Year 9, Week 32, n=59 | 0.19 (0.0 to 0.4) |
| C4, Year 9, Week 48, n=55 | 0.19 (0.0 to 0.4) |
| C4, Year 10, Week 16, n=54 | 0.2 (0.1 to 0.4) |
| C4, Year 10, Week 32, n=52 | 0.19 (0.0 to 0.5) |
| C4, Year 10, Week 48, n=51 | 0.18 (0.0 to 0.4) |
| C4, Year 11, Week 16, n=50 | 0.2 (0.1 to 0.4) |
| C4, Year 11, Week 32, n=48 | 0.20 (0.1 to 0.4) |
| C4, Year 11, Week 48, n=44 | 0.21 (0.1 to 0.4) |
| C4, Year 12, Week 16, n=41 | 0.18 (0.1 to 0.4) |
| C4, Year 12, Week 32, n=37 | 0.21 (0.1 to 0.4) |
| C4, Year 12, Week 48, n=31 | 0.18 (0.1 to 0.3) |
| C4, Year 13, Week 16, n=16 | 0.21 (0.1 to 0.4) |
| C4, Year 13, Week 32, n=3 | 0.29 (0.2 to 0.4) |
| C4, Exit, n=93 | 0.18 (0.0 to 0.4) |
Complement C3 and C4 levels were assessed in participants low at Baseline at Baseline, Week 16, 32, and 48 during Year 1 to 12, Week 16 and 32 during Year 13, and Exit visit. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value.
| Percent change | Belimumab 10 mg/kg IV |
|---|---|
| C3, Year 1, Week 16, n=86 | 8.87 (-32.1 to 72.1) |
| C3, Year 1, Week 32, n=88 | 8.43 (-68.0 to 68.5) |
| C3, Year 1, Week 48, n=86 | 11.71 (-33.3 to 56.5) |
| C3, Year 2, Week 16, n=83 | 13.10 (-29.5 to 83.8) |
| C3, Year 2, Week 32, n=83 | 13.21 (-19.5 to 135.3) |
| C3, Year 2, Week 48, n=76 | 17.16 (-25.0 to 74.6) |
| C3, Year 3, Week 16, n=75 | 15.48 (-50.8 to 129.4) |
| C3, Year 3, Week 32, n=75 | 19.05 (-42.4 to 176.0) |
| C3, Year 3, Week 48, n=73 | 16.46 (-61.7 to 182.0) |
| C3, Year 4, Week 16, n=74 | 22.51 (-34.2 to 178.0) |
| C3, Year 4, Week 32, n=72 | 30.41 (-56.8 to 158.0) |
| C3, Year 4, Week 48, n=67 | 26.58 (-34.1 to 148.0) |
| C3, Year 5, Week 16, n=65 | 27.38 (-47.7 to 156.0) |
| C3, Year 5, Week 32, n=65 | 23.17 (-39.5 to 148.0) |
| C3, Year 5, Week 48, n=65 | 35.96 (-26.2 to 129.4) |
| C3, Year 6, Week 16, n=61 | 29.41 (-20.8 to 158.0) |
| C3, Year 6, Week 32, n=59 | 31.03 (-21.7 to 138.0) |
| C3, Year 6, Week 48, n=57 | 28.24 (-36.7 to 151.0) |
| C3, Year 7, Week 16, n=50 | 20.95 (-32.5 to 149.0) |
| C3, Year 7, Week 32, n=54 | 29.25 (-63.8 to 168.0) |
| C3, Year 7, Week 48, n=52 | 39.88 (-51.7 to 186.0) |
| C3, Year 8, Week 16, n=46 | 28.35 (-62.5 to 167.3) |
| C3, Year 8, Week 32, n=48 | 30.88 (-34.2 to 138.8) |
| C3, Year 8, Week 48, n=45 | 32.88 (-34.5 to 200.0) |
| C3, Year 9, Week 16, n=49 | 36.99 (-45.9 to 208.8) |
| C3, Year 9, Week 32, n=46 | 21.76 (-26.1 to 186.8) |
| C3, Year 9, Week 48, n=47 | 23.29 (-34.1 to 180.0) |
| C3, Year 10, Week 16, n=43 | 22.35 (-35.6 to 206.0) |
| C3, Year 10, Week 32, n=45 | 23.81 (-60.7 to 186.8) |
| C3, Year 10, Week 48, n=44 | 26.90 (-38.6 to 172.1) |
| C3, Year 11, Week 16, n=43 | 26.97 (-48.5 to 146.0) |
| C3, Year 11, Week 32, n=42 | 30.36 (-36.4 to 148.7) |
| C3, Year 11, Week 48, n=37 | 20.78 (-39.0 to 149.3) |
| C3, Year 12, Week 16, n=31 | 15.58 (-43.2 to 181.2) |
| C3, Year 12, Week 32, n=28 | 26.39 (-39.5 to 123.7) |
| C3, Year 12, Week 48, n=28 | 14.1 (-58.0 to 114.5) |
| C3, Year 13, Week 16, n=12 | 35.33 (-8.3 to 97.2) |
| C3, Year 13, Week 32, n=2 | 22.04 (9.6 to 34.5) |
| C3, Exit, n=74 | 29.19 (-48.8 to 152.6) |
| C4, Year 1, Week 16, n=112 | 25.00 (-57.1 to 200.0) |
| C4, Year 1, Week 32, n=113 | 33.33 (-70.0 to 180.0) |
| C4, Year 1, Week 48, n=112 | 34.52 (-60.0 to 183.3) |
| C4, Year 2, Week 16, n=110 | 50.00 (-70.0 to 300.0) |
| C4, Year 2, Week 32, n=110 | 53.33 (-25.0 to 400.0) |
| C4, Year 2, Week 48, n=103 | 53.85 (-12.5 to 308.3) |
| C4, Year 3, Week 16, n=101 | 53.33 (-33.3 to 275.0) |
| C4, Year 3, Week 32, n=100 | 63.39 (-58.3 to 400.0) |
| C4, Year 3, Week 48, n=97 | 53.33 (-66.7 to 422.2) |
| C4, Year 4, Week 16, n=97 | 70.00 (-70.0 to 400.0) |
| C4, Year 4, Week 32, n=93 | 69.23 (-50.0 to 350.0) |
| C4, Year 4, Week 48, n=90 | 66.67 (-37.5 to 420.0) |
| C4, Year 5, Week 16, n=83 | 71.43 (-33.3 to 500.0) |
| C4, Year 5, Week 32, n=81 | 66.67 (-33.3 to 425.0) |
| C4, Year 5, Week 48, n=81 | 80.00 (-66.7 to 460.0) |
| C4, Year 6, Week 16, n=78 | 70.33 (-12.5 to 380.0) |
| C4, Year 6, Week 32, n=74 | 85.71 (-12.5 to 400.0) |
| C4, Year 6, Week 48, n=71 | 100.0 (-25.0 to 450.0) |
| C4, Year 7, Week 16, n=66 | 79.29 (-13.3 to 350.0) |
| C4, Year 7, Week 32, n=67 | 85.71 (-25.0 to 440.0) |
| C4, Year 7, Week 48, n=65 | 100.0 (-50.0 to 377.8) |
| C4, Year 8, Week 16, n=61 | 90.00 (-15.4 to 433.3) |
| C4, Year 8, Week 32, n=62 | 81.67 (-18.2 to 575.5) |
| C4, Year 8, Week 48, n=56 | 76.36 (-8.3 to 866.7) |
| C4, Year 9, Week 16, n=62 | 87.86 (-57.1 to 566.7) |
| C4, Year 9, Week 32, n=59 | 72.73 (-33.3 to 533.3) |
| C4, Year 9, Week 48, n=55 | 71.43 (-42.9 to 566.7) |
| C4, Year 10, Week 16, n=54 | 81.82 (-33.3 to 625.0) |
| C4, Year 10, Week 32, n=52 | 84.52 (-57.1 to 575.0) |
| C4, Year 10, Week 48, n=51 | 73.33 (-57.1 to 575.0) |
| C4, Year 11, Week 16, n=50 | 75.71 (-27.3 to 500.0) |
| C4, Year 11, Week 32, n=48 | 81.67 (-20.0 to 475.0) |
| C4, Year 11, Week 48, n=44 | 103.33 (-33.3 to 650.0) |
| C4, Year 12, Week 16, n=41 | 75.0 (-20.0 to 525.0) |
| C4, Year 12, Week 32, n=37 | 100.0 (-23.1 to 340.0) |
| C4, Year 12, Week 48, n=31 | 80.0 (-18.2 to 475.0) |
| C4, Year 13, Week 16, n=16 | 135.0 (0.0 to 400.0) |
| C4, Year 13, Week 32, n=3 | 190.0 (33.3 to 258.3) |
| C4, Exit, n=93 | 78.57 (-57.1 to 575.0) |
Daily prednisone dose reduction was assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13. Percentage of participants with daily prednisone dose reduced to \<=7.5 mg/day from \>7.5 mg/kg at the Baseline are summarized. Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.
| Percentage of participants | Belimumab 10 mg/kg IV |
|---|---|
| Year 1, Week 8, n=91 | 0 |
| Year 1, Week 16, n=90 | 5.6 |
| Year 1, Week 24, n=91 | 19.8 |
| Year 1, Week 32, n=91 | 19.8 |
| Year 1, Week 40, n=87 | 23.0 |
| Year 1, Week 48, n=88 | 27.3 |
| Year 2, Week 8, n=90 | 28.9 |
| Year 2, Week 16, n=89 | 31.5 |
| Year 2, Week 24, n=90 | 28.9 |
| Year 2, Week 32, n=88 | 34.1 |
| Year 2, Week 40, n=84 | 35.7 |
| Year 2, Week 48, n=83 | 34.9 |
| Year 3, Week 8, n=81 | 35.8 |
| Year 3, Week 16, n=81 | 34.6 |
| Year 3, Week 24, n=73 | 34.2 |
| Year 3, Week 32, n=77 | 36.4 |
| Year 3, Week 40, n=78 | 33.3 |
| Year 3, Week 48, n=75 | 30.7 |
| Year 4, Week 8, n=72 | 40.3 |
| Year 4, Week 16, n=74 | 41.9 |
| Year 4, Week 24, n=71 | 45.1 |
| Year 4, Week 32, n=69 | 37.7 |
| Year 4, Week 40, n=67 | 37.3 |
| Year 4, Week 48, n=68 | 38.2 |
| Year 5, Week 8, n=67 | 41.8 |
| Year 5, Week 16, n=63 | 42.9 |
| Year 5, Week 24, n=64 | 45.3 |
| Year 5, Week 32, n=65 | 38.5 |
| Year 5, Week 40, n=58 | 48.3 |
| Year 5, Week 48, n=60 | 41.7 |
| Year 6, Week 8, n=61 | 44.3 |
| Year 6, Week 16, n=57 | 43.9 |
| Year 6, Week 24, n=58 | 48.3 |
| Year 6, Week 32, n=59 | 44.1 |
| Year 6, Week 40, n=55 | 41.8 |
| Year 6, Week 48, n=55 | 38.2 |
| Year 7, Week 8, n=52 | 46.2 |
| Year 7, Week 16, n=51 | 39.2 |
| Year 7, Week 24, n=51 | 41.2 |
| Year 7, Week 32, n=51 | 39.2 |
| Year 7, Week 40, n=51 | 39.2 |
| Year 7, Week 48, n=51 | 39.2 |
| Year 8, Week 8, n=50 | 40.0 |
| Year 8, Week 16, n=49 | 38.8 |
| Year 8, Week 24, n=50 | 38.0 |
| Year 8, Week 32, n=49 | 36.7 |
| Year 8, Week 40, n=49 | 38.8 |
| Year 8, Week 48, n=48 | 41.7 |
| Year 9, Week 8, n=48 | 39.6 |
| Year 9, Week 16, n=49 | 38.8 |
| Year 9, Week 24, n=49 | 38.8 |
| Year 9, Week 32, n=48 | 39.6 |
| Year 9, Week 40, n=48 | 35.4 |
| Year 9, Week 48, n=45 | 37.8 |
| Year 10, Week 8, n=46 | 37.0 |
| Year 10, Week 16, n=43 | 39.5 |
| Year 10, Week 24, n=44 | 31.8 |
| Year 10, Week 32, n=44 | 31.8 |
| Year 10, Week 40, n=43 | 34.9 |
| Year 10, Week 48, n=43 | 32.6 |
| Year 11, Week 8, n=44 | 36.4 |
| Year 11, Week 16, n=41 | 34.1 |
| Year 11, Week 24, n=40 | 32.5 |
| Year 11, Week 32, n=39 | 35.9 |
| Year 11, Week 40, n=40 | 40.0 |
| Year 11, Week 48, n=35 | 34.3 |
| Year 12, Week 8, n=35 | 34.3 |
| Year 12, Week 16, n=32 | 31.3 |
| Year 12, Week 24, n=29 | 34.5 |
| Year 12, Week 32, n=30 | 40.0 |
| Year 12, Week 40, n=30 | 46.7 |
| Year 12, Week 48, n=26 | 53.8 |
| Year 13, Week 8, n=19 | 47.4 |
| Year 13, Week 16, n=13 | 38.5 |
| Year 13, Week 24, n=6 | 50.0 |
| Year 13, Week 32, n=2 | 50.0 |
| Year 13, Week 40, n=1 | 0.0 |
Serum immunoglobulin G values were assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study.
| grams per liter | Belimumab 10 mg/kg IV |
|---|---|
| Baseline, n=293 | 12.90 (3.3 to 39.5) |
| Year 1, Week 8, n=288 | 12.10 (3.4 to 38.1) |
| Year 1, Week 16, n=292 | 11.70 (3.3 to 34.3) |
| Year 1, Week 24, n=293 | 11.60 (3.6 to 48.5) |
| Year 1, Week 32, n=291 | 11.50 (3.8 to 32.6) |
| Year 1, Week 40, n=288 | 11.40 (3.5 to 34.6) |
| Year 1, Week 48, n=289 | 11.50 (3.5 to 33.8) |
| Year 2, Week 8, n=286 | 11.20 (3.8 to 42.0) |
| Year 2, Week 16, n=284 | 11.30 (3.2 to 41.7) |
| Year 2, Week 24, n=288 | 11.55 (3.4 to 35.6) |
| Year 2, Week 32, n=284 | 11.40 (3.2 to 32.2) |
| Year 2, Week 40, n=269 | 11.30 (4.0 to 23.8) |
| Year 2, Week 48, n=269 | 11.30 (3.1 to 24.5) |
| Year 3, Week 8, n=265 | 11.40 (2.8 to 24.9) |
| Year 3, Week 16, n=260 | 11.45 (3.2 to 27.2) |
| Year 3, Week 24, n=244 | 11.15 (3.5 to 30.9) |
| Year 3, Week 32, n=250 | 11.40 (3.2 to 27.0) |
| Year 3, Week 40, n=246 | 11.70 (2.8 to 25.8) |
| Year 3, Week 48, n=244 | 11.70 (3.3 to 28.3) |
| Year 4, Week 8, n=240 | 11.50 (3.0 to 26.9) |
| Year 4, Week 16, n=240 | 11.60 (3.0 to 28.5) |
| Year 4, Week 24, n=228 | 11.35 (3.0 to 26.3) |
| Year 4, Week 32, n=233 | 11.20 (3.0 to 24.0) |
| Year 4, Week 40, n=220 | 11.40 (3.0 to 24.6) |
| Year 4, Week 48, n=222 | 11.35 (3.0 to 26.8) |
| Year 5, Week 8, n=218 | 11.45 (2.5 to 28.1) |
| Year 5, Week 16, n=215 | 11.00 (2.8 to 26.7) |
| Year 5, Week 24, n=212 | 10.80 (2.3 to 29.2) |
| Year 5, Week 32, n=211 | 11.00 (2.8 to 27.1) |
| Year 5, Week 40, n=199 | 11.10 (2.6 to 31.3) |
| Year 5, Week 48, n=209 | 10.80 (2.7 to 28.2) |
| Year 6, Week 8, n=207 | 10.80 (2.9 to 25.0) |
| Year 6, Week 16, n=199 | 10.30 (2.7 to 23.6) |
| Year 6, Week 24, n=192 | 10.20 (2.7 to 26.7) |
| Year 6, Week 32, n=197 | 10.30 (2.7 to 24.9) |
| Year 6, Week 40, n=186 | 10.30 (2.4 to 24.4) |
| Year 6, Week 48, n=188 | 9.78 (2.1 to 23.7) |
| Year 7, Week 8, n=183 | 10.10 (2.2 to 19.5) |
| Year 7, Week 16, n=182 | 10.15 (2.0 to 24.6) |
| Year 7, Week 24, n=176 | 10.10 (2.1 to 26.3) |
| Year 7, Week 32, n=182 | 9.98 (2.0 to 23.4) |
| Year 7, Week 40, n=177 | 9.85 (1.7 to 23.2) |
| Year 7, Week 48, n=177 | 9.64 (1.7 to 22.6) |
| Year 8, Week 8, n=173 | 9.64 (2.6 to 26.3) |
| Year 8, Week 16, n=172 | 9.40 (2.0 to 22.7) |
| Year 8, Week 24, n=169 | 9.67 (3.5 to 23.6) |
| Year 8, Week 32, n=170 | 9.72 (2.9 to 18.8) |
| Year 8, Week 40, n=163 | 9.41 (2.2 to 22.6) |
| Year 8, Week 48, n=161 | 9.42 (2.3 to 22.4) |
| Year 9, Week 8, n=167 | 9.41 (2.0 to 24.6) |
| Year 9, Week 16, n=163 | 9.24 (4.0 to 21.7) |
| Year 9, Week 24, n=163 | 9.39 (1.6 to 25.6) |
| Year 9, Week 32, n=164 | 9.25 (2.0 to 24.2) |
| Year 9, Week 40, n=159 | 9.06 (2.8 to 24.5) |
| Year 9, Week 48, n=151 | 9.01 (3.0 to 23.9) |
| Year 10, Week 8, n=153 | 9.02 (3.2 to 25.4) |
| Year 10, Week 16, n=146 | 8.96 (2.7 to 27.3) |
| Year 10, Week 24, n=146 | 8.98 (2.7 to 26.6) |
| Year 10, Week 32, n=142 | 8.97 (2.4 to 23.1) |
| Year 10, Week 40, n=138 | 9.09 (0.3 to 25.7) |
| Year 10, Week 48, n=137 | 9.25 (2.6 to 26.3) |
| Year 11, Week 8, n=139 | 9.54 (2.3 to 24.1) |
| Year 11, Week 16, n=129 | 9.36 (2.5 to 15.3) |
| Year 11, Week 24, n=131 | 9.53 (2.5 to 23.9) |
| Year 11, Week 32, n=128 | 9.46 (2.5 to 23.0) |
| Year 11, Week 40, n=124 | 9.68 (2.3 to 16.9) |
| Year 11, Week 48, n=108 | 9.41 (2.6 to 16.8) |
| Year 12, Week 8, n=111 | 8.92 (2.4 to 18.9) |
| Year 12, Week 16, n=99 | 9.55 (2.2 to 17.0) |
| Year 12, Week 24, n=87 | 9.33 (3.0 to 17.0) |
| Year 12, Week 32, n=88 | 9.19 (2.1 to 17.1) |
| Year 12, Week 40, n=84 | 8.79 (1.1 to 16.0) |
| Year 12, Week 48, n=73 | 9.39 (3.2 to 15.6) |
| Year 13, Week 8, n=53 | 9.62 (2.6 to 15.6) |
| Year 13, Week 16, n=43 | 9.40 (2.6 to 16.4) |
| Year 13, Week 24, n=20 | 9.77 (2.7 to 14.6) |
| Year 13, Week 32, n=7 | 10.60 (6.8 to 11.2) |
| Year 13, Week 40, n=1 | 11.50 (11.5 to 11.5) |
| Exit, n=248 | 9.62 (1.8 to 23.5) |
| 8-Week follow-up, n=222 | 9.88 (1.8 to 30.3) |
| 24-Week follow-up, n=200 | 9.89 (1.3 to 29.1) |
Serum immunoglobulin G values were assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value.
| Percent change | Belimumab 10 mg/kg IV |
|---|---|
| Year 1, Week 8, n=285 | -6.09 (-46.4 to 116.5) |
| Year 1, Week 16, n=289 | -7.69 (-47.7 to 82.4) |
| Year 1, Week 24, n=290 | -8.78 (-69.6 to 165.0) |
| Year 1, Week 32, n=288 | -8.84 (-47.6 to 41.6) |
| Year 1, Week 40, n=285 | -10.32 (-44.4 to 32.2) |
| Year 1, Week 48, n=286 | -9.34 (-46.3 to 33.8) |
| Year 2, Week 8, n=283 | -11.40 (-46.0 to 43.3) |
| Year 2, Week 16, n=281 | -10.76 (-50.8 to 47.3) |
| Year 2, Week 24, n=285 | -11.19 (-51.7 to 66.3) |
| Year 2, Week 32, n=281 | -11.40 (-52.9 to 54.0) |
| Year 2, Week 40, n=266 | -10.29 (-49.9 to 93.0) |
| Year 2, Week 48, n=267 | -10.54 (-58.0 to 103.0) |
| Year 3, Week 8, n=263 | -10.28 (-50.4 to 62.9) |
| Year 3, Week 16, n=258 | -9.92 (-53.3 to 52.9) |
| Year 3, Week 24, n=242 | -9.77 (-56.6 to 60.3) |
| Year 3, Week 32, n=248 | -8.93 (-52.0 to 45.7) |
| Year 3, Week 40, n=244 | -8.04 (-54.9 to 46.3) |
| Year 3, Week 48, n=242 | -10.40 (-52.3 to 45.0) |
| Year 4, Week 8, n=238 | -10.70 (-55.3 to 46.2) |
| Year 4, Week 16, n=238 | -10.77 (-54.9 to 145.1) |
| Year 4, Week 24, n=226 | -11.73 (-72.6 to 37.5) |
| Year 4, Week 32, n=231 | -10.99 (-53.5 to 48.2) |
| Year 4, Week 40, n=218 | -10.47 (-54.9 to 47.7) |
| Year 4, Week 48, n=220 | -11.69 (-59.2 to 57.3) |
| Year 5, Week 8, n=216 | -13.20 (-61.8 to 45.6) |
| Year 5, Week 16, n=213 | -14.62 (-64.2 to 45.5) |
| Year 5, Week 24, n=210 | -14.61 (-59.9 to 89.6) |
| Year 5, Week 32, n=209 | -13.24 (-54.5 to 29.7) |
| Year 5, Week 40, n=197 | -15.97 (-54.8 to 42.4) |
| Year 5, Week 48, n=207 | -15.47 (-57.0 to 38.6) |
| Year 6, Week 8, n=205 | -17.13 (-73.7 to 40.9) |
| Year 6, Week 16, n=197 | -18.16 (-75.0 to 32.6) |
| Year 6, Week 24, n=190 | -18.67 (-64.5 to 36.4) |
| Year 6, Week 32, n=195 | -19.83 (-65.0 to 42.4) |
| Year 6, Week 40, n=184 | -19.84 (-61.9 to 26.6) |
| Year 6, Week 48, n=186 | -22.36 (-79.4 to 39.2) |
| Year 7, Week 8, n=181 | -21.26 (-64.4 to 29.4) |
| Year 7, Week 16, n=180 | -21.22 (-68.7 to 45.0) |
| Year 7, Week 24, n=175 | -21.39 (-71.5 to 39.9) |
| Year 7, Week 32, n=180 | -22.03 (-71.8 to 45.5) |
| Year 7, Week 40, n=175 | -22.31 (-71.7 to 24.5) |
| Year 7, Week 48, n=175 | -22.20 (-69.0 to 25.4) |
| Year 8, Week 8, n=171 | -24.44 (-74.3 to 46.9) |
| Year 8, Week 16, n=170 | -25.51 (-76.3 to 26.6) |
| Year 8, Week 24, n=167 | -24.91 (-76.6 to 32.4) |
| Year 8, Week 32, n=168 | -24.48 (-76.3 to 59.9) |
| Year 8, Week 40, n=161 | -25.50 (-76.8 to 87.8) |
| Year 8, Week 48, n=159 | -24.58 (-76.0 to 78.9) |
| Year 9, Week 8, n=165 | -25.41 (-77.8 to 100.4) |
| Year 9, Week 16, n=161 | -25.44 (-80.6 to 23.7) |
| Year 9, Week 24, n=161 | -27.23 (-78.8 to 155.8) |
| Year 9, Week 32, n=162 | -26.92 (-79.6 to 168.3) |
| Year 9, Week 40, n=157 | -27.63 (-78.9 to 164.8) |
| Year 9, Week 48, n=149 | -26.48 (-79.4 to 184.4) |
| Year 10, Week 8, n=151 | -28.65 (-78.7 to 125.4) |
| Year 10, Week 16, n=144 | -28.45 (-74.0 to 130.8) |
| Year 10, Week 24, n=144 | -28.78 (-73.8 to 211.3) |
| Year 10, Week 32, n=140 | -27.98 (-74.4 to 161.2) |
| Year 10, Week 40, n=137 | -28.57 (-97.6 to 98.6) |
| Year 10, Week 48, n=136 | -28.86 (-72.9 to 164.8) |
| Year 11, Week 8, n=138 | -28.91 (-71.9 to 61.7) |
| Year 11, Week 16, n=128 | -29.34 (-69.8 to 48.1) |
| Year 11, Week 24, n=130 | -29.64 (-68.0 to 180.9) |
| Year 11, Week 32, n=127 | -29.50 (-67.6 to 72.5) |
| Year 11, Week 40, n=123 | -27.58 (-68.9 to 202.3) |
| Year 11, Week 48, n=107 | -27.13 (-67.0 to 200.5) |
| Year 12, Week 8, n=110 | -29.27 (-68.5 to 220.2) |
| Year 12, Week 16, n=98 | -30.30 (-70.5 to 14.4) |
| Year 12, Week 24, n=86 | -30.25 (-66.0 to 28.5) |
| Year 12, Week 32, n=87 | -30.72 (-72.6 to 12.2) |
| Year 12, Week 40, n=83 | -32.96 (-96.4 to 9.9) |
| Year 12, Week 48, n=72 | -31.72 (-65.5 to 13.2) |
| Year 13, Week 8, n=52 | -32.23 (-65.7 to 5.3) |
| Year 13, Week 16, n=42 | -31.91 (-67.0 to 3.5) |
| Year 13, Week 24, n=20 | -28.18 (-54.9 to 5.3) |
| Year 13, Week 32, n=7 | -33.06 (-58.2 to -7.8) |
| Year 13, Week 40, n=1 | -12.9 (-12.9 to -12.9) |
| Exit, n=245 | -23.37 (-72.0 to 200.5) |
| 8-Week follow-up, n=220 | -24.79 (-75.1 to 270.3) |
| 24-Week follow-up, n=198 | -22.09 (-77.9 to 245.3) |
Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from Day 1 until follow-up (approximately up to 13 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belimumab 10 mg/kg IV | — | 182/296 (61.5%) | 293/296 (99%) |
| Event | Belimumab 10 mg/kg IV |
|---|---|
| PneumoniaInfections and infestations | 20/296 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 14/296 |
| Non-cardiac chest painGeneral disorders | 12/296 |
| PyrexiaGeneral disorders | 11/296 |
| CellulitisInfections and infestations | 10/296 |
| Abdominal painGastrointestinal disorders | 9/296 |
| CholelithiasisHepatobiliary disorders | 8/296 |
| Gastroenteritis viralInfections and infestations | 8/296 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 7/296 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 7/296 |
| Event | Belimumab 10 mg/kg IV |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 217/296 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 196/296 |
| HeadacheNervous system disorders | 155/296 |
| SinusitisInfections and infestations | 141/296 |
| NauseaGastrointestinal disorders | 140/296 |
| FatigueGeneral disorders | 137/296 |
| Urinary tract infectionInfections and infestations | 137/296 |
| Back painMusculoskeletal and connective tissue disorders | 124/296 |
| CoughRespiratory, thoracic and mediastinal disorders | 124/296 |
| DiarrhoeaGastrointestinal disorders | 114/296 |
| Age, Continuous(Years) | Belimumab 10 mg/kg IV |
|---|---|
| Mean | 43 ± 11.58 |
| Sex: Female, Male(Participants) | Belimumab 10 mg/kg IV |
|---|---|
| Female | 276 |
| Male | 20 |
| Race/Ethnicity, Customized(Participants) | Belimumab 10 mg/kg IV |
|---|---|
| American Indian or Alaska Native | 6 |
| Asian | 6 |
| Black or African American | 68 |
| Native Hawaiian or Other Pacific Islander | 1 |
| White | 215 |
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from May 2005 to primary completion in Feb 2016, 129 months.
Results were first posted in Apr 2017, 1 year 2 months after primary completion.
Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 129 months is above that.
Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab
Lupus Erythematosus, Systemic →
Human Genome Sciences Inc., a GSK Company →